US20080138293A1 - Cosmetic and pharmaceutical foam - Google Patents

Cosmetic and pharmaceutical foam Download PDF

Info

Publication number
US20080138293A1
US20080138293A1 US11894715 US89471507A US2008138293A1 US 20080138293 A1 US20080138293 A1 US 20080138293A1 US 11894715 US11894715 US 11894715 US 89471507 A US89471507 A US 89471507A US 2008138293 A1 US2008138293 A1 US 2008138293A1
Authority
US
Grant status
Application
Patent type
Prior art keywords
foam
composition
invention
present
skin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US11894715
Inventor
Dov Tamarkin
Doron Friedman
Meir Eini
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Foamix Pharmaceuticals Ltd
Original Assignee
Foamix Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/46Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01NPRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES, AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N25/00Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of application, e.g. seed treatment or sequential application; Substances for reducing the noxious effect of the active ingredients to organisms other than pests
    • A01N25/16Foams
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/4174Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52Purines, e.g. adenine
    • A61K31/522Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids
    • A61K31/565Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane, progesterone
    • A61K31/573Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane, progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/7036Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin digitoxin or digoxin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • A61K38/21Interferons [IFN]
    • A61K38/212IFN-alpha
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38Cellulose; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K8/00Cosmetics or similar toilet preparations
    • A61K8/02Cosmetics or similar toilet preparations characterised by special physical form
    • A61K8/04Dispersions; Emulsions
    • A61K8/046Aerosols; Foams
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K8/00Cosmetics or similar toilet preparations
    • A61K8/18Cosmetics or similar toilet preparations characterised by the composition
    • A61K8/30Cosmetics or similar toilet preparations characterised by the composition containing organic compounds
    • A61K8/60Sugars; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0002Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0007Effervescent
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0014Skin, i.e. galenical aspects of topical compositions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0034Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/107Emulsions ; Emulsion preconcentrates; Micelles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/12Aerosols; Foams
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/12Aerosols; Foams
    • A61K9/122Foams; Dry foams
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILET PREPARATIONS
    • A61Q17/00Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
    • A61Q17/02Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings containing insect repellants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILET PREPARATIONS
    • A61Q17/00Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
    • A61Q17/04Topical preparations for affording protection against sunlight or other radiation; Topical sun tanning preparations
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILET PREPARATIONS
    • A61Q19/00Preparations for care of the skin
    • A61Q19/02Preparations for care of the skin for chemically bleaching or whitening the skin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILET PREPARATIONS
    • A61Q19/00Preparations for care of the skin
    • A61Q19/04Preparations for care of the skin for chemically tanning the skin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILET PREPARATIONS
    • A61Q7/00Preparations for affecting hair growth
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILET PREPARATIONS
    • A61Q7/00Preparations for affecting hair growth
    • A61Q7/02Preparations for inhibiting or slowing hair growth
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K2800/00Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/74Biological properties of particular ingredients
    • A61K2800/75Anti-irritant

Abstract

The invention relates to an alcohol-free cosmetic or pharmaceutical foam carrier comprising water, a hydrophobic solvent, a foam adjuvant agent, a surface-active agent and a water gelling agent. The cosmetic or pharmaceutical foam carrier does not contain aliphatic alcohols, making it non-irritating and non-drying. The alcohol-free foam carrier is suitable for inclusion of both water-soluble and oil soluble pharmaceutical and cosmetic agents.

Description

  • [0001]
    This application claims priority to Related Applications of Israeli patent application No. 152486 filed Oct. 25, 2002 entitled “Alcohol-free Cosmetic and Pharmaceutical Foam Carrier”, and to U.S. provisional patent application No. 60/495,546, filed Nov. 29, 2002, entitled “Cosmetic and Pharmaceutical Foam”, which are incorporated herein in their entirety.
  • FIELD OF THE INVENTION
  • [0002]
    The invention relates to an alcohol-free, cosmetic or pharmaceutical foam carrier and its use. More specifically, the invention relates to a cosmetic or pharmaceutical foam carrier suitable for inclusion of both water soluble and oil soluble pharmaceutical and cosmetic agents.
  • BACKGROUND OF THE INVENTION
  • [0003]
    External topical administration is an important route for the administration of drugs in disease treatment. In external topical administration, the drug is absorbed into and/or through skin, mucous membrane or wound tissue. Many groups of drugs, including, for example, antibiotic, anti-fungal, anti-inflammatory, anesthetic, analgesic, anti-allergic, corticosteroid, retinoid and anti-proliferative medications are preferably administered in hydrophobic media, e.g. ointments or oils. However, due to the undesirable consistency of these hydrophobic carriers, their use is limited. For instance, ointments containing white petrolatum, e.g., Vaseline petroleum jelly, as the carrier often form an impermeable barrier, so that metabolic products and excreta from the wounds to which they are applied are not easily removed or drained away. Furthermore, it is difficult for the active drug dissolved in the carrier to pass through the white petrolatum barrier layer into the wound tissue, so the efficacy of the drug is reduced.
  • [0004]
    In addition, ointments and creams often do not create an environment for promoting respiration of the wound tissue and it is not favorable to the normal respiration of the skin. An additional disadvantage of petroleum jelly-based products relates to the greasy feeling left following their topical application onto the skin, mucosal membranes and wounds. Besides petroleum jelly, hydrophobic pharmaceutical carriers now in use include liquid paraffin, lanolin, beeswax, vegetable oil, glycerin monostearate, higher alcohols, polyethylene glycol and some emulsifying agents, which also have undesirable flow properties and skin feel.
  • [0005]
    Several hydrophobic liquid and semi-solid oils, e.g., mono- and poly-unsaturated oils from vegetable and marine sources, mineral oils, silicone oils, and liquid hydrophobic plant-derived oils, are known for their therapeutic benefits when applied topically, yet, their application in liquid form is not practical. Oils can also contain essential nutritional constituents, such as oil-soluble vitamins (e.g., vitamin A and vitamin E), minerals and other therapeutically beneficial constituents. Another class of therapeutic oils includes mineral and silicon oils useful for the treatment of skin dehydration and other medical disorders, which oils are liquid at ambient temperature. Such therapeutic oils unfortunately, cannot be applied by users in amounts sufficient to exert therapeutic affects because of they typically are liquid at use temperatures.
  • [0006]
    Other pharmaceutical active ingredients are water-soluble and require a water component in the carrier.
  • [0007]
    While semi-solid cosmetic and pharmaceutical formulations, such as creams, lotions, gels and ointments are commonly used by consumers, new forms are desirable, in order to achieve better control of the application, while maintaining or bestowing the skin beneficial properties of such products. Thus, the development of a new composition, having breakable foam consistency when extruded out of a container and liquid properties when applied onto the skin is advantageous. Ideally a foam should contain hydrophobic substances (solvents), which can act as emollients and provide the skin with soothing and nourishing properties. However, such hydrophobic solvents are difficult to formulate into a lather-producing or foam-producing product because the hydrophobic solvents interfere with the lather forming ability of the surfactant. Furthermore, addition of oils and other emollients to topical formulations can result in an unpleasant or annoying skin residue.
  • [0008]
    Use of emulsions in foam compositions is known. Emulsion systems provide a two-phase system including lipophilic or hydrophobic components in one phase and hydrophilic components in the second phase. The foamed emulsion typically is an oil-in-water emulsion in which the hydrophobic component is dispersed in the aqueous continuous phase. Surfactants for reducing surface tension and emulsifiers for improving foam stability are included in the foam composition.
  • [0009]
    Foams and, in particular, foam emulsions are complicated systems which do not form under all circumstances. Slight shifts in foam emulsion composition, such as by the addition of active ingredients, may destabilize the foam. Furthermore, many emulsions do not provide the high foam capacity, foam stability and/or fast-breaking action under stress or temperatures that are desired in a topical foam composition.
  • [0010]
    A particularly desirable type of oil-containing foam is such wherein all or part of the oil phase comprises silicone oil. Silicone oil is known for its skin protective features and its incorporation in topical products is beneficial. However, it is not obvious to produce silicone oil-based foams, since many silicone oils possess anti-foaming properties.
  • [0011]
    U.S. Pat. No. 6,126,920 discloses treatment of various skin diseases, and in particular, scalp psoriasis, using a foamable pharmaceutical composition containing a corticosteroid active substance, an aliphatic alcohol, water, a fatty alcohol, a surface-active agent, a propellant and a buffering agent. The foamable composition contains 40-90% w/w composition of an aliphatic alcohol. U.S. Pat. No. 6,126,920 is typical of many compositions that use aliphatic alcohols in the foam composition. The alcohol promotes fast drying and thereby attempts to address the sticky feeling left by many topical formulations after application; however, alcohols, and in particular the methyl, ethyl and isopropyl alcohols preferred in the '920 patent, are defatting agents and may cause skin to become dry and cracked. Hence, the presence of aliphatic alcohol in a therapeutic foam for external topical administration as taught in U.S. Pat. No. 6,126,920 is undesirable.
  • [0012]
    U.S. Pat. No. 5,536,743 to Borgman describes a buffered non-flowing composition suitable for the treatment of bacterial vaginosis which contains metronidazole. Suitable formulations include oil-in-water emulsions including an internal oil phase of about 10-40 wt % oil and anionic, cationic or nonionic surfactants. Suitable components of the oleaginous phase include long chain alcohols, esters, and acids, vegetable and animal oils and waxes. No other stabilizing agents are disclosed for use in foam aerosol compositions.
  • [0013]
    EP 0,598,412 describes a composition that is useful for skin protection against drying and harsh environmental substances. The protection is derived from the inclusion of poly(tetrafluoroethylene) (PTFE) in the composition. The composition includes low levels of both hydrophilic emollients and hydrophobic emollients. The compositions include high levels of surfactants, including ionic surfactants, and co-emulsifiers resulting in thick emulsions which are not flowable, and thus providing products which are inefficient foamers (or non-foaming) and too thick for spreading over large skin areas.
  • [0014]
    U.S. Pat. No. 6,423,323 describes an aqueous foam emulsion. The composition includes a hydrophobic phase including fatty acids, emulsifiers and co-emulsifiers, and an aqueous phase containing hydrophilic moisturizers and emulsifiers. An optional ingredient according to U.S. Pat. No. 6,423,323 is one or more refatting substances, in preferable concentrations of 0.5 to 2%, if the product is to be used for normal skin; and 3 to 6% for dry skin. Addition of high levels of co-emulsifiers such as fatty alcohols and fatty acids suggest that the foam is not stable. No other stabilizing agents are disclosed.
  • [0015]
    U.S. Pat. No. 5,635,469 describes a foamable cleansing liquid composition comprising about 0.05% to about 10% of an emollient, in addition to cleansing surfactants, humectants and water soluble cationic or nonionic polymers, but no propellants. Low density foams are achieved using a novel non-aerosol foam dispenser. The foaming is achieved by operating a manual pump, which is not convenient for operation. Emollients and humectants are included to improve the level of hydration and/or lipid content of the skin. However, the patent notes that emollients and humectants interfere with the lather forming ability of the surfactant.
  • [0016]
    U.S. Pat. No. 6,113,888 teaches a single water phase composition comprising a self-tanning agent, a nitrogen-free polymer, a nitrogen-free surfactant, and water.
  • [0017]
    U.S. Pat. No. 5,679,324 to Lisboa pertains to an aerosol foamable fragrance composition, translucent in its pre-dispensed state, which forms a fast breaking foam. Apparently the foam breaks spontaneously upon discharging from an aerosol container (with no need of any rubbing or sheer force application), thus, making is impractical for spreading over a skin surface. The composition contains surfactant, a propellant, a fragrance, a thickener, and a cosmetic vehicle (preferably water) wherein the ratio of the surfactant to propellant is from about 1:1 to about 1:10. Emollients including silicone oils, mineral oils and hydrocarbon oils may be included.
  • [0018]
    U.S. Pat. No. 6,251,369 discloses foamable dental fluoride compositions containing a water-soluble fluoride component, whereby said compositions include an oil in water emulsion. However, the patent fails to specify the identity or concentration of the oil component of the emulsion; and none of the compositions presented in the examples contain any oil component.
  • [0019]
    U.S. Pat. No. 5,961,957 describes a barrier foam composition comprising from 70 to 90% of water, from 7 to 9% of butane, from 2 to 4% of glyceryl monostearate, from 1.5 to 3.50% of dimethicone copolyol (a water-soluble silicone compound), from 1 to 3% of propane, from 0.5 to 2.5% of lanolin, from 0.5 to 2.5% of stearic acid and from 0.05 to 1.05% of at least one of methylchloroisothiazolinone and methylisothiazolinone.
  • [0020]
    A few dermatological foam products are available on the market.
  • [0021]
    Olux™ Foam, produced by Connetics, Inc., contains clobetasol propionate. Each gram of Olux™ Foam contains 0.5 mg clobetasol propionate, USP, in a thermolabile foam, which consists of ethanol (60%), purified water, propylene glycol, cetyl alcohol, stearyl alcohol, polysorbate 60, citric acid, and potassium citrate. It is dispensed from an aluminum can pressurized with a hydrocarbon propellant (propane/butane). Luxiq™ is another corticostroid foam medication, containing 1.2 mg betamethasone valerate per gram, in a vehicle, comprising ethanol (60.4%), purified water, propylene glycol, cetyl alcohol, stearyl alcohol, polysorbate 60, citric acid, and potassium citrate, and pressurized with a hydrocarbon propellant.
  • [0022]
    Cortifoam, a hydrocortisone acetate rectal foam is produced by Schwartz Pharma GmbH, wherein the hydrocortisone is present at 10% in a foam vehicle. Nonmedicinal ingredients of Cortifoam include cetyl alcohol, ethoxylated stearyl alcohol, methylparaben, polyoxyethylene-10 stearyl ether, propylene glycol, propylparaben, triethanolamine, water, and inert propellants, isobutene, and propane.
  • [0023]
    Thus, foam compositions for topical treatment, containing higher concentrations of oils, and do not comprise alcohol are still desirable. Foam compositions that are robust and suitable for inclusion of a wide range of active ingredients are desired.
  • SUMMARY OF THE INVENTION
  • [0024]
    Despite the commonly known fact that hydrophobic solvents are difficult to formulate into a lather-producing or foam-producing product and that addition of conventional hydrophobic solvents interferes with the lather forming ability of the surfactant, we have surprisingly discovered a series of foamable carrier compositions, which, upon admixing with a liquefied gas propellant in an aerosol container, produces a foamable composition that is suitable for topical administration. Upon discharge from an aerosol container, the composition forms a breakable foam, which is rich and creamy in appearance, and show very fine bubble structure. The foam does not break down immediately upon discharge, however, it collapses to spread easily onto a skin area upon slight rubbing.
  • [0025]
    In one or more embodiments of the present invention, the alcohol-free cosmetic or pharmaceutical foamable carrier composition includes water, a liquid, non-volatile hydrophobic solvent, a foam adjuvant agent selected from the group consisting of fatty acids and fatty alcohols, a surface-active agent and a water gelling agent. Such foamable carriers, when placed in an aerosol container and combined with a liquefied gas propellant, create an oil in water emulsion, which, upon release from the aerosol container, provides a therapeutically beneficial foam product. The foam retains its structure for a time sufficient for a user to apply and to rub the foam into the skin. The foam has a very low yield strength and, hence, it breaks upon touch and makes rubbing easy and efficient, and its application even.
  • [0026]
    In one or more embodiments of the present invention, the foamable carrier composition the hydrophobic solvent content is about 2-5% and has a composition as follows:
  • [0027]
    Class A Composition:
      • about 2-5% hydrophobic solvent;
      • about 80-98% water;
      • about 0.1% to 5% foam adjuvant agent;
      • about 0.1% to 5% surface-active agent; and
      • about 0.1% to 5% water gelling agent.
  • [0033]
    In one or more embodiments of the present invention, the foamable composition the hydrophobic solvent content is about 5-10% and has a composition as follows:
  • [0034]
    Class B Composition:
      • about 5-10% hydrophobic solvent;
      • about 75-95% water;
      • about 0.1% to 5% foam adjuvant agent;
      • about 0.1% to 5% surface-active agent; and
      • about 0.1% to 5% water gelling agent.
  • [0040]
    In one or more embodiments of the present invention, the foamable composition the hydrophobic solvent content is about 10-20% and has a composition as follows:
  • [0041]
    Class C Composition:
      • about 10-20% hydrophobic solvent;
      • about 60-90% water;
      • about 0.1% to 5% foam adjuvant agent;
      • about 0.1% to 5% surface-active agent; and
      • about 0.1% to 5% water gelling agent.
  • [0047]
    In one or more embodiments of the present invention, the foamable composition the hydrophobic solvent content is about 20-75% and has a composition as follows:
  • [0048]
    Class A Composition:
      • about 20-75% hydrophobic solvent;
      • about 25-75% water;
      • about 0.1% to 5% foam adjuvant agent;
      • about 0.1% to 5% surface-active agent; and
      • about 0.1% to 5% water gelling agent.
  • [0054]
    All % values are provided on a weight (w/w) basis, based on the composition with out propellant (unless otherwise specified).
  • [0055]
    The cosmetic or pharmaceutical foamable carrier composition is liquid. The foamable of the present invention does not contain short chain aliphatic alcohols, making it non-irritating and non-drying. Alcohols penetrate the skin's protective barrier and break down the intercellular matrix. In a recent publication by the American Academy of Dermatology (AAD), titled “Facing the Facts about Skin Care Products” it is stated “[i]ndividuals with dry skin should avoid astringents and any product with alcohol because they easily strip away moisture from the skin” (see: www.aad.org/PressReleases FacingFacts.html). Another AAD publication, titled “Sensitive About Your Skin?”, recommends to “[a]void solvents that penetrate the skin including, propylene glycol and ethanol” (see: www.aad.org/PressReleases/sensitive.html).
  • [0056]
    The alcohol-free foam carrier is formulated as an oil-in-water or water-in-oil emulsion, so that it is suitable for inclusion of either water-soluble and oil soluble active agents (or both). The foamable carrier composition of the present invention, when admixed with a propellant substance in an amount of about 5-25% by weight of the total composition in an aerosol container, produces lightweight breakable foam, suitable for facile application onto the skin, and other body areas, which may accept topically-applied products. Since the propellant, in the pressurized container is in liquid state, upon admixing the foamable carrier composition with the propellant, a stable emulsion, comprising the oil and the propellant (jointly as the “oil phase” component of such emulsion) is formed.
  • [0057]
    In one or more embodiments of the present invention, an alcohol-free cosmetic or pharmaceutical product is provided. The product includes a foam carrier composition according to one or more embodiments of the present invention and an active cosmetic or pharmaceutical ingredient in a therapeutically effective concentration. Cosmetic and pharmaceutical agents can be included in each of the compositions described above and in the detailed description that follows. Pharmaceutical products are intended for topical treatment of human and animal skin disorders, or any other disorder, that requires topical application of a drug. Cosmetic products are intended for beautifying the skin and improving its appearance.
  • [0058]
    Cosmetic and medical disorders that are best treated using the alcohol-free foam carrier and the alcohol-free cosmetic or pharmaceutical product are identified, and the advantages of such carrier and products is demonstrated as compared to currently available options.
  • [0059]
    The foam of the present invention is advantageous to current options, for one or more of the following reasons:
      • (1) The foam is lightweight and thus, economical.
      • (2) The foam contains a hydrophobic solvent, in any desirable concentration, which provides a refatting and skin soothing effect, as well as a carrier for hydrophobic active agents.
      • (3) The foam contains silicone oil in a therapeutically effective concentration
      • (4) The foam includes active agent, both water soluble and oil soluble.
      • (5) The foam is easily spreadable, allowing treatment of large areas such as the arms, back, legs and the breast.
      • (6) Due to its flow properties, it spreads effectively into folds and wrinkles, providing uniform distribution of the active agent without the need of extensive rubbing and absorbs into the skin.
    BRIEF DESCRIPTION OF THE DRAWINGS
  • [0066]
    A more complete appreciation of the present invention and many of its advantages will be understood by reference to the following detailed description when considered in connection with the following drawings, which are presented for the purpose of illustration only are not intended to limit the scope of the appended claims, and in which:
  • [0067]
    FIG. 1 illustrates the improvement in the treatment of psoriasis using Bethasone valerate 0.12% foam; and
  • [0068]
    FIG. 2 illustrates the improvement in the treatment of atopic dermatitis using Bethasone vale rate 0.12% foam.
  • DETAILED DESCRIPTION OF THE INVENTION
  • [0069]
    Hydrophobic Solvent
  • [0070]
    A hydrophobic solvent according to the present invention is a liquid material having solubility in distilled water at ambient temperature of less than about 1 gm per 100 mL, more preferable less than about 0.5 gm per 100 mL, and most preferably less than about 0.1 gm per 100 mL. It is liquid at ambient temperature.
  • [0071]
    The total content of hydrophobic solvent may vary from 2% to 75% (w/w) of the foamable composition. However, different ranges (herein “composition classes A-D”) have been designated, in order to facilitate a choice of an appropriate class, according to the anticipated cosmetic or pharmaceutical need. As a rule of thumb, higher hydrophobic solvent concentrations are more appropriate for the treatment of dry skin, and/or for the treatment of a disease, which is more responsive to drugs delivered in an oily vehicle. Likewise, the higher oil-content composition classes provide an enhanced occlusive effect, which in turn induces the skin penetration of an active agent. Another consideration relates to user acceptance of a product containing a high concentration of the hydrophobic solvent (from about 25% of the composition), which would leave some oily feeling post-application. Thus, a particular composition of the present invention is selected having a hydrophobic solvent concentration in view of the target population and its specific needs.
  • [0072]
    In one or more embodiments of the present invention, the hydrophobic solvent is mineral oil. Mineral oil (Chemical Abstracts Service Registry number 8012-95-1) is a mixture of aliphatic, naphthalenic, and aromatic liquid hydrocarbons that are derived from petroleum. It is typically liquid; its viscosity is in the range of about 35 CST to about 100 CST (at 40° C.), and its pour point (the lowest temperature at which an oil can be handled without excessive amounts of wax crystals forming) is below 0° C. By contrast, white petrolatum, also termed “Vaseline”, is disadvantageous, due to its waxy nature. It is known to leave waxy and sticky feeling after application and occasionally stain cloths. Thus, white petrolatum and other semi-solid oils are not a preferred hydrophobic solvent according to the present invention.
  • [0073]
    Yet another preferred hydrophobic solvents are liquid oils from vegetable, marine or animal sources. By way of example, the unsaturated oil may be selected from the group consisting of olive, corn, soybean, canola, cottonseed, coconut, sesame, sunflower, borage seed, syzigium aromaticum, hempseed, herring, cod-liver, salmon, flaxseed, wheat germ and evening primrose oils and mixtures thereof, at any proportion.
  • [0074]
    A particularly preferred class of oils includes polyunsaturated oils, e.g., esters, and in particular glyceryl esters, of omega-3 and omega-6 fatty acids. Examples of such polyunsaturated fatty acids are linoleic and linolenic acid, gamma-linoleic acid (GLA), eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA). Thus, in one or more embodiments of the present invention the hydrophobic solvent includes at least 6% by weight foamable composition of an oil selected from omega-3 oil, omega-6 oil, and mixtures thereof.
  • [0075]
    Another class of oils suitable for use as a phydrophobic solvent is liquid hydrophobic plant-derived oils, or essential oils, e.g. “therapeutic oils” containing active biologically occurring molecules that have a therapeutic effect when applied topically. Examples of such oils include rosehip oil, which contain retinoids and is known to reduce acne and post-acne scars, and tea tree oil, which possess antibacterial, antifungal and antiviral properties. Other examples of essential oils are oils of basil, camphor, cardamom, carrot, citronella, clary sage, clove, cypress, frankincense, ginger, grapefruit, hyssop, jasmine, lavender, lemon, mandarin, marjoram, myrrh, neroli, nutmeg, petitgrain, sage, tangerine, vanilla, verbena, as well as any other therapeutically beneficial oil, know in the art of herbal medication.
  • [0076]
    In one or more embodiments of the present invention, the hydrophobic solvent is an “emollient”. An emollient is a hydrophobic agent that softens, smoothens and improves lipid content of the skin or other mucous membranes. In one or more embodiments of the present invention, the emollient is a liquid. Without derogating the generality of this definition, examples of suitable emollients for use include isostearic acid derivatives, isopropyl palmitate, lanolin oil, diisopropyl dimerate, diisopropyl adipate, dimethyl isosorbide, maleated soybean oil, octyl palmitate, isopropyl isostearate, cetyl lactate, cetyl ricinoleate, tocopheryl acetate, acetylated lanolin alcohol, cetyl acetate, phenyl trimethicone, glyceryl oleate, tocopheryl linoleate, wheat germ glycerides, arachidyl propionate, myristyl lactate, decyl oleate, propylene glycol ricinoleate, isopropyl lanolate, pentaerythrityl tetrastearate, neopentylglycol dicaprylate/dicaprate, hydrogenated coco-glycerides, isononyl isononanoate, isotridecyl isononanoate, myristyl myristate, triisocetyl citrate, octyl dodecanol, octyl hydroxystearate and mixtures thereof. Other examples of other suitable emollients can also be found in the Cosmetic Bench Reference, pp. 1.19-1.22 (1996). In one or more embodiments, the hydrophobic solvent is a mixture of a mineral oil or silicone oil and an emollient.
  • [0077]
    In one or more embodiments of the present invention, silicone oil is a component of the hydrophobic solvent. Silicone oils are used in the foamable compositions due to their known skin protective and occlusive properties. Suitable silicone oils for use in the invention include non-volatile silicones, such as polyalkyl siloxanes, polyaryl siloxanes, polyalkylaryl siloxanes and polyether siloxane copolymers, polydimethylsiloxanes (dimethicones) and poly(dimethylsiloxane)-(diphenyl-siloxane) copolymers. These are preferably chosen from cyclic or linear polydimethylsiloxanes containing from about 3 to about 9, preferably from about 4 to about 5, silicon atoms. Volatile silicones such as cyclomethicones can also be used. Water-soluble silicones, such as dimethicone copolyol are not included in the definition of silicone oils (as hydrophobic solvents) according to the present invention.
  • [0078]
    In one or more embodiments of the present invention, the composition comprises at least 2% (w/w foamable composition) silicone oil, alone or as part of the hydrophobic solvent. Yet, in other embodiments, the composition comprises at least 5% (w/w) silicone oil alone or as part of the hydrophobic solvent.
  • [0079]
    The hydrophobic solvent of the present invention may comprise a mixture of two or more of the above hydrophobic solvents in any proportion.
  • [0080]
    Foam Adjuvant Agents
  • [0081]
    Foam adjuvants are included in the foamable compositions of the present invention to increase the foaming capacity of surfactants and/or to stabilize the foam. In one or more embodiments of the present invention, the foam adjuvant agents includes fatty alcohols having 15 or more carbons in their carbon chain, such as cetyl alcohol and stearyl alcohol (or mixtures thereof). Other examples of fatty alcohols are arachidyl alcohol (C20), behenyl alcohol (C22), 1-triacontanol (C30), as well as alcohols with longer carbon chains (up to C50). Fatty alcohols, derived from beeswax, including a mixture of alcohols, a majority of which has at least 20 carbon atoms in their carbon chain, are especially well suited as foam adjuvant agents according to the present invention. The concentration of the fatty alcohol, required to support the foam system is inversely related to the length of its carbon chains.
  • [0082]
    In one or more embodiments of the present invention, the foam adjuvant agent includes fatty acids having 16 or more carbons in their carbon chain, such as hexadecanoic acid (C16) stearic acid (C18), arachidic acid (C20), behenic acid (C22), octacosanoic acid (C28), as well as fatty acids with longer carbon chains (up to C50), or mixtures thereof.
  • [0083]
    Optionally, the carbon atom chain of the fatty alcohol or the fatty acid may have at least one double bond. A further class of foam adjuvant agent according to the present invention comprises a long chain fatty alcohol or fatty acid, wherein the carbon atom chain is branched. The carbon chain of the fatty acid or fatty alcohol can be substituted with a hydroxyl group, such as 12-hydroxy stearic acid.
  • [0084]
    The foam adjuvant agent according to one or more embodiments of the present invention includes a mixture of fatty alcohols, fatty acids and hydroxy fatty acids and derivatives thereof in any proportion, providing that the total amount is 0.1% to 5% (w/w) of the carrier mass. More preferably, the total amount is 0.4%-2.5% (w/w) of the carrier mass.
  • [0085]
    While fatty alcohols and fatty acids serve to stabilize the resultant foam composition, they often provide additional therapeutic properties. Long chain saturated and mono unsaturated fatty alcohols, e.g., stearyl alcohol, erycyl alcohol, arachidyl alcohol and docosanol have been reported to possess antiviral, anti infective, anti-proliferative and anti-inflammatory properties (U.S. Pat. No. 4,874,794). Longer chain fatty alcohols, e.g., tetracosanol, hexacosanol, heptacosanol, octacosanol, triacontanol, etc. are also known for their metabolism modifying properties and tissue energizing properties. Long chain fatty acids have also been reported to possess anti-infective characteristics. Thus, the pharmaceutical or cosmetic carrier, containing the foam adjuvant agent of the present invention provides an extra therapeutic benefit in comparison with currently used vehicles, which are inert and non-active.
  • [0086]
    Surface-Active Agents
  • [0087]
    Surface-active agents, according to the present invention include any agent linking oil and water in the composition.
  • [0088]
    The surface-active agent is suitably selected from anionic, cationic, nonionic, zwitterionic, amphoteric and ampholytic surfactants, as well as mixtures of these surfactants. Such surfactants are well known to those skilled in the pharmaceutical and cosmetic formulation art. Nonlimiting examples of possible surfactants include polysorbates, such as polyoxyethylene (20) sorbitan monostearate (Tween 60) and poly(oxyethylene) (20) sorbitan monooleate (Tween 80); poly(oxyethylene) (POE) fatty acid esters, such as Myrj 45, Myq 49 and Myrj 59; poly(oxyethylene) alkylyl ethers, such as poly(oxyethylene) cetyl ether, poly(oxyethylene) palmityl ether, polyethylene oxide hexadecyl ether, polyethylene glycol cetyl ether, brij 38, brij 52, brij 56 and brij W1; sucrose esters, partial esters of sorbitol and its anhydrides, such as sorbitan monolaurate and sorbitan monolaurate; mono or diglycerides, isoceteth-20, sodium methyl cocoyl taurate, sodium methyl oleoyl taurate, sodium lauryl sulfate, triethanolamine lauryl sulfate and betaines.
  • [0089]
    A combination of surface active agents is possible. Any surface-active agent or combinations thereof may be used as surface-active agent. According to one or more embodiments of the present invention, the surface-active agent (or agents) has an HLB of higher than 9.
  • [0090]
    In one or more embodiments of the present invention, the surface-active agent is selected from the groups of non ionic surfactants, cationic surfactants, amphoteric and zwitterionic surfactants, and, in particular, the surface-active agent is a non-ionic surfactant. Ionic surfactants (including cationic, anionic, amphotheric and zwitterionic surfactants) are known to be skin irritants. Therefore, non-ionic surfactants are preferred in applications including sensitive skin such as found in most dermological disorders. We have surprisingly found that non-ionic surfactants alone provide foams of excellent quality, i.e. a score of “E” according to the grading scale discussed below.
  • [0091]
    In one or more embodiments of the present invention, the surface active agent is solely non-ionic, comprising one or more non-ionic surfactants.
  • [0092]
    In one or more embodiments of the present invention, the surface active agent include a ratio of non-ionic surfactants to ionic surfactants in the range of 100:1 to 6:1; in some embodiments the non-ionic to ionic surfactant ratio is greater than 6:1, or greater than 8:1; or greater than 14:1, or greater than 16:1, or greater than 20:1.
  • [0093]
    Exemplary non-ionic surfactants include polyethoxylated fatty acids, fatty acid diesters, polyethylene glycol glycerol fatty acid esters, alcohol-oil transesterification products, polyglycerized fatty acids, sterol and sterol derivatives, polyethylene glycol sorbitan fatty acid esters, polyethylene glycol alkyl ethers, sugar esters, polyethylene glycol alkyl phenols, polyoxyethylene-polyoxypropylene block copolymers, sorbitan fatty acid esters and lower alcohol fatty acid esters.
  • [0094]
    Although polyethylene glycol (PEG) itself does not function as a surfactant, a variety of PEG-fatty acid esters have useful surfactant properties. Exemplary monoesters include esters of lauric acid, oleic acid, and stearic acid, e.g., PEG-8 laurate, PEG-8 oleate, PEG-8 stearate, PEG-9 oleate, PEG-10 laurate, PEG-10 oleate, PEG-12 laurate, PEG-12 oleate, PEG-15 oleate, PEG-20 laurate and PEG-20 oleate. Polyethylene glycol fatty acid diesters suitable for use as non-ionic surfactants in the compositions of the present invention include PEG-20 dilaurate, PEG-20 dioleate, PEG-20 distearate, PEG-32 dilaurate and PEG-32 dioleate. Suitable polyethylene glycol glycerol fatty acid esters include PEG-20 glyceryl laurate, PEG-30 glyceryl laurate, PEG-40 glyceryl laurate, PEG-20 glyceryl oleate, and PEG-30 glyceryl oleate.
  • [0095]
    A large number of surfactants of different degrees of hydrophobicity or hydrophilicity can be prepared by reaction of alcohols or polyalcohols with a variety of natural and/or hydrogenated oils. Most commonly, the oils used are castor oil or hydrogenated castor oil, or an edible vegetable oil such as corn oil, olive oil, peanut oil, palm kernel oil, apricot kernel oil, or almond oil. Preferred alcohols include glycerol, propylene glycol, ethylene glycol, polyethylene glycol, sorbitol, and pentaerythritol. Among these alcohol-oil transesterified surfactants, preferred hydrophilic surfactants are PEG-35 castor oil (Incrocas-35), PEG-40 hydrogenated castor oil (Cremophor RH 40), PEG-25 trioleate (TAGAT® TO), PEG-60 corn glycerides (Crovol M70), PEG-60 almond oil (Crovol A70), PEG-40 palm kernel oil (Crovol PK70), PEG-50 castor oil (Emalex C-50), PEG-50 hydrogenated castor oil (Emalex HC-50), PEG-8 caprylic/capric glycerides (Labrasol), and PEG-6 caprylic/capric glycerides (Softigen 767). Preferred hydrophobic surfactants in this class include PEG-5 hydrogenated castor oil, PEG-7 hydrogenated castor oil, PEG-9 hydrogenated castor oil, PEG-6 corn oil (Labrafil® M 2125 CS), PEG-6 almond oil (Labrafil® M 1966 CS), PEG-6 apricot kernel oil (Labrafil® M 1944 CS), PEG-6 olive oil (Labrafil® M 1980 CS), PEG-6 peanut oil (Labrafil® M 1969 CS), PEG-6 hydrogenated palm kernel oil (Labrafil® M 2130 BS), PEG-6 palm kernel oil (Labrafil® M 2130 CS), PEG-6 triolein (Labrafil® b M 2735 CS), PEG-8 corn oil (Labrafil® WL 2609 BS), PEG-20 corn glycerides (Crovol M40), and PEG-20 almond glycerides (Crovol A40). The latter two surfactants are reported to have HLB values of 10, which is generally considered to be the approximate border line between hydrophilic and hydrophobic surfactants.
  • [0096]
    Alcohol-oil transesterification derivatives of oil soluable vitamins (e.g., vitamins A, D, E, K, etc.), such as tocopheryl PEG-100 succinate (TPGS, available from Eastman), are also suitable surfactants.
  • [0097]
    Polyglycerol esters of fatty acids are also suitable non-ionic surfactants for the present invention. Among the polyglyceryl fatty acid esters, exemplary use hydrophobic surfactants include polyglyceryl oleate (Plurol Oleique), polyglyceryl-2 dioleate (Nikkol DGDO), and polyglyceryl-10 trioleate. Preferred hydrophilic surfactants include polyglyceryl-10 laurate (Nikkol Decaglyn 1-L), polyglyceryl-10 oleate (Nikkol Decaglyn 1-O), and polyglyceryl-10 mono, dioleate (Caprol® PEG 860), Polyglyceryl polyricinoleates (Polymuls) are hydrophilic and hydrophobic surfactants of this class.
  • [0098]
    Sterols and derivatives of sterols are suitable surfactants for use in the present invention. These surfactants can be hydrophilic or hydrophobic. Preferred derivatives include the polyethylene glycol derivatives. An exemplary hydrophobic surfactant in this class is cholesterol. An exemplary hydrophilic surfactant in this class is PEG-24 cholesterol ether (Solulan C-24).
  • [0099]
    A variety of PEG-sorbitan fatty acid esters are suitable for use as non-ionic surfactants in the present invention. In general, these surfactants are hydrophilic, although several hydrophobic surfactants of this class can be used. Among the PEG-sorbitan fatty acid esters, exemplary hydrophilic surfactants include PEG-20 sorbitan monolaurate (Tween-20), PEG-20 sorbitan monopalmitate (Tween-40), PEG-20 sorbitan monostearate (Tween-60), and PEG-20 sorbitan monooleate (Tween-80).
  • [0100]
    Ethers of polyethylene glycol and alkyl alcohols are suitable non-ionic surfactants for use in the present invention. Exemplary hydrophobic ethers include PEG-3 oleyl ether (Volpo 3) and PEG-4 lauryl ether (Brij 30).
  • [0101]
    The polyoxyethylene-polyoxypropylene (POE-POP) block copolymers are a unique class of polymeric surfactants. The unique structure of the surfactants, with hydrophilic POE and hydrophobic POP moieties in well-defined ratios and positions, provides a wide variety of surfactants suitable for use in the present invention. These surfactants are available under various trade names, including Synperonic PE series (ICI), Pluronic® series (BASF), Emkalyx, Lutrol (BASF), Supronic, Monolan, Pluracare, and Plurodac. The generic term for these polymers is “poloxamer” (CAS 9003-11-6). Exemplary hydrophilic surfactants of this class include Poloxamers 108, 188, 217, 238, 288, 338, and 407. Exemplary hydrophobic surfactants in this class include Poloxamers 124, 182, 183, 212, 331, and 335.
  • [0102]
    Sorbitan esters of fatty acids are suitable non-ionic surfactants for use in the present invention. Among these esters, preferred hydrophobic surfactants include sorbitan monolaurate (Arlacel 20), sorbitan monopalmitate (Span-40), sorbitan monooleate (Span-80), sorbitan monostearate, and sorbitan tristearate.
  • [0103]
    Esters of lower alcohols (C2 to C4) and fatty acids (C8 to C18) are suitable non-ionic surfactants for use in the present invention. Among these esters, preferred hydrophobic surfactants include ethyl oleate (Crodamol EO), isopropyl myristate (Crodamol IPM), and isopropyl palmitate (Crodamol IPP).
  • [0104]
    In one or more embodiments of the present invention, the surface-active agent comprise mono-, di- and tri-esters of sucrose with food fatty acids (sucrose esters), prepared from sucrose and methyl and ethyl esters of food fatty acids or by extraction from sucroglycerides. Exemplary sucrose esters include sucrose monopalmitate and sucrose monolaurate. Suitable sucrose esters include those having a high monoester content, which have higher HLB values.
  • [0105]
    In one or more embodiments of the present invention, a combination of a non-ionic surfactant and an anionic surfactant (such as sodium lauryl sulphate) is employed, at a ratio of between 1:1 and 20:1, or at a ratio of 4:1 to 10:1. The resultant foam has a low specific gravity, e.g., less than 0.1 g/ml, which upon rubbing (shear stress) onto the skin collapses easily, to allow facile absorption.
  • [0106]
    Unlike prior art foamable compositions, the total surfactant employed to obtain a foam that is stable, of low specific gravity and has a fine bubble structure is low. Lower surfactant levels, particularly of ionic surfactants, are preferred to reduce skin irritations. Total surfactant is in the range of 0.1 to 5.0 wt % of the foamable composition, and is typically less than 2 wt %, or even less than 1 wt %.
  • [0107]
    Water Gelling Agents
  • [0108]
    The water gelling agent according to one or more embodiments of the present invention stablizes the acqueons phase by, for example, increasing viscosity and linking capability. Exemplary water gelling agents that can be used in accordance with one or more embodiments of the present invention include for example, but are not limited to, naturally-occurring polymeric materials such as, locust bean gum, sodium alginate, sodium caseinate, egg albumin, gelatin agar, carrageenin gum sodium alginate, xanthan gum, quince seed extract, tragacanth gum, starch, chemically modified starches and the like, semi-synthetic polymeric materials such as cellulose ethers (e.g. hydroxyethyl cellulose, methyl cellulose, carboxymethyl cellulose, hydroxy propylmethyl cellulose), polyvinylpyrrolidone, polyvinylalcohol, guar gum, hydroxypropyl guar gum, soluble starch, cationic celluloses, cationic guars and the like and synthetic polymeric materials such as carboxyvinyl polymers, polyvinylpyrrolidone, polyvinyl alcohol polyacrylic acid polymers, polymethacrylic acid polymers, polyvinyl acetate polymers, polyvinyl chloride polymers, polyvinylidene chloride polymers and the like. Mixtures of the above compounds are contemplated.
  • [0109]
    Further exemplary water gelling agents include the acrylic acid/ethyl acrylate copolymers and the carboxyvinyl polymers sold, for example, by the B.F. Goodrich Company under the trademark of Carbopol Registered TM resins. These resins consist essentially of a colloidal water-soluble polyalkenyl polyether crosslinked polymer of acrylic acid crosslinked with from 0.75% to 2% of a crosslinking agent such as polyallyl sucrose or polyallyl pentaerythritol. Examples include Carbopol 934, Carbopol 940, Carbopol 950, Carbopol 980, Carbopol 951 and Carbopol 981. Carbopol 934 is a water-soluble polymer of acrylic acid crosslinked with about 1% of a polyallyl ether of sucrose having an average of about 5.8 allyl groups for each sucrose molecule.
  • [0110]
    The gelling agent is present in an amount in the range of about 0.1% to about 5.0 wt % of the foamable composition. In one or more embodiments, it is typically less than 1 wt % of the foamable composition.
  • [0111]
    “Alcohol Free”
  • [0112]
    Unlike the composition disclosed in U.S. Pat. No. 6,126,920, which contains a 40-90 wt % aliphatic alcohol, the composition of the present invention does not contain such amount alcohols. For the purpose of the present application, the term “alcohol free” shall mean that the composition contains no more than an incidental amount of an aliphatic alcohol, e.g. less than about 7.5% of any aliphatic alcohol, having one to six carbon atoms in their carbon backbone, or no more than 7.5% of any mixture of such aliphatic alcohols. Alcohols at these low levels are not considered to have a negative effect on skin or mucous membranes. In one or more embodiments, the foamable compositions do not contain any alcohol.
  • [0113]
    Optional Ingredients
  • [0114]
    The pharmaceutical or cosmetic foam carrier of the present invention may further optionally comprise a variety of pharmaceutical or cosmetic ingredients, which are added in order to fine-tune the consistency of the formulation, protect the formulation components from degradation and oxidation and bestow their cosmetic acceptability. Such excipients, may be selected, for example, from the group consisting of diglycerides, triglycerides, stabilizing agents, antioxidants, humectants, flavoring, colorant and odorant agents and other formulation components, used in the art of pharmaceutical and cosmetic formulary. A pharmaceutical or cosmetic composition manufactured using the foam carrier according to the present invention is very easy to use. When applied onto the afflicted body surface of humans or animals, it is in a foam state, allowing free application without spillage. Upon further application of a mechanical force, e.g., by rubbing the composition onto the body surface, it freely spreads on the surface and is rapidly absorbed.
  • [0115]
    Propellant Aerosol
  • [0116]
    Aerosol propellants are used to generate and administer the foamable composition as a foam. The total composition including propellant, foamable compositions and optional ingredients is referred to as the foamable carrier. The propellant makes up about 5-25 wt % of the foamable carrier. Examples of suitable propellants include volatile hydrocarbons such as butane, propane, isobutane or mixtures thereof, and fluorocarbon gases.
  • [0117]
    Composition and Foam Physical Characteristics
  • [0118]
    1. Composition Flow Properties:
  • [0119]
    It is important to have a composition, including water, hydrophobic solvents, formulation excipients and propellant, in a stable emulsion, which ascertain acceptable shelf-life of the product.
  • [0120]
    Yet, another crucial property is that said composition has to be free flowing, since otherwise, it cannot flow through the dip-tube of the aerosol container and create acceptable foam. It has been noted that in the context of the composition of the present invention, compositions comprising semi-solid hydrophobic solvents, e.g., white petrolatum, are excessively viscous and demonstrate poor flowability.
  • [0121]
    The combination of a surface active agent, foaming adjuvant and water gelling agent according to one or more embodiments of the invention provides a low specific gravity foam having superior flow properties and sheer breakability (among other attributes). According to one or more embodiments of the present invention, the total amount of surface active agent, foaming adjuvant and water gelling agent, in combination does not exceed 8% (w/w) of foamable composition. In other embodiments, the combined amounts of surface active agent, foaming adjuvant and water gelling agent is less than 5% (w/w) of foamable composition. The low solids content improves the flow properties of the foam, reduces unpleasant skin residue and reduces the cost of manufacture. As is demonstrated herein, the foam quality and foam breakability is excellent, despite the low levels of these components in the foam.
  • [0122]
    2. Foam Properties:
  • [0123]
    The following scale for foam quality is used to evaluate foams.
  • [0124]
    E (excellent): very rich and creamy in appearance, does not show any bubble structure or shows a very fine (small) bubble structure.
  • [0125]
    G (good): rich and creamy in appearance, very small bubble size, “dulls” more rapidly than an excellent foam.
  • [0126]
    FG (fairly good): a moderate amount of creaminess noticeable, bubble structure is noticeable.
  • [0127]
    F (fair): very little creaminess noticeable, larger bubble structure than a “fairly good” foam.
  • [0128]
    P (poor): no creaminess noticeable, large bubble structure.
  • [0129]
    VP (very poor): dry foam, large very dull bubbles, difficult to spread on the skin.
  • [0130]
    Foams, adequate for topical administration according to the present invention have to be of quality grade E or G, upon release from the aerosol container. Smaller bubbles mean more stable foam, which does not collapse spontaneously immediately upon discharge from the container. The finer foam structure looks and feels smoother, thus increasing its usability and appeal.
  • [0131]
    A crucial aspect of foam properties, according to the present invention is breakability. Sheer-force breakability of the foam, as attained by the composition of the present invention is clearly advantageous to thermally-induced breakability, present, for example in U.S. Pat. No. 6,126,920, and the respective Olux and Luxiq products, as demonstrated by the fact that according to the use instructions of Olux and Luxiq, the foam cannot be applied on the hand and afterwards delivered to the afflicted area, since it immediately collapses upon exposure to skin temperature.
  • [0132]
    Yet, another important property is specific gravity of the foam, as measured upon release from the aerosol can. Typically, foams according to the present invention have specific gravity of less than 0.1 g/mL and more preferably, less than 0.05 g/mL.
  • [0133]
    Fields of Pharmaceutical Applications
  • [0134]
    By including an appropriate therapeutic agent in the foamable carrier, the foam composition of the present invention is useful in the therapy of a variety of dermatological disorders (also termed “dermatoses”), including, in a non-limiting exemplary manner:
  • [0135]
    Dermatitis
      • Contact Dermatitis
      • Atopic Dermatitis
      • Seborrheic Dermatitis
      • Nummular Dermatitis
      • Chronic Dermatitis Of The Hands And Feet
      • Generalized Exfoliative Dermatitis
      • Stasis Dermatitis
      • Lichen Simplex Chronicus
  • [0144]
    Bacterial Infections
      • Cellulitis
      • Acute Lymphangitis
      • Lymphadenitis
      • Erysipelas
      • Cutaneous Abscesses
      • Necrotizing Subcutaneous Infections
      • Staphylococcal Scalded Skin Syndrome
      • Folliculitis
      • Furuncles
      • Hidradenitis Suppurativa
      • Carbuncles
      • Paronychial Infections
      • Erythrasma
  • [0158]
    Fungal Infections
      • Dermatophyte Infections
      • Yeast Infections
  • [0161]
    Parasitic Infections
      • Scabies
      • Pediculosis
      • Creeping Eruption
  • [0165]
    Viral Infections
  • [0166]
    Disorders of Hair Follicles and Sebaceous Glands
      • Acne
      • Rosacea
      • Perioral Dermatitis
      • Hypertrichosis (Hirsutism)
      • Alopecia, including male pattern baldness, alopecia greata, alopecia universalis and alopecia totalis
      • Pseudofolliculitis Barbae
      • Keratinous Cyst
  • [0174]
    Scaling Papular Diseases
      • Psoriasis
      • Pityriasis Rosea
      • Lichen Planus
      • Pityriasis Rubra Pilaris
  • [0179]
    Benign Tumors
      • Moles
      • Dysplastic Nevi
      • Skin Tags
      • Lipomas
      • Angiomas
      • Pyogenic Granuloma
      • Seborrheic Keratoses
      • Dermatofibroma
      • Keratoacanthoma
      • Keloid
  • [0190]
    Malignant Tumors
      • Basal Cell Carcinoma
      • Squamous Cell Carcinoma
      • Malignant Melanoma
      • Paget's Disease Of The Nipples
      • Kaposi's Sarcoma
  • [0196]
    Reactions To Sunlight
      • Sunburn
      • Chronic Effects of Sunlight
      • Photosensitivity
  • [0200]
    Bullous Diseases
      • Pemphigus
      • Bullous Pemphigoid
      • Dermatitis Herpetiformis
      • Linear Immunoglobulin A Disease
  • [0205]
    Pigmentation Disorders
      • Hypopigmentation
        • Vitiligo
        • Albinism
        • Postinflammatory hypopigmentation
      • Hyperpigmentation
        • Melasma (chloasma)
        • Drug-induced hyperpigmentation
        • Postinflammatory hyperpigmentation
  • [0214]
    Disorders of Cornification
      • Ichthyosis
      • Keratosis Pilaris
      • Calluses And Corns
      • Actinic keratosis
  • [0219]
    Pressure Sores
  • [0220]
    Disorders of Sweating
  • [0221]
    Inflammatory reactions
      • Drug Eruptions
      • Toxic Epidermal Necrolysis
      • Erythema Multiforme
      • Erythema Nodosum
      • Granuloma Annulare
  • [0227]
    In one or more embodiments of the present invention, the foam composition of the present invention is useful in the therapy of non-dermatological disorders, which respond to transdermal delivery of an active agent. By way of example, such disorders include localized pain in general, as well as joint pain, muscle pain, back pain, rheumatic pain, arthritis, ostheoarthritis and acute soft tissue injuries and sports injuries. Other disorders of this class include conditions, which respond to hormone therapy, such as hormone replacement therapy, transdermal nicotine administration, and other respective disorders, known in the art of drug delivery. The foam composition of the present invention is also useful in the delivery of local anesthetic agents.
  • [0228]
    Active Pharmaceutical Agents (Drugs)
  • [0229]
    The active pharmaceutical agents, also referred to as “drug(s)”, may consist of a single drug or a combination of drugs that can be dissolved in the water phase or the hydrophobic phase of the carrier composition. Examples of such drugs are antibiotic, antibacterial, antifungal, antiviral, antiinflammatory, anesthetic, analgesic, antiallergic, corticosteroid, retinoid and antiproliferative medications and mixtures thereof at any proportion. The concentration of drugs may be adopted to exert a therapeutic effect on a disease when applied to an afflicted area.
  • [0230]
    Antibacterial Agents
  • [0231]
    One important class of drugs comprises antibacterial agents. It is well known that bacterial infections are involved in a variety of superficial disorders of the skin, eye, mucosal membrane, oral cavity, vagina and rectum. The antibacterial drug can be active against gram positive and gram-negative bacteria, protozoa, aerobic bacteria and unaerobic ones.
  • [0232]
    By way of example, the antibacterial drugs can be selected from the group of chloramphenicol, tetracyclines, synthetic and semi-synthesic penicillins, beta-lactames, quinolones, fluoroquinolnes, macrolide antibiotics, metronidaziole and its derivatives and analogs, dicarboxylic acids, such as azelaic acid, slicylates, peptide antibiotics, cyclosporines and any combination thereof at a therapeutically effective concentration. Another group of antibacterial agents which is non-specific, comprises strong oxidants and free radical liberating compounds, such as hydrogen peroxide, bleaching agents (e.g., sodium, calcium or magnesium hypochloride and the like) iodine, chlorohexidine and benzoyl peroxide.
  • [0233]
    Antibacterial compositions according to the present invention may be used to treat infections of the skin. An example of a very common skin infection is acne, which involve infestation of the sebaceous gland with p. acnes, as well staphylococus aurus and pseudomonas. Various antibacterial agents have been utilized to treat acne, however, their efficacy is limited due to their low penetration into the hydrophobic environment of the skin layers and sebaceous glands. The composition of the present invention, comprising a hydrophobic component, would facilitate an enhanced rate of penetration. Furthermore, the intrinsic antibacterial and antiinflammatory effects of the foam adjuvant agents, i.e., fatty alcohols and acids, provides a combined effect that should result in a better therapeutic response to treatment.
  • [0234]
    The composition of the present invention is particularly useful and beneficial in the prevention and treatment of secondary infections, accompanying skin-structure damage, such as in cuts, wounds, burns and ulcers. In all such cases, the present formulation is easy to use, being in foam state when applied and becoming liquid instantly upon rubbing onto the skin.
  • [0235]
    While being useful in the prevention and treatment of infections, the antibacterial foam of the present invention is also applicable for decontaminating areas, afflicted with bacterial warfare organisms, such as anthrax and smallpox.
  • [0236]
    The same advantage is expected when the composition of the present invention is topically applied to mucosal membranes, the oral cavity, the vagina and the rectum.
  • [0237]
    Anti-Fungal Agents
  • [0238]
    Fungal infections are another object of treatment using the composition of the present invention. Superfidal fungal infection of the skin is one of the commonest skin diseases seen in general practice. Dermatophytosis is probably the most common superficial fungal infection of the skin. It is caused by a group of fungi, which are capable of metabolizing the keratin of human epidermis, nails or hair. There are 3 genera of dermatophytes causing dermatophytosis, i.e, microsporum, trichophyton and epidermophyton.
  • [0239]
    Candidiasis is an infection caused by the yeast like fungus candida albicans or occasionally other species of candida. Clinical syndromes of candidiasis include: (a) oral candidiasis (oral thrush); (b) candidiasis of the skin and genital mucous membrane; and (c) candida paronychia, which inflicts the nail.
  • [0240]
    The pharmaceutical composition may comprise an antifungal drug, which is active against dermatophytes and candida, selected from the group of, but not limited to azoles, diazoles, triazoles, miconazole, fluconazole, ketoconazole, clotrimazole, itraconazole griseofulvin, ciclopirox, amorolfine, terbinafine, Amphotericin B, potassium iodide, flucytosine (5FC) and any combination thereof at a therapeutically effective concentration.
  • [0241]
    It is useful, for example for the treatment of tinea corporis, tinea pedis, tinea rubrum, tinea unguium, tinea cruris, tinea barbae and tinea versicolor, as well as yeast Infections, such as candidiasis, and candidal vaginitis
  • [0242]
    Anti-Viral Agents
  • [0243]
    The composition of the present invention is particularly beneficial in the case of viral infections. Cold sores are caused by the herpes simplex Type 1 virus and are sometimes referred to as facial herpes. Mollusca are small viral growths that appear singly or in groups on the face, trunk, lower abdomen, pelvis, inner thighs, or penis. Shingles (herpes zoster), which usually only occurs once in a lifetime, appears as a rash (clusters of blisters with a red base). It is caused by the same virus responsible for chickenpox. Warts are a common, benign skin tumor caused by viral infection.
  • [0244]
    Viral infections are currently treated with various antiviral agents, as summarized in the following table:
  • [0000]
    Chemical
    Drug Viruses Type
    Vidarabine Herpesviruses Nucleoside
    analogue
    Acyclovir Herpes simplex Nucleoside
    (HSV) analogue
    Gancyclovir Cytomegalovirus Nucleoside
    (CMV) analogue
    Nucleoside-analog reverse transcriptase Retroviruses Nucleoside
    inhibitors (NRTI): AZT (Zidovudine), (HIV) analogue
    ddl (Didanosine), ddC (Zalcitabine),
    d4T (Stavudine), 3TC (Lamivudine)
    Non-nucleoside reverse transcriptase Retroviruses Nucleoside
    inhibitors (NNRTI): Nevirapine, (HIV) analogue
    Delavirdine
    Protease Inhibitors: Saquinavir, HIV Peptide
    Ritonavir, Indinavir, Nelfinavir analogue
    Ribavirin Broad spectrum: Triazole
    HCV, HSV, carboxamide
    measles, mumps,
    Lassa fever
    Amantadine/Rimantadine Influenza A Tricyclic
    strains amine
    Interferons Hepatitis B Protein
    and C
  • [0245]
    Any of the above antiviral drugs, in a therapeutically effective concentration, can be incorporated in the foam composition of the present invention. The composition of the present invention, which comprises a hydrophobic solvent, would facilitate an enhanced rate of penetration and better topical distribution of any of the above listed antiviral drugs. Furthermore, the intrinsic antiviral effects of the foam adjuvant agents, i.e., fatty alcohols and acids, provides a combined effect that should result in a better therapeutic response to treatment.
  • [0246]
    Antiinflammatory or Antiallergic Agents
  • [0247]
    Yet, according to another embodiment according to the present invention the drug is an antiinflammatory or antiallergic agent. Antiinflammatory or antiallergic agent can be selected from the group of corticosteroids, non-steroidal antiinflammatory drugs (NSAIDs), anti-histamines, immunosuppressants and any combination thereof at a therapeutically effective concentration.
  • [0248]
    The following table provides a summary of currently available corticosteroid agent and their typical therapeutically effective concentration.
  • [0000]
    Potency Compound Formulation
    Very high Clobetasol proprionate Cream or ointment 0.05%
    Halobetasol proprionate Cream or ointment 0.05%
    High Betamethasone diproprionate Cream or ointment 0.05%
    Betamethasone valerate Ointment 0.1%
    Fluocinolone acetonide Cream 0.02%
    Halcinonide Cream or ointment 0.1%
    Medium Betamethasone valerate Cream 0.1%
    Fluocinolone acetonide Cream or ointment 0.020%
    Hydrocortisone valerate Cream or ointment 0.2%
    Triamcinolone acetonide Cream, ointment, or lotion
    0.1% or 0.020%
    Low Hydrocortisone Cream, ointment, or lotion
    1.0% or 2.5%
  • [0249]
    The concentrations of corticosteroid drugs, as presented in the above table are provided herein only as example, and any therapeutically effective concentration of such corticosteroids can be incorporated in the composition of the present invention.
  • [0250]
    Since all corticosteroid drugs are typically hydrophobic, the carrier of the present invention, comprising a hydrophobic solvent, is most suitable as a vehicle to facilitate better topical distribution and an enhanced rate of penetration of any of the above listed drugs. Furthermore, the intrinsic antiviral, antibacterial and antiinflammatory effects of the foam adjuvant agents, i.e., fatty alcohols and acids, provides a combined effect that should result in a better therapeutic response to treatment.
  • [0251]
    Psoriasis is a very common chronic skin disease, which may be the target of treatment using the composition of the present invention. It is marked by periodic flare-ups of sharply defined red patches covered by a silvery, flaky surface.
  • [0252]
    Corticosteroid ointments, greasy preparations containing little or no water, are commonly used for treating psoriasis. Their main disadvantage is in their sticky feeling, which remains so long after treatment is over. By contrast, the foam of the present invention, while comprising considerable concentration of an oil (hydrophobic solvent), spreads very easily throughout the afflicted area and absorbs into the skin without leaving any untoward sensation or look. Examples of other inflammatory disorders, which can be treated by the composition of the present invention, wherein the drug is a steroid are atopic dermatitis, seborrhea, seborrheic dermatitis of the face and trunk, seborrheic blepharitis, contact dermatitis, stasis dermatitis (gravitational eczema; varicose eczema), exfoliative dermatitis (erythroderma), lichen simplex chronicus, pityriasis rosea and pemphigus.
  • [0253]
    Topical antihistaminic preparations currently available include 1% and 2% diphenhydramine (Benadryl® and Caladryl®), 5% doxepin (Zonalon®) cream, phrilamine maleate, chlorpheniramine and tripelennamine, phenothiazines, promethazine hydrochloride (Phenergan®) and dimethindene maleate. These drugs, as well as additional antihistamins can also be incorporated in the composition of the present invention.
  • [0254]
    It is pointed out that polyunsaturated fatty acids, containing omega-3 and omega-6 fatty acids (e.g., linoleic and linolenic acid, gamma-linoleic acid (GLA), eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) are beneficial in the treatment of psoriasis and other skin inflammation conditions.
  • [0255]
    A second class of anti-inflammatory agents, which is useful in the foam of the present invention, includes the nonsteroidal anti-inflammatory agents (NSAIDs). The variety of compounds encompassed by this group is well-known to those skilled in the art. Specific non-steroidal anti-inflammatory agents useful in the composition invention include, but are not limited to:
  • [0256]
    1) Oxicams, such as piroxicam, isoxicam, tenoxicam, sudoxicam;
  • [0257]
    2) Salicylates, such as salicylic acid, ethyl salicylate, methyl salycilate, aspirin, disalcid, benorylate, trilisate, safapryn, solprin, diflunisal, and fendosal;
  • [0258]
    3) Acetic acid derivatives, such as diclofenac, fenclofenac, indomethacin, sulindac, tolmetin, isoxepac, furofenac, tiopinac, zidometacin, acematacin, fentiazac, zomepirac, clindanac, oxepinac, felbinac, and ketorolac;
  • [0259]
    4) Fenamates, such as mefenamic, meclofenamic, flufenamic, niflumic, and tolfenamic acids;
  • [0260]
    5) Propionic acid derivatives, such as ibuprofen, naproxen, benoxaprofen, flurbiprofen, ketoprofen, fenoprofen, fenbufen, indopropfen, pirprofen, carprofen, oxaprozin, pranoprofen, miroprofen, tioxaprofen, suprofen, alminoprofen, and tiaprofenic; and
  • [0261]
    6) Pyrazoles, such as phenylbutazone, oxyphenbutazone, feprazone, azapropazone, and trimethazone.
  • [0262]
    Any further steroidal and nonsteroidal compounds, having the capacity to prevent, alleviate the symptoms of, treat or cure inflammation processes, are generally included, as possible anti-inflammatory agents, according to the present invention.
  • [0263]
    The pharmaceutical composition of the present invention may also comprise an antiinflammatory or antiallergic agent, wherein said agent reduces the occurrence of pro-inflammatory cytokines or inhibits the effect of pro-inflammatory cytokines.
  • [0264]
    Mixtures of such anti-inflammatory agents may also be employed, as well as the dermatologically acceptable salts, esters, amides, prodrugs and derivatives of these agents.
  • [0265]
    Topical application of a foam, comprising a safe and effective dose of an NSAID can be useful in the prevention and/or alleviation of the symptoms of rheumatoid arthritis, osteoarthritis and pain. Topical NSAIDs, incorporated in the foam of the present invention can be also used in the treatment of dermatological disorders, such as acne, rosacea, hair growth disorders, actinic keratosis and certain skin cancer conditions.
  • [0266]
    Topical Anesthetics
  • [0267]
    The compositions of the present invention may contain a safe and effective amount of a topical anesthetic. Examples of topical anesthetic drugs include benzocaine, lidocaine, bupivacaine, chlorprocaine, dibucaine, etidocaine, mepivacaine, tetracaine, dyclonine, hexylcaine, procaine, cocaine, ketamine, pramoxine, phenol, and pharmaceutically acceptable salts thereof. Mixtures of such anesthetic agents may be synergistically beneficial.
  • [0268]
    Keratolytically Active Agents
  • [0269]
    The term “keratolytically active agent” is used herein to mean a compound which loosens and removes the stratum corneum of the skin, or alters the structure of the keratin layers of skin.
  • [0270]
    Keratolytically active agents are used in the treatment of many dermatological disorders, which involve dry skin, hyperkeratiinization (such as prsoriasis), skin itching (such as xerosis), acne and rosacea.
  • [0271]
    Suitable keratolytically active agent include phenol and substituted phenolic compounds. Such compounds are known to dissolve and loosen the intracellular matrix of the hyperkeratinized tissue. As such, they are used in the treatment of dermatological disorders. Dihydroxy benzene and derivatives thereof have been recognized as potent keratolytic agents. Resorcinol (m-dihydroxybenzene) and derivatives thereof are used in anti-acne preparations. Hydroquinone (p-dihydroxybenzene), besides its anti-pigmentation properties, is also keratolytic. These compounds also exhibit antiseptic properties. Cresols also possess bactericidal and keratolytic properties.
  • [0272]
    Vitamin A and its derivatives, such as retinoic acid, isoretinoic acid, retinol and retinal are another preferred class of keratolytically active agents.
  • [0273]
    Another group of keratolytically active agents include alpha-hydroxy acids, such as lactic acid and glycolic acid and their respective salts and derivatives; and beta-hydroxy acids, such as Salicylic acid (o-hydroxybenzoic acid) and its salts and pharmaceutically acceptable derivatives, which typically possess anti-inflammatory, as well as keratolytic, activity.
  • [0274]
    Yet, another class of preferred keratolytically active agents includes urea and its derivatives.
  • [0275]
    Retinoids
  • [0276]
    Another preferred group of active agents comprise retinol, retinal, all trans retinoic acid and derivatives, isomers and analogs thereof, collectively termed “retinoids”. Etretinate, actiretin, isotretinoin, adapalene and tazarotene are further examples of said retinoid isomers and analogs. Compositions according to the present invention, which contain retinoids as the active drug, can be used for the treatment of acne, seborrhea, various dermatoses, inflammation of the skin, mucosal membranes, vagina and the rectum, psoriasis, actinic keratosis and skin cancers, by application onto the affected area.
  • [0277]
    Insecticide and Insect Repellents Agents
  • [0278]
    Insects, such as mosquitoes, biting flies, mites, gnats, fleas, chiggers, punkies, sand flies, lice and ticks can be annoying and sometimes pose a serious risk to human and animal health. In certain areas of the United States, mosquitoes can transmit diseases like equine and St. Louis encephalitis. Biting flies can inflict a painful bite that can persist for days, swell, and become infected. Ticks can transmit serious diseases like Lyme disease and Rocky Mountain spotted fever.
  • [0279]
    There are several types of insect repellents to use when protecting people and animals from flying or biting insects, spiders, ticks and mites. By way of example, these may include DEET (N,N-diethyl-m-toluamide), dimethyl phthalate, piperonyl butoxide and permethrin. Insect repelling terpenoids, have been reported by Hwang, et al, J. Chem. Ecol., 11, 1297 (1985); and Ruledge, J. Am. Mosquito Control Assoc. 4, 414 (1988).
  • [0280]
    A particularly preferred group of insect repellents includes the terpenoid compounds, described in U.S. Pat. No. 5,411,992, including:
  • [0281]
    (1) Terpenoid-alcohol or terpene-ols are terpenoids which have at least one hydroxyl group. Examples of terpene-ols include: C10H16O compounds, perillyl alcohol, carveol, myrtenol, and cis-verbenol; C10H18O compounds, myrtanol, iso-pinocampheol, dihydrocarveol, isopulegol, terpineol, terpinen-4-ol, nerol, geraniol, and linalool, and C10H20O compounds, menthol, beta-citronellol, and dihydro-myrcenol.
  • [0282]
    (2) Terpenoid-esters are terpenoids, which have at least one ester group which is the product of the bonding of the hydroxyl group of a terpene-ol with an aliphatic carboxylic acid that can contain functional groups such as the hydroxyl or amine on the aliphatic chain. Examples of suitable aliphatic carboxylic acids include acetic acid, propionic acid, lactic acid, and various amino acids. Examples of terpenoid-esters include: carvyl acetate, carvyl propionate, and menthyl lactate.
  • [0283]
    (3) Essential oils which contain terpenoids and perfumes which contain terpenoids. Non-limiting examples of essential oils which have high content of terpene-ols and esters include bergamot (62% terpenoids); sage (>50% terpenoids); styrax (>50% terpenoids); peppermint (>50% terpenoids); and pine Siberian (75% terpenoids %). Terpenes, aldehydes and ketones vary in their usefulness but as a general group have potential as insect-repellent.
  • [0284]
    The foam of the present invention is particularly suitable for the effective uniform spreading of an insect repellent agent onto large areas of the skin of humans and animals. The hydrophobic solvent present in the foam composition helps retain the insect repellent on the skin surface for an extended period of time.
  • [0285]
    Yet, in a further embodiment, the foam is suitable for delivery of insect-killing agents (insecticides) to an afflicted external surface area of humans and animals. Thus, the pharmaceutical or cosmetic composition may comprise an insecticide, known in the art of parasitology. By way of example, such insecticide can be selected from the group of permethrin, hexachlorobenzene, carbamate, naturally occurring pyrethroids, permethrin, allethrin, malathion, piperonyl butoxide and any combination thereof at a therapeutically effective concentration. Its application is very convenient and it spreads easily, even over hairy areas. The hydrophobic solvent present in the foam composition helps retain the insecticide on the treated area for an extended period of time. Furthermore, the presence of a hydrophobic solvent in the foam eases mechanical removal of lice and nits with a comb.
  • [0286]
    Anti Cancer Drugs
  • [0287]
    Anti cancer drugs can also be used according to the present invention as the drug of choice from skin malignant tumors, such as basal cell carcinoma, squamous sell carcinoma, melanoma and Kaposi's sarcoma, as well as the pre-cancerous condition actinic keratosis. In certain cases, topical cytotoxic and antiproliferative drugs are used to treat or prevent such cancers, including 5-fluorouracil, also called 5-FU. 5-FU, as well as any other anti-cancer agents, know in the art of cancer medicine, can be incorporated in the foam at therapeutically effective levels.
  • [0288]
    A preferred family of anticancer drugs, suitable for usage in the foam of the present formulation comprises antiestrogens, such as tamoxifen. Tamoxifen blocks the effects of the hormone estrogen in the body. It is used to prevent or delay the return of breast cancer or to control its spread.
  • [0289]
    Photodynamic Therapy Agents
  • [0290]
    The foam composition of the present invention is also useful to deliver photo-sensitizing agents, known in the art of photodynamic therapy. By way of example, such photosensitizers can be selected from the group comprising modified porphyrins, chlorins, bacteriochlorins, phthalocyanines, naphthalocyanines, pheophorbides, purpurins, m-THPC, mono-L-aspartyl chlorin e6, bacteriochlorins, phthalocyanines, benzoporphyrin derivatives, as well as photosensitiser precursors, such as aminolevulinic acid (ALA).
  • [0291]
    Active Agents for Burns, Wounds, Cuts and Ulcers
  • [0292]
    The treatment of burns, wounds, cuts and ulcers, using the composition of the present invention is particularly advantageous. The foam can include both anti-infective agents (against bacteria, fungi and/or viruses), antiinflammatory agents (steroidal and/or NSAIDs) and pain relieving components. Upon application, the foam spreads easily, covering the surface of the affected area, and without causing pain.
  • [0293]
    Skin Care Active Agents
  • [0294]
    The foam of the present invention is useful and advantageous for skin care and cosmetic care. The combination of oil and water, having moisture-retaining properties, in a spreadable foam form, can be used to substitute currently used cosmetic skin care creams, lotions, gels, etc. The cosmetic foam compositions of the present invention are suitable for the further application as “cosmeceutical” preparation (cosmetic products with therapeutic benefit), to treat “cosmetic” skin disorders, such as aging skin, wrinkles, hyperpigmentation (melasma, chloasma, freckles, etc.), scaly skin and other skin undesirable properties.
  • [0295]
    The CTFA Cosmetic Ingredient Handbook describes a wide variety of nonlimiting cosmetic and pharmaceutical ingredients commonly used in the skin care industry, which are suitable for use in the compositions of the present invention. Examples of these ingredient classes include: abrasives, absorbents, aesthetic components such as fragrances, pigments, colorings/colorants, essential oils, astringents, etc. (e.g., clove oil, menthol, camphor, eucalyptus oil, eugenol, menthyl lactate, witch hazel distillate), anti-acne agents, antimicrobial agents (e.g., iodopropyl butylcarbamate), antioxidants, binders, biological additives, buffering agents, bulking agents, chelating agents, chemical additives, colorants, cosmetic astringents, cosmetic biocides, denaturants, drug astringents, external analgesics, film formers or materials, e.g., polymers, for aiding the film-forming properties and substantivity of the composition (e.g., copolymer of eicosene and vinyl pyrrolidone), opacifying agents, pH adjusters, propellants, reducing agents, sequestrants, skin bleaching and lightening agents (e.g., hydroquinone, kojic acid, ascorbic acid, magnesium ascorbyl phosphate, ascorbyl glucosamine), skin-conditioning agents (e.g., humectants, including miscellaneous and occlusive), skin soothing and/or healing agents (e.g., panthenol and derivatives (e.g., ethyl panthenol), aloe vera, pantothenic acid and its derivatives, allantoin, bisabolol, and dipotassium glycyrrhizinate), skin treating agents, thickeners, and vitamins and derivatives thereof.
  • [0296]
    In any embodiment of the present invention, however, the active agents useful herein can be categorized by the benefit they provide or by their postulated mode of action. It is to be understood that the active agents useful herein can in some instances provide more than one benefit or operate via more than one mode of action. Therefore, classifications herein are made for the sake of convenience and are not intended to limit the active to that particular application or applications listed.
  • [0297]
    Anti-Acne Active Agents
  • [0298]
    The compositions of the present invention may contain a safe and effective amount of one or more pharmaceutically or cosmetically acceptable anti-acne active agents. Examples of useful anti-acne actives include resorcinol, sulfur, salicylic acid and salicylates, alpha-hydroxy acids, nonsteroidal anti-inflammatory agents, benzoyl peroxide, retinoic acid, isoretinoic acid and other retinoid compounds, adapalene, tazarotene, azelaic acid and azelaic acid derivatives, antibiotic agents, such as erythromycin and clyndamycin, zinc salts and complexes, and combinations thereof, in a therapeutically effective concentration.
  • [0299]
    Anti-Wrinkle Active Agents/Anti-Atrophy Active Agents and Agents to Treat Dry and Scaly Skin (Xerosis and Ichthyosis)
  • [0300]
    The compositions of the present invention may further contain a safe and effective amount of one or more anti-wrinkle actives or anti-atrophy actives, which can be easily delivered by spreading a foam onto the skin. Exemplary anti-wrinkle/anti-atrophy active agents suitable for use in the compositions of the present invention include sulfur-containing D and L amino acids and their derivatives and salts, particularly the N-acetyl derivatives; thiols; hydroxy acids (e.g., alpha-hydroxy acids such as lactic acid and glycolic acid and their derivatives and salts; or beta-hydroxy acids such as salicylic acid and salicylic acid salts and derivatives), urea, hyaluronic acid, phytic acid, lipoic acid; lysophosphatidic acid, skin peel agents (e.g., phenol, resorcinol and the like), vitamin B3 compounds (e.g., niacinamide, nicotinic acid and nicotinic acid salts and esters, including non-vasodilating esters of nicotinic acid (such as tocopheryl nicotinate), nicotinyl amino acids, nicotinyl alcohol esters of carboxylic acids, nicotinic acid N-oxide and niacinamide N-oxide), vitamin B5 and retinoids (e.g., retinol, retinal, retinoic acid, retinyl acetate, retinyl palmitate, retinyl ascorbate). In the case of dry, scaly skin (xerosis) and ichthyosis such agents can alleviate the symptoms by temporary relief of itching associated with these conditions.
  • [0301]
    Anti-Oxidants/Radical Scavengers
  • [0302]
    A safe and effective amount of an anti-oxidant/radical scavenger may be added to the compositions of the subject invention, preferably from about 0.1% to about 10% (w/w), more preferably from about 1% to about 5% (w/w), of the composition.
  • [0303]
    Anti-oxidants/radical scavengers such as ascorbic acid (vitamin C) and its salts, ascorbyl esters of fatty acids, ascorbic acid derivatives (e.g., magnesium ascorbyl phosphate, sodium ascorbyl phosphate, ascorbyl sorbate), tocopherol (vitamin E), tocopherol sorbate, tocopherol acetate, other esters of tocopherol, butylated hydroxy benzoic acids and their salts, 6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid (commercially available under the tradename Trolox.sup.R), gallic acid and its alkyl esters, especially propyl gallate, uric acid and its salts and alkyl esters, sorbic acid and its salts, lipoic acid, amines (e.g., N,N-diethylhydroxylamine, amino-guanidine), sulfhydryl compounds (e.g., glutathione), dihydroxy fumaric acid and its salts, lycine pidolate, arginine pilolate, nordihydroguaiaretic acid, bioflavonoids, curcumin, lysine, methionine, proline, superoxide dismutase, silymarin, tea extracts, grape skin/seed extracts, melanin, and rosemary extracts may be used.
  • [0304]
    The foam of the present invention is suitable for delivering skin protecting and revitalizing anti-oxidants/radical scavengers. It is further pointed out that polyunsaturated fatty acids, containing omega-3 and omega-6 fatty acids (e.g., linoleic and linolenic acid, gamma-linoleic acid (GLA), eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) are beneficial in the treatment of psoriasis and other skin inflammation conditions. Likewise, emollients and silicone oils exert moisture-retaining and skin protective effects on the skin. Thus in a preferred embodiment, a skin protective foam is provided, wherein the hydrophobic solvent comprises in full or in part, a solvent, selected from the group of emollients, silicone oil and oils, rich in unsaturated fatty acids, thus, affording a synergistic therapeutic effect of the anti-oxidants/radical scavenger agent and the vehicle components.
  • [0305]
    Self-Tanning Active Agents
  • [0306]
    The foam of the present invention is particularly suitable for the uniform delivery of a tanning active agent onto large areas of the skin. It is preferable that the compositions contain from about 0.1% to about 20%, more preferably from about 2% to about 7%, and still more preferably from about 3% to about 6%, of the composition, of dihydroxyacetone, or any other compound, know in the art as an artificial tanning active agent.
  • [0307]
    Skin Lightening and Whitening Agents
  • [0308]
    The foam of the present invention is particularly suitable for the uniform delivery of a skin lightening agent. When used, the compositions preferably contain from about 0.1% to about 10%, more preferably from about 0.2% to about 5%, of the composition, of a skin-lightening agent. Suitable skin lightening or whitening agents include those known in the art, including hydroquinone, azelaic acid and other related dicarboxylic acids, and salts and derivatives thereof, retinoids, kojic acid, arbutin, nicotinic acid and its precursors, salts and derivatives, arbutin, ascorbic acid and salts and derivatives thereof (e.g., magnesium ascorbyl phosphate or sodium ascorbyl phosphate), and herbal extracts (e.g., licorice extract, mulberry extract, placental extract).
  • [0309]
    In one or more embodiments of the present invention, the foam composition comprises a combination of a skin whitening agent and a sunscreen agent.
  • [0310]
    In one or more embodiments of the present invention, the foam composition comprises a combination of a skin whitening agent and an inorganic sunscreen agent. When inorganic sunscreen agents, e.g. TiO2, are rubbed onto the skin, they leave a white coating, which provides an immediate (although transient) whitening effect, which is highly desirable by the consumer, who wishes to see instant change in his/her appearance. The whitening agent, in combination with the inorganic sunscreen agent in the foam carrier can be easily and uniformly distributed on the skin surface, thereby affording an even instant whitening effect, unlike creams that are difficult to spread evenly on skin areas.
  • [0311]
    Sunscreens
  • [0312]
    Exposure to ultraviolet light can result in excessive scaling and texture changes of the stratum corneum. The foam of the present invention is advantageous for the delivery of sunscreen agents. Its application is very convenient and it spreads easily over large skin areas. The presence of a hydrophobic solvent in the foam ensures long lasting effect, even while bathing.
  • [0313]
    As used herein, “sunscreen active” or “sunscreen agent” includes both sunscreen agents and physical sunblocks. Suitable sunscreen actives may be organic or inorganic.
  • [0314]
    Inorganic sunscreens useful herein include the following metallic oxides; titanium dioxide having an average primary particle size of from about 15 nm to about 100 nm, zinc oxide having an average primary particle size of from about 15 nm to about 150 nm, zirconium oxide having an average primary particle size of from about 15 nm to about 150 nm, iron oxide having an average primary particle size of from about 15 nm to about 500 nm, and mixtures thereof. When used herein, the inorganic sunscreens are present in the amount of from about 0.1% to about 20%, preferably from about 0.5% to about 10%, more preferably from about 1% to about 5%, of the composition.
  • [0315]
    A wide variety of conventional organic sunscreen actives are suitable for use herein. Specific suitable sunscreen actives include, for example: p-aminobenzoic acid, its salts and its derivatives (ethyl, isobutyl, glyceryl esters; p-dimethylaminobenzoic acid); anthranilates (i.e., o-amino-benzoates; methyl, menthyl, phenyl, benzyl, phenylethyl, linalyl, terpinyl, and cyclohexenyl esters); salicylates (amyl, phenyl, octyl, benzyl, menthyl, glyceryl, and di-pro-pyleneglycol esters); cinnamic acid derivatives (menthyl and benzyl esters, a-phenyl cinnamonitrile; butyl cinnamoyl pyruvate); dihydroxycinnamic acid derivatives (umbelliferone, methylumbelliferone, methylaceto-umbelliferone); trihydroxy-cinnamic acid derivatives (esculetin, methylesculetin, daphnetin, and the glucosides, esculin and daphnin); hydrocarbons (diphenylbutadiene, stilbene); dibenzalacetone and benzalacetophenone; naphtholsulfonates (sodium salts of 2-naphthol-3,6-disulfonic and of 2-naphthol-6,8-disulfonic acids); di-hydroxynaphthoic acid and its salts; o- and p-hydroxybiphenyldisulfonates; coumarin derivatives (7-hydroxy, 7-methyl, 3-phenyl); diazoles (2-acetyl-3-bromoindazole, phenyl benzoxazole, methyl naphthoxazole, various aryl benzothiazoles); quinine salts (bisulfate, sulfate, chloride, oleate, and tannate); quinoline derivatives (8-hydroxyquinoline salts, 2-phenylquinoline); hydroxy- or methoxy-substituted benzophenones; uric and violuric acids; tannic acid and its derivatives (e.g., hexaethylether); (butyl carbotol) (6-propyl piperonyl)ether; hydroquinone; benzophenones (oxybenzene, sulisobenzone, dioxybenzone, benzoresorcinol, 2,2′,4,4′-tetrahydroxybenzophenone, 2,2′-dihydroxy-4,4′-dimethoxybenzophenone, octabenzone; 4-isopropyldibenzoylmethane; butylmethoxydibenzoylmethane; etocrylene; octocrylene; [3-(4′-methylbenzylidene bornan-2-one), terephthalylidene dicamphor sulfonic acid and 4-isopropyl-di-benzoylmethane.
  • [0316]
    A safe and effective amount of the organic sunscreen active is used, typically from about 1% to about 20%, more typically from about 2% to about 10% of the composition. Exact amounts will vary depending upon the sunscreen or sunscreens chosen and the desired Sun Protection Factor (SPF).
  • [0317]
    Agents for Hair Growth Disorders
  • [0318]
    Agents, which affect the pattern of hair growth, can be suitably incorporated in the foam of the present invention. Male pattern baldness (MPB), the commonest cause of balding, is induced by the activity of the male hormone dihydrotestosterone (DHT), which converted from the hormone testosterone by the enzymes 5 alpha reductase. Current treatments of MPB include minoxidil and agents, which inhibit 5 alpha reductase, such as finasteride, spironolactone, azelaic acid and azelaic acid derivatives and salts. Such agents, as well as other agents known in the art, can be incorporated in the foam of the present invention.
  • [0319]
    It is further pointed out that polyunsaturated fatty acids, i.e., such which include any of the essential fatty acids (EFA's): linoleic and linolenic acid, gamma-linoleic acid (GLA), eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), are also known to contribute to hair growth. Thus in a preferred embodiment, a hair growth foam is provided, wherein the hydrophobic solvent comprises in full or in part, an oil, rich in such unsaturated fatty acids.
  • [0320]
    Figure-Forming Agents; Agents to Treat Cellulite/Slimming
  • [0321]
    Figure forming agents such as used in the treatment of cellulite and in slimming products, can be suitably incorporated in the foam of the present invention. A non-limiting exemplary list of active agents, known in the treatment of cellulite and in the induction of a slimming effect include herbal extracts, such as baldderwack extract, butcher's, broom, cayenne, dandelion, red clover, ginkgo biloba, horse chestnut, witch hazel and borage oil, omega 3 and omega 6 oils, caffeic acid and salts and derivatives thereof, xanthine agents, such as caffeine, theophiline and pentoxyphilline, and nicotinic acid and salts and derivatives thereof.
  • [0322]
    Agents to Treat Sunburn, Heat Burn, Radiation Burn, Rash and Itch
  • [0323]
    Cosmetic and pharmaceutical ingredients which are known in the art of pharmacology and cosmetology to treat dermatitis, minor skin irritations, sunburn, heat burn, radiation burn, and inhibit inflammation can be beneficially incorporated in the foam of the present invention.
  • [0324]
    Examples of such active agents include chamomile extract (matricaria recutitia), cucumber distillate (cucumis sativus), lavender water (lavendula angustifolia), rose water (rosa damascena), witch hazel (hamamelis virginiana), allantoin, bisabolol, rosehip oil, calendula oil, azulaene, menthol and camphor.
  • [0325]
    Use of the Foam as a Lubricating and Protective Foam
  • [0326]
    There are several potential uses of the foam, particularly the silicone-oil based foam, as a lubricating foam. Typical examples are shaving foam, moisture protection foam and antifriction foam. For such purposes, the foam can be used in its basic composition (without additional formulation aids and active ingredients), or with the addition of such additives.
  • [0327]
    Foam for Neutralization and/or Decontamination of Hazardous Chemicals and Treatment of Heat Burns
  • [0328]
    It has been reported that povidone iodine antiseptic, a popular iodine product, can ameliorate damage to guinea pig skin exposed to mustard gas and other chemical irritants and further reduces, and many times prevents, damage to human skin after accidental heat burns caused by hot water, oil or hot steam.
  • [0329]
    Other active compound, having decontamination abilities, comprise strong oxidants and free radical liberating compounds, such as hydrogen oxide, bleaching agents (e.g., sodium, calcium or magnesium hypochloride and the like) iodine, chlorohexidine and benzoyl peroxide.
  • [0330]
    The alcohol-free foam of the present invention, comprising one or more of the above decontaminating and neutralizing agents can be applied onto the contaminated skin to form a preventive layer, prior to contamination measure or as a decontamination/neutralization means, right after contamination has occurred.
  • [0331]
    Penetration Enhancers
  • [0332]
    A penetration enhancer or permeation enhancer is an agent used to increase the permeability of the skin to a pharmacologically active agent to increase the rate at which the drug diffuses through the skin and enters the tissues and bloodstream. A chemical skin penetration enhancer increases skin permeability by reversibly altering the physiochemical nature of the stratum corneum to reduce its diffusional resistance. In a review of the technical and patent literature up to 1996, numerous chemical compounds were cited as skin penetration enhancers. Most of the compounds are generally recognized as safe (GRAS) ingredients that would often be considered inert by a formulator (Osborne D W, Henke J J, Pharmaceutical Technology, November 1997, pp 58-86.)
  • [0333]
    Examples of penetration enhancers, according to the present invention include: polyols, such as propylene glycol, hexylene glycol, diethylene glycol, propylene glycol n-alkanols, terpenes, di-terpenes, tri-terpenes, terpen-ols, limonene, terpene-ol, l-menthol, dioxolane, ethylene glycol, other glycols, and glycerol; sulfoxides, such as dimethylsulfoxide (DMSO), dimethylformamide, methyl dodecyl sulfoxide, dimethylacetamide; monooleate of ethoxylated glycerides (with 8 to 10 ethylene oxide units); Azone (1-dodecylazacycloheptan-2-one), 2-(n-nonyl)-1,3-dioxolane; esters, such as isopropyl myristate/palmitate, ethyl acetate, butyl acetate, methyl proprionate, capric/caprylic triglycerides, octylmyristate, dodecyl-myristate; myristyl alcohol, lauryl alcohol, lauric acid, lauryl lactate ketones; amides, such as acetamide oleates such as triolein; various surfactants, such as sodium lauryl sulfate; various alkanoic acids such as caprylic acid; lactam compounds, such as azone; alkanols, such as oleyl alcohol; dialkylamino acetates, and admixtures thereof.
  • [0334]
    Lower alcohols, such as ethanol, propanol, isopropanol, butanol, iso-butanol, t-butanol and pentanol are not considered appropriate penentartion enhancers according to the present invention, due to their skin drying and irritation properties.
  • [0335]
    Yet, another preferred class of penetration enhancers in the cyclodextrines and related compounds. Cyclodextrins are structurally related cyclic oligomaltoses which form a new group of pharmaceutical excipients. These are torus-shaped molecules with a hydrophilic outer surface and a lipophilic central cavity. Cyclodextrins are capable of forming water-soluble inclusion complexes with a wide variety of lipophilic water-insoluble drugs by taking up a whole drug molecule, or some part of it, into the cavity. The cyclodextrin molecules are relatively large (molecular weight ranging from almost 1000 to over 1500), with a hydrated outer surface, and under normal conditions, cyclodextrin molecules will only permeate the skin barrier with considerable difficulty. It is generally believed that the cyclodextrin molecules act as tnue carriers by keeping lipophilic drug molecules in solution and deliver them to the skin surface where they partition from the cyclodextrin cavity into the skin.
  • [0336]
    Further Technical Parameters
  • [0337]
    The composition of the present invention may be contained in and dispensed from a container capable of withstanding the pressure of the propellant gas and having an appropriate valve/nozzle for dispensing the composition as foam under pressure. A customary liquefied or compressed gas propellant can be added, in the amount of about 5-25% of the total composition. Liquefied propellants are gases that exist as liquids under pressure, including high purity hydrocarbons such as propane, isobutane and n-butane, dimethyl ether and chlorofluorocarbons (CFCs). Compressed gasses are exemplified by air, nitrogen and carbon dioxide.
  • [0338]
    A specific embodiment according to the present invention comprises placing the composition of the present invention on a patch, occlusive tape or the skin-contact compartment of a transdermal delivery apparatus and applying such object onto the skin, in order to attain effective superficial treatment or enhanced penetration of the drug into the skin or through the skin.
  • [0339]
    Utilizing such strategy, one can apply drugs, which are currently administered systemically or that require transdermal delivery, in the preferred therapeutic system of the present invention. Examples for such drugs are nicotine, testosterone and other male hormones and male hormone precursors, estrogen and other female hormones and hormone precursors, growth hormone, insulin, caffeine, steroidal and non-steroidal antiinflammatory agents and thyroid hormone substitutes.
  • [0340]
    The general process, as typically exemplified in Example 1 may be applied in order to produce the composition of the present invention.
  • [0341]
    The pharmaceutical carrier according to the present invention can also be used to prepare cosmetics for beauty purpose by adding into skin care agents and perfume.
  • EXAMPLES
  • [0342]
    The invention is described with reference to the following examples. This invention is not limited to these examples and experiments. Many variations will suggest themselves and are within the full intended scope of the appended claims.
  • Example 1 General Procedure for Preparing Foamable Composition
  • [0343]
    Aqueous Phase: Water gelling agent and surface-active agent are dissolved in water, with agitation. The solution is warmed to 50-70° C. Water soluble cosmetic or pharmaceutical active ingredients and optional water soluble ingredients are added with agitation to the Aqueous Phase mixture.
  • [0344]
    Hydrophobic Phase: The hydrophobic solvent is heated to same temperature. Foam adjuvant agent is added to preheated hydrophobic solvent. Oil soluble cosmetic or pharmaceutical active ingredients* and optional oil soluble formulation ingredients are added with agitation to the Hydrophobic Phase mixture.
  • [0345]
    The warm Hydrophobic Phase is gradually poured into the warm Aqueous Phase, with agitation, followed by Ultraturax homogenization. The mixture is allowed to cool down to ambient temperature. In case of heat sensitive active ingredients, the active ingredient is added with agitation to the mixture after cooling to ambient temperature. The mixture, at ambient temperature, is added to an aerosol container, the container is sealed and appropriate amount of propellant (5-25 w % of the composition mass) is added under pressure into the container.
  • Example 2 Vegetable Oil-Based Foam Carrier Composition
  • [0346]
  • [0000]
    Version Version Version
    No. 1 No. 2 No. 3
    Ingredient % (W/W)
    Hydrophobic solvent Soybean oil 40 30.5 20
    Water Water 48.5 32.5 61
    Foam adjuvant agent Stearyl Alcohol 0.8 1.05 0.73
    Surface-active agent Sucrose ester SP70 0.64 0.45 0.8
    Water gelling agent Xanthan Gum 0.16 0.11 0.1
    Methocel ELV15 0.32 0.22 0.28
    Other Ingredients Antioxidant 0.02 0.02 0.02
    Preservatives 0.3 0.3 0.3
    Fragrance 0.2 0.2 0.2
    Foam Specific gravity 0.10 0.15 0.065
    (gr/mL)
  • [0347]
    The compositions use a non-ionic surfactant and contain a combined amount of surface-active agent, foam adjuvant and water gelling agent ranging from 1.83% to 1.92% (w/w). The foam of this example is useful as a carrier of active pharmaceutical and/or cosmetic active ingredients, as exemplified below. It also can be used as a protective product. Additionally, it is also useful as lubricating foam, for various purposes.
  • Example 3 Silicone Oil-Based Foam Carrier Composition
  • [0348]
  • [0000]
    Version Version
    No. 1 No. 2
    Specific Ingredient % (W/W)
    Hydrophobic solvent Dimeticone 350* 25 10
    Water Water 72 87
    Foam adjuvant agent Stearyl Alcohol 0.2 0.2
    Surface-active agent Sucrose ester SP70 0.8
    Myrj 49P 0.8
    Water gelling agent Xanthan Gum 0.2 0.2
    Methocel ELV15 0.4 0.4
    Other Ingredients Antioxidant 0.02 0.02
    Preservatives 1 1
    Fragrance 0.2 0.2
    Foam Specific gravity 0.10 ND
    (gr/mL)
    *Dimethylpolysiloxane of 350 cps viscosity.
  • [0349]
    The compositions use only non-ionic surfactant and contain a combined amount of surface-active agent, foam adjuvant and water gelling agent of 1.6% (w/w). The foam of this example is useful as a carrier of active pharmaceutical and/or cosmetic active ingredients, as exemplified below. It also can be used as a protective product. Additionally, it is also useful as lubricating foam, for various purposes.
  • Example 6 Mineral Oil-Based Foam Carrier Composition
  • [0350]
  • [0000]
    Version Version Version Version Version
    No. 1 No. 2 No. 3 No. 4 No. 5
    Ingredient % (W/W)
    Hydrophobic Mineral oil 69 50 50 25 25
    solvent
    Water Water 28.4 46.7 46.7 71.88 71.9
    Foam adjuvant Stearyl Alcohol 0.7 1 1 0.5 0.5
    agent
    Surface-active Sucrose ester SP70 0.4 0.64 0 0.8 0
    agent PEG S-40 0 0 0.64 0 0
    Polysorbate-60 0 0 0 0 0.8
    Water gelling Xanthan Gum 0.1 0 0.14 0.2 0.2
    agent Methocel ELV15 0.2 0.4 0.32 0.4 0.4
    Other Antioxidant 0.02 0.02 0.02 0.02 0.02
    Ingredients Preservatives 1 1 1 1 1
    Fragrance 0.2 0.2 0.2 0.2 0.2
    Foam Specific ND ND ND ND 0.1
    gravity (gr/mL)
  • [0351]
    The compositions use only non-ionic solvents, and the total amount of surface active agent, foam adjuvants and water gelling agents ranges from 1.4 to 2.1% (w/w). The foam of this example is useful as a carrier of active pharmaceutical and/or cosmetic active ingredients, as exemplified in examples below. It is also useful as lubricating foam, for various purposes.
  • Example 7 Mixed Oils Foam Carrier Composition
  • [0352]
  • [0000]
    Version Version
    No. 1 No. 2
    Ingredient 25% Oil 12.5% Oil
    Hydrophobic solvent Mineral oil 11.2%  5.6%
    Isopropyl myristate 5.0% 2.5%
    MCT oil 7.5% 3.8%
    Foam adjuvant agent Stearyl Alcohol 0.5% 0.25% 
    Water Water 73.0%  85.2% 
    Surface-active agent Sucrose ester SP70 0.8% 0.8%
    Distilled monoglyceride 1.2% 0.6%
    Sodium lauryl sulphate 0.1% 0.1%
    Water gelling agent Xanthan Gum 0.3% 0.3%
    Methocel ELV15 0.6% 0.6%
  • [0353]
    The foams of this example have a non-ionic surfactant to ionic surfactant ratio (w/w) of 20:1 and 14:1 for versions 1 and 2, respectively. Total amounts of surface active agent foam adjuvant and water gelling agent is in the range of 1.75-3.5% (w/w). It is useful as a carrier of active pharmaceutical and/or cosmetic active ingredients, as exemplified in examples below. It is also useful as lubricating foam, for various purposes.
  • [0354]
    The following examples, representing optional drug-containing foams, are prototype formulations, which have not been optimized for stability and inter-component compatibility. Such optimization is a customary need, which can be done, using means, known to those skilled in the art of pharmaceutical formulation
  • Example 8 Antibacterial Foam Composition
  • [0355]
  • [0000]
    Version 2 Version 3 Version 4 Version 5
    Version 1 “Triple “Fucidic “Metro- “Triple
    Ingredient “Mupirocin” Antibiotic” Acid” nidazole” Antibiotic”
    Carrier Ingredients
    Mineral oil 48.8%  11.2%  48.8%  5.6% 5.6%
    Isopropyl myristate 5.0% 2.5% 2.5%
    MCT oil 7.5% 3.8% 3.8%
    Stearyl Alcohol 0.8% 0.5% 0.8% 0.25%  0.25% 
    Water  50% 73.0%   50% 85.2%  85.2% 
    Sucrose ester SP70 0.8% 0.8% 0.8%
    Myrj 40 0.8%
    Distilled 1.2% 0.6% 0.6%
    monoglyceride
    Tween 60 0.8%
    Sodium lauryl 0.05%  0.1% 0.1%
    sulphate
    Xanthan Gum 0.2% 0.3% 0.2% 0.3% 0.3%
    Methocel ELV15 0.2% 0.6% 0.2% 0.6% 0.6%
    Active Ingredients
    Mupirocin   2%
    Polymyxin B Sulfate 10,000 10,000
    Units/gr Units/gr
    Bacitracin Zinc 500 500
    Units/gr Units/gr
    Neomycin Sulfate* 0.05%  0.05% 
    Pramoxine HCl   1%   1%
    Fucidic acid   2%
    Metronidazole   1%
  • [0356]
    The foams of this example contain 100% non-ionic surfactant or have a non-ionic surfactant to ionic surfactant ratio ranging from 20:1 to 8:1. Total amounts of surface active agent, foam adjuvant and water gelling agent ranges from 2.05-3.5% (w/w). It is useful for the treatment of bacterial skin infection (general), cellulites, open wounds, cutaneous abscesses, furuncles, insect bite, impetigo, acne, acne-rosacea, and trichomonas vaginitis.
  • [0357]
    In certain embodiments, the foam of this example is useful for the prevention, decontamination and/or neutralization hazardous bacterial infestation (such as warfare organisms).
  • Example 9 Antifungal Foam Composition
  • [0358]
  • [0000]
    Version 1 Version 2 Version 3 Version 4
    Ingredient “Terbinafine” “Clotrimazole” “Nystatin” “Nystatin”
    Carrier Ingredients
    Mineral oil 48.8%  11.2%  48.8%  5.6%
    Isopropyl myristate 5.0% 2.5%
    MCT oil 7.5% 3.8%
    Stearyl Alcohol 0.8% 0.5% 0.8% 0.25% 
    Water  50% 73.0%   50% 85.2% 
    Sucrose ester SP70 0.8% 0.8% 0.8%
    Myrj 40 0.8%
    Tween 80 0.8%
    Distilled monoglyceride 1.2% 0.6%
    Sodium lauryl sulphate 0.05%  0.1% 0.1%
    Xanthan Gum 0.2% 0.3% 0.2% 0.3%
    Methocel ELV15 0.2% 0.6% 0.2% 0.6%
    Active Ingredients
    Terbinafine   1%
    clotrimazole   2%
    Nystatin 100,000 100,000
    Units/gr Units/gr
  • [0359]
    The foams of this example have 100% non-ionic surfactant or have a non-ionic surfactant to ionic surfactant ratio ranging from 20:1 to 8:1. Total surface active agent, foaming adjuvant and water gelling agent ranges from 2.05 to 3.5% (w/w). It is useful in the treatment of dermatophyte infections, Tinea corporis, Tinea pedis, Tinea rubrum, Tinea unguium, Tinea cruris, Tinea barbae, and yeast infections, such as Candidiasis, Tinea versicolor and Candidal vaginitis.
  • Example 10 Corticosteroid Foam Composition
  • [0360]
  • [0000]
    Version 1 Version 2 Version 3
    “Hydro- “Beta- “Dexa-
    Ingredient cortisone” methasone” methasone”
    Carrier Ingredients
    Mineral oil 48.8%  11.2%  5.6%
    Isopropyl myristate 5.0% 2.5%
    MCT oil 7.5% 3.8%
    Stearyl Alcohol 0.8% 0.5% 0.25% 
    Water  50% 73.0%  85.2% 
    Sucrose ester SP70 0.8% 0.4% 0.8%
    Tween 80 0.4%
    Distilled 1.2% 0.6%
    monoglyceride
    Sodium lauryl 0.05%  0.1%
    sulphate
    Xanthan Gum 0.2% 0.3% 0.3%
    Methocel ELV15 0.2% 0.6% 0.6%
    Active Ingredients
    Hydrocortisone   1%
    Betamethasone 0.05% 
    dipropionate
    Dexamethasone 0.1%
    acetate
    Version 4 Version 5
    Ingredient “Triamcinolone” “Flumetasone”
    Carrier Ingredients
    Mineral oil 48.8%  48.8% 
    Stearyl Alcohol 0.8% 0.8%
    Water  50%  50%
    Sucrose ester SP70 0.8% 0.8%
    Sodium lauryl 0.05%  0.05% 
    sulphate
    Xanthan Gum 0.2% 0.2%
    Methocel ELV15 0.2% 0.2%
    Active Ingredients
    Triamcinolone 0.1%
    acetonide
    Flumetasone 0.02% 
    pivalate
  • [0361]
    The foams of this example have either 100% non-ionic surfactant or have a non-ionic surfactant to ionic surfactant ratio ranging from 20:1 to 16:1. Total surface active agent, foaming adjuvant and water gelling agent ranges from 2.05 to 3.5% (w/w). Indications include psoriasis, contact dermatitis, atopic dermatitis, seborrheic dermatitis, nummular dermatitis, inflammatory acne, chronic dermatitis of the hands and feet, generalized exfoliative dermatitis, stasis dermatitis, lichen simplex chronicus, herpes gestationis and pruritic urticarial papules and plaques of pregnancy.
  • Example 11 Antiviral Foam Composition
  • [0362]
  • [0000]
    Version 1 Version 2 Version 3
    Ingredient “Acyclovir” “Acyclovir” “α-Interferon”
    Carrier Ingredients
    Mineral oil 48.8%  11.2%  5.6%
    Isopropyl myristate 5.0% 2.5%
    MCT oil 7.5% 3.8%
    Stearyl Alcohol 0.8% 0.5% 0.25% 
    Water  50% 73.0%  85.2% 
    Sucrose ester SP70 0.8% 0.8%
    Tween 80 0.8%
    Distilled monoglyceride 1.2% 0.6%
    Sodium lauryl sulphate 0.1%
    Xanthan Gum 0.2% 0.3% 0.3%
    Methocel ELV15 0.2% 0.6% 0.6%
    Active Ingredients
    Acyclovir   5%   5%
    α-Interferon 105 IU/g
  • [0363]
    The foams of this example have either 100% non-ionic surfactant or have a non-ionic surfactant to ionic surfactant ratio of 14:1. Total surface active agent, foaming adjuvant and water gelling agent ranges from 2.05 to 3.5% (w/w). Indications include Herpes simplex, Herpes zoster, Herpes gestationis and Herpes simplex genital ulcers.
  • Example 12 Insect Repellent Foam Composition
  • [0364]
  • [0000]
    Ingredient %
    Isopropyl myristate 2.0%
    MCT oil 2.0%
    Stearyl Alcohol 1.2%
    Water 64.0% 
    Sucrose ester SP70 0.8%
    Sodium lauryl sulphate 0.1%
    Xanthan Gum 0.3%
    Methocel ELV15 0.6%
    Propylene glycol  15%
    DEET  15%
  • Example 14 Comparative Tolerability and Acceptability Study of a Corticosteroid Foam Composition Vs. a Conventional Ointment
  • [0365]
    A panel of eight testers was requested to apply about 0.5 gr. of the foam preparation of example 10, Version 2 on one arm and 0.5 gr. of commercial Betamethasone valerate ointment, in a double blind fashion. They were asked to describe their feeling about the ease of application, ease of spreading, spreadability and penetrability of each of the products and to give their general rating for each of the products on a scale of 0-3 (0=poor; 1=barely acceptable; 2=acceptable and 3=excellent).
  • [0366]
    As demonstrated in the following table, the foam preparation of example 10, Version 2 obtained higher rates in all aspects of the test.
  • [0000]
    Commercial Betamethasone
    Foam Preparation Valerate Ointment
    Property Mean Rating Mean Rating
    Ease of application 2.3 1.6
    Ease of spreading 2.5 1.9
    Spreadability 2.9 1.2
    Penetrability 2.0 1.5
    Lack of sticky feeling 2.4 1.0
    Lack of greasy feeling 2.2 1.0
    Lack of shiny look 1.9 1.4
    Overall rating 2.5 1.4
  • Example 15 Human Safety and Efficacy Study of a Corticosteroid Composition in Psoriasis Patients
  • [0367]
    Two patients with mild to moderate psoriasis were administered topically a Betamethasone 0.12% foam (example 10, Version 2) twice daily for two weeks. Both patients improved significantly, as manifested by clearance of the psoriatic plaques flattening of the thickened lesions. FIG. 1 provides an exemplary response to treatment in the elbows of one of these patients. While betamethasone is know for its effect in psoriasis, such a beneficial effect after 14 days treatment is exceptional. The accelerated effect was attributed to the improved convenience and therefore, improved compliance.
  • Example 16 Human Safety and Efficacy Study of a Corticosteroid Composition in Psoriasis Patients
  • [0368]
    Four patients with moderate to severe, disseminated atopic dermatitis were administered topically a Betamethasone 0.12% foam (example 10, Version 2) twice daily for two weeks. All patients improved significantly, as manifested by complete clearance of all treated lesions. FIG. 2 provides exemplary responses to treatment in different body areas, after 10 days of treatment. While betamethasone is know for its effect in atopic dermatitis, such a beneficial effect after 10 days treatment is exceptional. The patients claimed that the use of the foam of the present invention was significantly more convenient than the corresponding cream and ointment. Thus, the accelerated effect was attributed to the improved convenience and therefore, improved compliance.
  • Example 17 Foam Compositions with Urea
  • [0369]
  • [0000]
    Component % w/w
    Mineral oil 6.00 6.00 6.00 6.00
    Isopropylmeristat 6.00 6.00 6.00 6.00
    Glyceryl monostearate 0.50 0.50 0.50 0.50
    Stearyl alcohol 0.20 0.20 0.20 1.00
    Urea 10.00 10.00 10.00 10.00
    Xantan gum 0.30 0.30 0.30 0.30
    Methocel K100M 0.30 0.30 0.30 0.30
    Myrj 52 3.00
    TWEEN 80 1.00
    Myrj 49p 3.00
    TWEEN 60 1.00 1.00 1.00
    Cocamidopropylbetain 0.50 0.50
    Phenonip 0.30 0.30 0.30 0.30
    Water to 100.0 to 100.0 to 100.0 to 100.0
    Butane/propane 8.00 8.00 18.00 18.00
    FoamQuality E E E E
    Density n/a 0.023 n/a 0.024
  • Example 18 Compositions with Various Penetration Enhancers
  • [0370]
  • [0000]
    Component % w/w
    Mineral oil 6.00 6.00 6.00 6.00 6.00
    Isopropyl myristate 6.00 6.00 6.00 6.00 6.00
    Glyceryl monostearate 0.50 0.50 0.50 0.50 0.50
    Stearyl alcohol 1.00 1.00 1.00 1.00 1.00
    Xantan gum 0.30 0.30 0.30 0.30 0.30
    Methocel K100M 0.30 0.30 0.30 0.30 0.30
    TWEEN 60 1.00
    TWEEN 80 1.00 1.00 1.00 1.00
    MYRJ 49p 3.00 3.00 3.00 3.00 3.00
    Propylen glycol 5.00
    Glycofurol 1.00 10.00
    Urea 10.00
    Cocoamidopropyl- 0.50 0.50 0.50 0.50 0.50
    bethaine
    Lidocain base 4.00 4.00 4.00 4.00 4.00
    Phenonip 0.30 0.30 0.30 0.30 0.30
    Water to 100 to 100 to 100 to 100 to 100
    Butane/propane 8 8 8 16 10
    Foam Quality E E E E E
    Density 0.020 0.018 0.019 0.019 0.018
  • [0000]
    Component % w/w % w/w
    Isopropyl myristate 30.00 30.00
    Glyceryl monostearate 0.50 0.50
    Stearic acid 0.45 0.45
    Xantan gum 0.30 0.30
    Methocel K100M 0.30 0.30
    TWEEN 80 1.00 1.00
    MYRJ 49p 3.00 3.00
    Cocoamidopropylbethaine 0.50 0.50
    Transcutol p 20.00 20.00
    Hydrophilic drug Effective
    concentration
    Hydrophobic drug Effective
    concentration
    Phenonip 0.30 0.30
    Water to 100.0 to 100.0
    Butane/propane 8.00 8.00
    FoamQuality E E
    Density 0.020 0.020

Claims (2)

  1. 1. An alcohol-free foamable pharmaceutical or cosmetic carrier, comprising:
    (a) a foamable composition comprising:
    about 2-75% by weight of composition of a liquid, non-volatile hydrophobic solvent;
    about 80-98% by weight of composition of water;
    about 0.1% to 5% by weight of composition of a foam adjuvant agent selected from the group consisting of fatty alcohols, fatty acids, hydroxyl-substituted fatty alcohols, hydroxyl-substituted fatty acids, and fatty acids and fatty alcohols including at least one double bond in its carbon atom chain;
    about 0.1% to 5% by weight of composition of a surface-active agent; and
    about 0.1% to 5% by weight of composition of a water gelling agent.
    and
    (b) a liquefied or compressed gas propellant in a container,
    which upon release provides a breakable foam suitable for topical or muscosal administration.
  2. 2-87. (canceled)
US11894715 2002-10-24 2007-08-20 Cosmetic and pharmaceutical foam Abandoned US20080138293A1 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
IL15248602 2002-10-25
IL152486 2002-10-25
US42954602 true 2002-11-29 2002-11-29
US10532618 US20060140984A1 (en) 2002-10-25 2003-10-24 Cosmetic and pharmaceutical foam
PCT/IB2003/005527 WO2004037225A3 (en) 2002-10-25 2003-10-24 Cosmetic and pharmaceutical foam
US11894715 US20080138293A1 (en) 2002-10-24 2007-08-20 Cosmetic and pharmaceutical foam

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11894715 US20080138293A1 (en) 2002-10-24 2007-08-20 Cosmetic and pharmaceutical foam
US15238543 US20160354473A1 (en) 2002-10-25 2016-08-16 Cosmetic and Pharmaceutical Foam

Related Parent Applications (2)

Application Number Title Priority Date Filing Date
US10532618 Continuation US20060140984A1 (en) 2002-10-25 2003-10-24 Cosmetic and pharmaceutical foam
PCT/IB2003/005527 Continuation WO2004037225A3 (en) 2002-10-25 2003-10-24 Cosmetic and pharmaceutical foam

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US15238543 Continuation US20160354473A1 (en) 2002-10-24 2016-08-16 Cosmetic and Pharmaceutical Foam

Publications (1)

Publication Number Publication Date
US20080138293A1 true true US20080138293A1 (en) 2008-06-12

Family

ID=32178937

Family Applications (7)

Application Number Title Priority Date Filing Date
US10532618 Pending US20060140984A1 (en) 2002-10-25 2003-10-24 Cosmetic and pharmaceutical foam
US11116761 Active 2028-01-04 US8840869B2 (en) 2002-10-25 2005-04-28 Body cavity foams
US11894715 Abandoned US20080138293A1 (en) 2002-10-24 2007-08-20 Cosmetic and pharmaceutical foam
US13786902 Active US8722021B2 (en) 2002-10-25 2013-03-06 Foamable carriers
US14272551 Active US9713643B2 (en) 2002-10-25 2014-05-08 Foamable carriers
US15238543 Abandoned US20160354473A1 (en) 2002-10-24 2016-08-16 Cosmetic and Pharmaceutical Foam
US15464638 Pending US20170274084A1 (en) 2002-10-25 2017-03-21 Body Cavity Foams

Family Applications Before (2)

Application Number Title Priority Date Filing Date
US10532618 Pending US20060140984A1 (en) 2002-10-25 2003-10-24 Cosmetic and pharmaceutical foam
US11116761 Active 2028-01-04 US8840869B2 (en) 2002-10-25 2005-04-28 Body cavity foams

Family Applications After (4)

Application Number Title Priority Date Filing Date
US13786902 Active US8722021B2 (en) 2002-10-25 2013-03-06 Foamable carriers
US14272551 Active US9713643B2 (en) 2002-10-25 2014-05-08 Foamable carriers
US15238543 Abandoned US20160354473A1 (en) 2002-10-24 2016-08-16 Cosmetic and Pharmaceutical Foam
US15464638 Pending US20170274084A1 (en) 2002-10-25 2017-03-21 Body Cavity Foams

Country Status (6)

Country Link
US (7) US20060140984A1 (en)
EP (1) EP1556009B1 (en)
JP (1) JP2006505583A (en)
KR (1) KR101108439B1 (en)
CA (1) CA2502986C (en)
WO (1) WO2004037225A3 (en)

Cited By (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060188561A1 (en) * 1996-01-22 2006-08-24 Pliva, Inc. (Formerly Known As Sidmak Laboratories, Inc.) Pharmaceutical compositions for lipophilic drugs
US7700076B2 (en) 2002-10-25 2010-04-20 Foamix, Ltd. Penetrating pharmaceutical foam
US7704518B2 (en) 2003-08-04 2010-04-27 Foamix, Ltd. Foamable vehicle and pharmaceutical compositions thereof
US20100183528A1 (en) * 2008-12-17 2010-07-22 Harmony Laboratories, Inc. Acne treatment powder foundation
US7820145B2 (en) 2003-08-04 2010-10-26 Foamix Ltd. Oleaginous pharmaceutical and cosmetic foam
US20110120958A1 (en) * 2009-11-22 2011-05-26 United Laboratories International, Llc Wastewater Treatment
US8119150B2 (en) 2002-10-25 2012-02-21 Foamix Ltd. Non-flammable insecticide composition and uses thereof
US8119106B2 (en) 2003-04-28 2012-02-21 Foamix Ltd Foamable iodine compositions
US8119109B2 (en) 2002-10-25 2012-02-21 Foamix Ltd. Foamable compositions, kits and methods for hyperhidrosis
US8263580B2 (en) 1998-09-11 2012-09-11 Stiefel Research Australia Pty Ltd Vitamin formulation
US20120238535A1 (en) * 2009-02-23 2012-09-20 Smith Jan G Topical formulation of low level clobetasol propionate for treating disorders of the skin and mucous membranes
US8298515B2 (en) 2005-06-01 2012-10-30 Stiefel Research Australia Pty Ltd. Vitamin formulation
US8343945B2 (en) 2007-12-07 2013-01-01 Foamix Ltd. Carriers, formulations, methods for formulating unstable active agents for external application and uses thereof
US8486376B2 (en) 2002-10-25 2013-07-16 Foamix Ltd. Moisturizing foam containing lanolin
US8486374B2 (en) 2003-08-04 2013-07-16 Foamix Ltd. Hydrophilic, non-aqueous pharmaceutical carriers and compositions and uses
US8512718B2 (en) 2000-07-03 2013-08-20 Foamix Ltd. Pharmaceutical composition for topical application
US8518376B2 (en) 2007-12-07 2013-08-27 Foamix Ltd. Oil-based foamable carriers and formulations
US8618081B2 (en) 2009-10-02 2013-12-31 Foamix Ltd. Compositions, gels and foams with rheology modulators and uses thereof
US8636982B2 (en) 2007-08-07 2014-01-28 Foamix Ltd. Wax foamable vehicle and pharmaceutical compositions thereof
US8709385B2 (en) 2008-01-14 2014-04-29 Foamix Ltd. Poloxamer foamable pharmaceutical compositions with active agents and/or therapeutic cells and uses
US20140121188A1 (en) * 2009-10-02 2014-05-01 Foamix Ltd. Compositions for the improved treatment of acne and related disorders
US8722021B2 (en) 2002-10-25 2014-05-13 Foamix Ltd. Foamable carriers
US8795635B2 (en) 2006-11-14 2014-08-05 Foamix Ltd. Substantially non-aqueous foamable petrolatum based pharmaceutical and cosmetic compositions and their uses
US8795693B2 (en) 2003-08-04 2014-08-05 Foamix Ltd. Compositions with modulating agents
US8900554B2 (en) 2002-10-25 2014-12-02 Foamix Pharmaceuticals Ltd. Foamable composition and uses thereof
US9072667B2 (en) 2009-07-29 2015-07-07 Foamix Pharmaceuticals Ltd. Non surface active agent non polymeric agent hydro-alcoholic foamable compositions, breakable foams and their uses
US9167813B2 (en) 2009-07-29 2015-10-27 Foamix Pharmaceuticals Ltd. Non surfactant hydro-alcoholic foamable compositions, breakable foams and their uses
US9211259B2 (en) 2002-11-29 2015-12-15 Foamix Pharmaceuticals Ltd. Antibiotic kit and composition and uses thereof
US9265725B2 (en) 2002-10-25 2016-02-23 Foamix Pharmaceuticals Ltd. Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof
US9302016B2 (en) 2012-03-30 2016-04-05 Sancilio & Company, Inc. Omega-3 fatty acid ester compositions
US9320705B2 (en) 2002-10-25 2016-04-26 Foamix Pharmaceuticals Ltd. Sensation modifying topical composition foam
US9439857B2 (en) 2007-11-30 2016-09-13 Foamix Pharmaceuticals Ltd. Foam containing benzoyl peroxide
US9480651B2 (en) 2012-03-30 2016-11-01 Sancilio & Company, Inc. Omega-3 fatty acid ester compositions unitary pharmaceutical dosage forms
US9539208B2 (en) 2002-10-25 2017-01-10 Foamix Pharmaceuticals Ltd. Foam prepared from nanoemulsions and uses
US9622947B2 (en) 2002-10-25 2017-04-18 Foamix Pharmaceuticals Ltd. Foamable composition combining a polar solvent and a hydrophobic carrier
US9668972B2 (en) 2002-10-25 2017-06-06 Foamix Pharmaceuticals Ltd. Nonsteroidal immunomodulating kit and composition and uses thereof
WO2017095696A1 (en) * 2015-12-02 2017-06-08 L'oreal Aerosol oil foam compositions comprising a triglyceride-based oil and surfactant
US9849142B2 (en) 2009-10-02 2017-12-26 Foamix Pharmaceuticals Ltd. Methods for accelerated return of skin integrity and for the treatment of impetigo
US9884017B2 (en) 2009-04-28 2018-02-06 Foamix Pharmaceuticals Ltd. Foamable vehicles and pharmaceutical compositions comprising aprotic polar solvents and uses thereof

Families Citing this family (97)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080031907A1 (en) * 2002-10-25 2008-02-07 Foamix Ltd. Cosmetic and pharmaceutical foam
US20060018937A1 (en) * 2002-10-25 2006-01-26 Foamix Ltd. Steroid kit and foamable composition and uses thereof
US20060233721A1 (en) * 2002-10-25 2006-10-19 Foamix Ltd. Foam containing unique oil globules
US20050271596A1 (en) * 2002-10-25 2005-12-08 Foamix Ltd. Vasoactive kit and composition and uses thereof
US20050186142A1 (en) * 2002-10-25 2005-08-25 Foamix Ltd. Kit and composition of imidazole with enhanced bioavailability
US20050205086A1 (en) * 2002-10-25 2005-09-22 Foamix Ltd. Retinoid immunomodulating kit and composition and uses thereof
JP4828404B2 (en) * 2003-01-24 2011-11-30 ステフェル リサーチ オーストラリア プロプライエタリー リミティッド Clindamycin phosphate foam
WO2005018530A3 (en) 2003-08-25 2005-10-20 Meir Eini Penetrating pharmaceutical foam
WO2005032521A3 (en) * 2003-10-02 2005-09-15 Collegium Pharmaceutical Inc Non-flammable topical anesthetic liquid aerosols
US20060188449A1 (en) * 2003-10-03 2006-08-24 Jane Hirsh Topical aerosol foams
EP1667657A1 (en) * 2003-10-03 2006-06-14 Collegium Pharmaceutical, Inc. Topical aerosol foams
US8940321B2 (en) 2003-12-12 2015-01-27 Otic Pharma Ltd. Compositions for treatment of ear disorders and methods of use thereof
ES2552936T3 (en) * 2003-12-12 2015-12-03 Otic Pharma Ltd. Compositions for the treatment of disorders in the ear and methods for use thereof
US20050222169A1 (en) * 2004-01-16 2005-10-06 Nawaz Ahmad Compositions and methods of treating infections
CA2565754A1 (en) * 2004-04-28 2005-10-28 Foamix Ltd. Body cavity foams
WO2006010589A3 (en) * 2004-07-29 2006-08-03 Mipharm S P A Post foaming gel mousse
WO2006029070A3 (en) * 2004-09-03 2007-05-31 Univ Virginia Commonwealth Prevention of ventilator associated pneumonia (vap)
US9457163B2 (en) 2004-09-03 2016-10-04 Virginia Commonwealth University Prevention of ventilator associated pneumonia (VAP)
WO2007054818A3 (en) * 2005-05-09 2008-10-23 Foamix Ltd Foamable vehicle and pharmaceutical compositions thereof
CN101193641B (en) 2005-05-10 2013-05-29 德米普瑟尔有限公司 Compositions and methods for treating hyperproliferative epidermal diseases
WO2007099396A3 (en) * 2005-06-07 2008-03-13 Foamix Ltd Antibiotic kit and composition and uses thereof
WO2007085899A3 (en) * 2005-07-06 2008-07-10 Foamix Ltd Foamable arthropocidal composition for tropical application
WO2007085902A3 (en) * 2005-07-19 2007-11-29 Foamix Ltd Foamable composition combining a polar solvent and a hydrophobic carrier
EP1940437B1 (en) * 2005-07-28 2013-09-04 Biosynexus Incorporated Compositions and methods for treating bacteria
FR2890560B1 (en) * 2005-09-13 2011-06-24 Galderma Sa dermatological foams and emulsions based metronidazole for their preparation
FR2890559B1 (en) * 2005-09-13 2011-06-24 Galderma Sa dermatological foams and emulsions based metronidazole for the preparation
DE202006004676U1 (en) * 2005-09-28 2007-02-08 Neubourg Skin Care Gmbh & Co. Kg Formulation, useful as foam skin cream and to treat e.g. dermatitis and psoriasis, comprises an aqueous emulsion, propellant gas, urea emulsion, hyaluronic acid, free fatty acid and at least two emulsions
WO2007044745A1 (en) * 2005-10-11 2007-04-19 Biosynexus Incorporated Lantibiotic and mupirocin compositions for treating bacterial infections
WO2007050543A3 (en) 2005-10-24 2007-09-07 Collegium Pharmaceutical Inc Topical pharmaceutical foam composition
FR2893845B1 (en) * 2005-11-30 2010-10-29 Galderma Sa spray form composition comprising a corticosteroid and an oil phase
EP1981480A1 (en) * 2006-01-19 2008-10-22 Disphar International B.V. Foam-forming composition
EP1810666A1 (en) * 2006-01-19 2007-07-25 Ferring International Center S.A. Foam-Forming composition
US7915472B2 (en) * 2006-02-07 2011-03-29 Battelle Energy Alliance, Llc Surface decontamination compositions and methods
US7846888B2 (en) * 2006-02-07 2010-12-07 Battelle Energy Alliance, Llc Long lasting decontamination foam
US8058303B2 (en) * 2006-03-08 2011-11-15 Nihon Nohyaku Co, Ltd Pharmaceutical composition for external use
CA2645058C (en) * 2006-03-08 2013-07-30 Nihon Nohyaku Co., Ltd. Pharmaceutical composition for external use
US8349882B2 (en) * 2006-03-08 2013-01-08 Nihon Nohyaku Co., Ltd. Pharmaceutical composition for external use
US20070224143A1 (en) * 2006-03-21 2007-09-27 Kamedis Ltd. Cosmetic and pharmaceutical foam carrier
CA2647127C (en) 2006-03-31 2015-10-06 Stiefel Research Australia Pty Ltd Foamable suspension gel
JP4956532B2 (en) * 2006-05-02 2012-06-20 日本曹達株式会社 Liquid composition, a method of manufacturing a liquid composition, as well as mammals and birds ectoparasite-controlling agent
DE102006031758A1 (en) * 2006-07-04 2008-01-10 Kilic, Cuma Composition, useful e.g. for the reduction of the penetration of body fluids into urethra, comprises at least two different hydrophobic compound such as vegetable oil, where the composition lock the urethra over the cross-section
EP2494959B1 (en) 2006-07-05 2014-11-19 Foamix Ltd. Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof
ES2393761T3 (en) 2006-07-14 2012-12-27 Stiefel Research Australia Pty Ltd pharmaceutical foam fatty acid
KR20090094245A (en) * 2006-10-10 2009-09-04 래크리드 인코포레이티드 Methods and compositions for the treatment of vaginal diseases employing peroxide-producing enzymes and peroxidases
FR2909554B1 (en) * 2006-12-08 2013-11-01 Biorecept Lab anti-wrinkle cosmetic composition comprising hyaluronic acid
EP1938801A1 (en) * 2006-12-22 2008-07-02 Biofrontera Bioscience GmbH Nanoemulsion
WO2008088756A1 (en) * 2007-01-12 2008-07-24 Bridge Pharma, Inc. Dermal compositions of substituted amides and the use thereof as medication for pain and pruritus
WO2008141180A1 (en) * 2007-05-11 2008-11-20 Bristol-Myers Squibb Company Ostomy appliance
DE202007007455U1 (en) * 2007-05-25 2008-10-09 Schwan-Stabilo Cosmetics Gmbh & Co. Kg Pigmented ink polymer-based
WO2009056991A3 (en) 2007-09-04 2009-11-05 Foamix Ltd. Device for delivery of a foamable composition
WO2009031644A1 (en) * 2007-09-05 2009-03-12 Pola Pharma Inc. Antifungal pharmaceutical composition
CN101808637B (en) * 2007-09-05 2013-07-24 宝丽制药股份有限公司 Pharmaceutical composition
CN101808638B (en) * 2007-09-05 2012-07-25 宝丽制药股份有限公司 Antifungal composition
EP2042154A1 (en) * 2007-09-28 2009-04-01 Koninklijke Coöperatie Cosun U.A. Cosmetic mousse
US20090185995A1 (en) * 2008-01-18 2009-07-23 Stacy Vochecowicz Lubricious, non-tacky personal lubricant
US8652443B2 (en) 2008-02-14 2014-02-18 Precision Dermatology, Inc. Foamable microemulsion compositions for topical administration
US20090312428A1 (en) 2008-06-13 2009-12-17 Fernando Figueredo Biocide Compositions Comprising Quaternary Ammonium and Urea and Methods for Their Use
CN102245169A (en) * 2008-10-15 2011-11-16 昆诺瓦制药公司 Salicylic acid composition
CA2741028A1 (en) * 2008-10-21 2010-04-29 Novodermix International Limited Composition for treatment of epithelial tissue
US9532717B2 (en) * 2008-10-28 2017-01-03 The Procter & Gamble Company Method for diagnosing vulvovaginal disorders
ES2364692T3 (en) 2008-12-23 2011-09-12 Intendis Gmbh foamable composition essentially free of pharmaceutically active ingredients for the treatment of human skin.
CA2745457A1 (en) * 2008-12-23 2010-07-01 Galderma S.A. Topical pharmaceutical composition containing a water-sensitive active principle
EP3196647A3 (en) * 2010-01-17 2017-09-27 The Procter & Gamble Company Biomarker-based methods for identifying and formulating compositions that improve skin quality and reduce the visible signs of aging in skin
WO2010096868A1 (en) 2009-02-25 2010-09-02 Stiefel Research Australia Pty Ltd Topical foam composition
WO2010103505A1 (en) 2009-03-08 2010-09-16 Trima - Israel Phramaceutical Products Maabarot Ltd. Foamable topical composition
FR2943914A1 (en) * 2009-04-06 2010-10-08 Fabre Pierre Dermo Cosmetique Bottle foamer comprising a pharmaceutical composition
EP2416758B8 (en) 2009-04-09 2017-10-18 Pola Pharma Inc. Antimycotic pharmaceutical composition
DE102009028156A1 (en) * 2009-07-31 2011-02-03 Evonik Stockhausen Gmbh Whippable o / w emulsion
WO2011024620A1 (en) 2009-08-25 2011-03-03 Pola Pharma Inc. Antimycotic pharmaceutical composition
CN102665734A (en) * 2009-09-25 2012-09-12 法马索尔有限公司 Surface coatings for skin
US8716203B2 (en) * 2009-10-18 2014-05-06 Eli D Ehrenpreis Water-soluble colonoscopy lubricant
WO2011061516A3 (en) 2009-11-23 2011-11-03 Cipla Limited Topical foam composition
EP2544662A2 (en) * 2010-03-10 2013-01-16 Nuvo Research Inc. Foamable formulation
DE202010004750U1 (en) * 2010-04-09 2011-10-11 Biofrontera Bioscience Gmbh Pharmaceutical and / or cosmetic composition for treating the skin
US20120022178A1 (en) * 2010-06-17 2012-01-26 Diversified Glogal Technologies, Llc Methods of embedding foam with additives
US8978936B2 (en) 2010-07-12 2015-03-17 Foamix Pharmaceuticals Ltd. Apparatus and method for releasing a unit dose of content from a container
EP2616037A2 (en) 2010-09-14 2013-07-24 Trima - Israel Phramaceutical Products Maabarot Ltd. Foamable topical composition
WO2012057894A1 (en) * 2010-10-26 2012-05-03 Quinnova Pharmaceuticals, Inc. Econazole composition and methods of treatment therewith
JP5430601B2 (en) * 2011-04-01 2014-03-05 マルホ株式会社 Non-aerosol type foam composition for
EP2782584A4 (en) 2011-11-23 2015-12-23 Therapeuticsmd Inc Natural combination hormone replacement formulations and therapies
US20150133421A1 (en) 2012-11-21 2015-05-14 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
GB201122235D0 (en) 2011-12-23 2012-02-01 Givaudan Sa Composition
RU2505301C2 (en) * 2012-05-05 2014-01-27 Федеральное государственное бюджетное учреждение науки Институт нефтехимии и катализа Российской академии наук Agent for hair growth stimulation
FR2994386B1 (en) * 2012-08-07 2016-06-24 Thorel Jean-Noel Inhibition of pathogenic microorganisms by accession a sucrose ester and / or sorbitan in the cosmetic treatment of cutaneous atopy
RU2494746C1 (en) * 2012-08-13 2013-10-10 Федеральное бюджетное учреждение науки "Казанский научно-исследовательский институт эпидемиологии и микробиологии" Роспотребнадзора Antibacterial composition containing water-soluble low-molecular chitosan
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US9499772B2 (en) 2013-03-13 2016-11-22 Battelle Energy Alliance, Llc Methods of decontaminating surfaces and related compositions
WO2014165471A1 (en) * 2013-04-03 2014-10-09 Isp Investments Inc. Composition comprising cyclodextrin as uv- and ir-radiation screen agent
JP2015000871A (en) * 2013-06-18 2015-01-05 ロレアル Foam aerosol cosmetic composition
JP5671118B1 (en) * 2013-10-09 2015-02-18 近代化学株式会社 Repelling foamable composition pest
US20170333472A1 (en) * 2014-12-30 2017-11-23 3M Innovative Properties Company Bactericidal composition
WO2017035501A1 (en) * 2015-08-27 2017-03-02 Academia Sinica Sialyltransferase inhibitors and uses thereof
FR3041536A1 (en) * 2015-09-29 2017-03-31 Galderma Res & Dev chemical foam leave-containing trifarotene, and its use in the treatment of acne.
FR3041535A1 (en) * 2015-09-29 2017-03-31 Galderma Res & Dev chemical foam leave-containing trifarotene, and its use in the treatment of ichthyosis.
US9931349B2 (en) 2016-04-01 2018-04-03 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition
CN105961414A (en) * 2016-06-27 2016-09-28 山东美罗福农业科技股份有限公司 Water-based plant-source pesticide with diosgenin and method for preparing water-based plant-source pesticide

Citations (102)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6180669B2 (en) *
US513714A (en) * 1894-01-30 Card-holder
US2586287A (en) * 1948-12-11 1952-02-19 Colagte Palmolive Peet Company Aluminum sulfamate antiperspirant preparation
US2968628A (en) * 1958-10-17 1961-01-17 Shulton Inc Propellant composition
US3236457A (en) * 1963-08-21 1966-02-22 John R Kennedy Composite spray container assembly
US3298919A (en) * 1962-12-26 1967-01-17 Dow Corning Shaving cream containing polysiloxanes
US3301444A (en) * 1965-08-12 1967-01-31 Oel Inc Aerosol metering valve
US3303970A (en) * 1964-07-14 1967-02-14 Jerome Marrow Device for simultaneously dispensing from plural sources
US3366494A (en) * 1967-02-15 1968-01-30 Du Pont Pressurized aerosol food emulsions
US3369034A (en) * 1964-04-27 1968-02-13 Eversharp Inc Process for separating saponifiables and unsaponifiables in marine animal oils
US3559890A (en) * 1968-09-03 1971-02-02 William R Brooks Foam dispenser
US3561262A (en) * 1967-10-26 1971-02-09 Magnaflux Corp Water soluble developer
US3563098A (en) * 1968-06-28 1971-02-16 Rex Chainbelt Inc Automatic quick release mechanism
US3787566A (en) * 1969-07-29 1974-01-22 Holliston Labor Inc Disinfecting aerosol compositions
US3865275A (en) * 1973-07-30 1975-02-11 Raymond Lee Organization Inc Apparatus for operating an aerosol can
US3866800A (en) * 1969-02-12 1975-02-18 Alberto Culver Co Non-pressurized package containing self-heating products
US4001391A (en) * 1969-04-18 1977-01-04 Plough, Inc. Means for depositing aerosol sprays in buttery form
US4001442A (en) * 1973-07-18 1977-01-04 Elastin-Werk Aktiengesellschaft Collagen-containing preparations
US4252787A (en) * 1976-12-27 1981-02-24 Cambridge Research And Development Group Anti-fertility composition and method
US4278206A (en) * 1979-04-13 1981-07-14 Ae Development Corporation Non-pressurized dispensing system
US4310510A (en) * 1976-12-27 1982-01-12 Sherman Kenneth N Self administrable anti-fertility composition
US4309995A (en) * 1980-01-28 1982-01-12 Sacco Susan M Vaginal irrigation apparatus
US4427670A (en) * 1980-03-27 1984-01-24 Mitsubishi Chemical Industries Limited Skin preparation
US4725609A (en) * 1983-11-21 1988-02-16 Burroughs Wellcome Co. Method of promoting healing
US4798682A (en) * 1985-06-18 1989-01-17 Henkel Kommanditgesellschaft Auf Aktien Oil-in-water emulsions with increased viscosity under shear stress
US4804674A (en) * 1986-03-26 1989-02-14 Euroceltique, S.A. Vaginal pharmaceutical composition
US4806262A (en) * 1985-08-14 1989-02-21 The Procter & Gamble Company Nonlathering cleansing mousse with skin conditioning benefits
US4808388A (en) * 1986-08-20 1989-02-28 Merz + Co. Gmbh & Co. Foamable creams
US4897262A (en) * 1988-03-22 1990-01-30 Playtex Jhirmack, Inc. Non-aerosol hair spray composition
US4902281A (en) * 1988-08-16 1990-02-20 Corus Medical Corporation Fibrinogen dispensing kit
US4981845A (en) * 1988-09-09 1991-01-01 Chesebrough Pond's U.S.A. Co., Division Of Conopco, Inc. Cosmetic composition
US4981679A (en) * 1983-06-08 1991-01-01 Briggs Joseph H Method and composition for the treatment of burns
US4981367A (en) * 1989-07-28 1991-01-01 Stranco, Inc. Portable mixing apparatus
US4981677A (en) * 1987-09-23 1991-01-01 L'oreal Petrolatum-containing aerosol foam concentrate
US4985459A (en) * 1984-02-08 1991-01-15 Richardson-Vicks, Inc. Analgesic and anti-inflammatory compositions comprising diphenhydramine and methods of using same
US4992478A (en) * 1988-04-04 1991-02-12 Warner-Lambert Company Antiinflammatory skin moisturizing composition and method of preparing same
US4993496A (en) * 1987-07-06 1991-02-19 Total Walther Feuerschutz Gmbh Quick release valve for sprinkler head
US5082651A (en) * 1989-04-26 1992-01-21 Smith Kline & French Laboratories Limited Pharmaceutical compositions
US5087618A (en) * 1982-05-18 1992-02-11 University Of Florida Redox carriers for brain-specific drug delivery
US5089252A (en) * 1982-01-15 1992-02-18 L'oreal Cosmetic composition for treating keratin fibres, and process for treating the latter
US5091111A (en) * 1990-09-19 1992-02-25 S. C. Johnson & Son, Inc. Aqueous emulsion and aersol delivery system using same
US5279819A (en) * 1991-03-18 1994-01-18 The Gillette Company Shaving compositions
US5286475A (en) * 1990-11-09 1994-02-15 L'oreal Anhydrous cosmetic composition in the aerosol form forming a foam
US5378451A (en) * 1989-10-19 1995-01-03 Dow B. Hickam, Inc. Topical medicinal pressurized aerosol compositions and method of preparation, method of use and article of manufacture thereof
US5378730A (en) * 1988-06-09 1995-01-03 Alza Corporation Permeation enhancer comprising ethanol and monoglycerides
US5380761A (en) * 1991-04-15 1995-01-10 Chinoin Gyogyszer- Es Vegyeszeti Termekek Gyara Rt. Transdermal compositions
US5384308A (en) * 1993-06-14 1995-01-24 Henkin; R. I. Composition and method for enhancing wound healing
US5385943A (en) * 1988-03-30 1995-01-31 Schering Aktiengesellschaft Use of topically applicable preparations for treatment of presbyderma
US5389676A (en) * 1991-03-22 1995-02-14 E. B. Michaels Research Associates, Inc. Viscous surfactant emulsion compositions
US5482965A (en) * 1991-03-19 1996-01-09 Rajadhyaksha; Vithal J. Compositions and method comprising aminoalcohol derivatives as membrane penetration enhancers for physiological active agents
US5491245A (en) * 1993-03-26 1996-02-13 Th. Goldschmidt Ag Method for the synthesis of amphoteric surfactants
US5603940A (en) * 1993-10-08 1997-02-18 L'oreal Oil-in-water emulsion which may be used for obtaining a cream
US5605679A (en) * 1994-06-03 1997-02-25 L'oreal Photoprotective/cosmetic compositions comprising at least one solid organic sunscreen compound and diphenylacrylate solvent therefor
US5705472A (en) * 1995-07-18 1998-01-06 Petroferm Inc. Neutral aqueous cleaning composition
US5716611A (en) * 1996-01-02 1998-02-10 Euro-Celtique, S.A. Emollient antimicrobial formulations containing povidone iodine
US5716621A (en) * 1996-07-03 1998-02-10 Pharmadyn, Inc. Nonocclusive drug delivery device and process for its manufacture
US5719197A (en) * 1988-03-04 1998-02-17 Noven Pharmaceuticals, Inc. Compositions and methods for topical administration of pharmaceutically active agents
US5719122A (en) * 1992-10-20 1998-02-17 Smithkline Beecham Farmaceutici S.P.A. Pharmaceutical compositions containing a calcitonin
US5856452A (en) * 1996-12-16 1999-01-05 Sembiosys Genetics Inc. Oil bodies and associated proteins as affinity matrices
US5858371A (en) * 1997-02-05 1999-01-12 Panacea Biotech Limited Pharmaceutical composition for the control and treatment of anorectal and colonic diseases
US5866040A (en) * 1990-06-15 1999-02-02 Shiseido Company, Ltd. Complex and emulsified composition
US5865347A (en) * 1997-10-27 1999-02-02 William T. Wilkinson Multi-chamber dispenser for flowable materials
US5869529A (en) * 1994-07-20 1999-02-09 Agis Industries (1983) Ltd. Topical preparation for the prevention and treatment of lesions and sores associated with a herpes virus
US5871720A (en) * 1997-11-20 1999-02-16 Colgate-Palmolive Company Cosmetic compositions with DBS and functionalized silicones
US6168576B1 (en) * 1999-05-24 2001-01-02 Irene N. Reynolds Device for dispensing vaginal medication
US6171347B1 (en) * 1996-11-16 2001-01-09 Wella Aktiengesellschaft Compositions, methods and kits for reductively removing color from dyed hair
US6180669B1 (en) * 1996-11-12 2001-01-30 Tamarkin Pharmaceutical Innovation Ltd. Method for treatment of dermatological disorders
US6335022B1 (en) * 1998-12-17 2002-01-01 L'oreal Nanoemulsion based on oxyethylenated or non-oxyethylenated sorbitan fatty esters, and its uses in the cosmetics, dermatological and/or ophthalmological fields
US20020002151A1 (en) * 2000-05-23 2002-01-03 Showa Yakuhin Kako Co., Ltd. Minocycline-containing compositions
US20020004063A1 (en) * 1999-09-28 2002-01-10 Jie Zhang Methods and apparatus for drug delivery involving phase changing formulations
US6341717B2 (en) * 2000-04-01 2002-01-29 Megaplast Gmbh & Co. Kg Metering pump dispenser with at least two metering pumps
US20020013481A1 (en) * 1998-02-24 2002-01-31 Uwe Schonrock Use of flavones flavanones and flavonoids for protecting ascorbic acid and/or ascorbyl compounds from oxidation
US6375936B1 (en) * 1998-07-09 2002-04-23 L'oreal Photoprotective cosmetic composition containing an anionic surfactant, compounds for screening out ultraviolet radiation and a cationic or zwitterionic amphiphilic compound, and use thereof
US20030006193A1 (en) * 1999-09-06 2003-01-09 Katsunori Ikeda Apparatus for purifying nucleic acids and proteins
US6511655B1 (en) * 1999-08-16 2003-01-28 Beiersdorf Ag Cosmetic or dermatological preparations of the oil-in-water type
US20040002550A1 (en) * 2002-06-28 2004-01-01 Mercurio Anthony Fred Post foaming compositions
US6672483B1 (en) * 1999-02-05 2004-01-06 Rexam Sofab Dispenser for chemically unstable products
US6682726B2 (en) * 2001-04-30 2004-01-27 The Gillette Company Self-foaming shaving lotion
US6682750B2 (en) * 2001-03-03 2004-01-27 Clariant Gmbh Surfactant-free cosmetic, dermatological and pharmaceutical compositions
US20040018228A1 (en) * 2000-11-06 2004-01-29 Afmedica, Inc. Compositions and methods for reducing scar tissue formation
US20050002976A1 (en) * 2003-06-19 2005-01-06 The Procter & Gamble Company Polyol-in-silicone emulsions
US6843390B1 (en) * 2003-03-17 2005-01-18 Joe G. Bristor Multiple fluid closed system dispensing device
US20050013853A1 (en) * 2000-11-29 2005-01-20 Irit Gil-Ad Anti-proliferative drugs
US20060008432A1 (en) * 2004-07-07 2006-01-12 Sebastiano Scarampi Gilsonite derived pharmaceutical delivery compositions and methods: nail applications
US20060018937A1 (en) * 2002-10-25 2006-01-26 Foamix Ltd. Steroid kit and foamable composition and uses thereof
US20060018938A1 (en) * 1997-08-18 2006-01-26 Stephanie Neubourg Foam skin cream, use of the foam skin protection cream and a process of its preparation
USRE38964E1 (en) * 1995-01-09 2006-01-31 Becton Dickinson And Company One hand needle release system
US20070010580A1 (en) * 2003-05-30 2007-01-11 Gianfranco De Paoli Ambrosi Formulation for chemical peeling
US20070009607A1 (en) * 2005-07-11 2007-01-11 George Jones Antibacterial/anti-infalmmatory composition and method
US20070020213A1 (en) * 2002-10-25 2007-01-25 Foamix Ltd. Foamable composition combining a polar solvent and a hydrophobic carrier
US20070020304A1 (en) * 2002-10-25 2007-01-25 Foamix Ltd. Non-flammable insecticide composition and uses thereof
US20070017696A1 (en) * 2005-07-22 2007-01-25 Hon Hai Precision Industry Co., Ltd. Multi-layer printed circuit board
US20080008397A1 (en) * 2006-07-04 2008-01-10 Pavel Kisilev Feature-aware image defect removal
US20080015271A1 (en) * 2006-07-14 2008-01-17 Stiefel Research Austrialia Pty Ltd Fatty acid pharmaceutical foam
US20080015263A1 (en) * 2002-02-27 2008-01-17 Bolotin Elijah M Compositions for delivery of therapeutics and other materials
US7645803B2 (en) * 2005-05-09 2010-01-12 Foamix Ltd. Saccharide foamable compositions
US20110002857A1 (en) * 2003-08-04 2011-01-06 Foamix Ltd. Oleaginous pharmaceutical and cosmetic foam
US20110002969A1 (en) * 2008-02-29 2011-01-06 Lipotec, S.A. Cosmetic or pharmaceutical compositions comprising metalloproteinase inhibitors
US20110008266A1 (en) * 2008-01-14 2011-01-13 Foamix Ltd. Poloxamer foamable pharmaceutical compositions with active agents and/or therapeutic cells and uses
US8343945B2 (en) * 2007-12-07 2013-01-01 Foamix Ltd. Carriers, formulations, methods for formulating unstable active agents for external application and uses thereof
US20130011342A1 (en) * 2009-10-02 2013-01-10 Foamix Ltd. Surfactant-free, water-free formable composition and breakable foams and their uses
US8362091B2 (en) * 2003-08-04 2013-01-29 Foamix Ltd. Foamable vehicle and pharmaceutical compositions thereof

Family Cites Families (1058)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1159250A (en) 1914-05-01 1915-11-02 Frank Moulton Vaginal irrigator.
US1666684A (en) 1926-01-15 1928-04-17 Carstens Mfg Co H Vaginal douche
US1924972A (en) 1929-04-15 1933-08-29 Carl J Beckert Stabilized egg product
US2085733A (en) 1935-07-15 1937-07-06 John C Bird Shaving cream
US2390921A (en) 1943-03-23 1945-12-11 Ethel Hudson Clark Applicator for facial creams
US2524590A (en) 1946-04-22 1950-10-03 Carsten F Boe Emulsion containing a liquefied propellant gas under pressure and method of spraying same
US2617754A (en) 1949-08-29 1952-11-11 Procter & Gamble Cosmetic cream
US3062715A (en) 1953-11-18 1962-11-06 George S Pfaus Vaginal tablet
US2767712A (en) 1954-03-01 1956-10-23 Neil S Waterman Medicinal applicator
GB808104A (en) 1955-01-04 1959-01-28 Udylite Res Corp Electrodeposition of copper from aqueous alkaline cyanide solutions
GB808105A (en) 1956-06-15 1959-01-28 Ici Ltd New pharmaceutical compositions
US3092555A (en) 1958-04-21 1963-06-04 Roy H Horn Relatively collapsible aerosol foam compositions
US3144386A (en) 1958-05-09 1964-08-11 Merck & Co Inc Mastitis aerosol foam
US3142420A (en) 1959-11-09 1964-07-28 Neotechnic Eng Ltd Metering dispenser for aerosol with fluid pressure operated piston
US3178352A (en) 1959-02-27 1965-04-13 Erickson Roy Shaving method and composition therefor
US3141821A (en) 1959-03-17 1964-07-21 Lehn & Fink Products Corp Synergistic combination of alkyl sulfonates, alkylaryl sulfonates and topical antibacterial agents for local antisepsis
US3004894A (en) 1959-04-07 1961-10-17 Upjohn Co Therapeutic composition comprising tetracycline and a dioxolane
GB922930A (en) 1959-09-21 1963-04-03 Sunnen Joseph Spermicidal composition and method of making same
US3092255A (en) 1960-02-05 1963-06-04 Robert F Hohman Sorting apparatus
US3067784A (en) 1960-04-14 1962-12-11 Esta Medical Lab Inc Adapter connecting aerosol container valve stem to dispenser for filling said dispenser
NL270627A (en) 1960-10-26
US3154075A (en) * 1960-11-02 1964-10-27 Norwich Pharma Co Vaginal applicator
GB998490A (en) 1961-06-03 1965-07-14 Albert Fritz Albach A foam projector
DE1926796U (en) 1961-10-12 1965-11-11 Heidolph Elektro K G Fan.
BE624833A (en) 1962-02-28
US3330730A (en) 1962-08-03 1967-07-11 Colgate Palmolive Co Pressurized emulsion quick breaking foam compositions
US3252859A (en) 1962-10-24 1966-05-24 Masti Kure Company Inc Colloidal silica-oil composition and method of using same
US3244589A (en) 1962-10-26 1966-04-05 Sunnen Alkyl phenoxy polyethoxy ether spermicidal aerosol
US3261695A (en) 1962-12-24 1966-07-19 Gen Foods Corp Process for preparing dehydrated foods
US3383280A (en) 1963-01-09 1968-05-14 Miles Lab Dermatological abradant stick-type applicator
FR1355607A (en) 1963-01-22 1964-03-20 Improvements to cannulas sensors and their applications
US3149543A (en) 1963-03-04 1964-09-22 Ingersoll Rand Co Non-lubricated piston
FR3476M (en) 1963-05-31 Mediline Ag bactericidal composition is sprayed.
US3824303A (en) 1963-07-24 1974-07-16 Yardley Of London Inc Collapsible foam pre-electric shave lotion containing diester lubricants
GB1081949A (en) 1963-08-12 1967-09-06 Avon Prod Inc Improvements in cosmetic mask
US3333333A (en) 1963-08-14 1967-08-01 Rca Corp Method of making magnetic material with pattern of embedded non-magnetic material
US3263867A (en) 1963-12-26 1966-08-02 Valve Corp Of America Metering button-type aerosol actuator
US3395214A (en) 1964-01-09 1968-07-30 Scholl Mfg Co Inc Antiperspirant composition providing a readily collapsible sprayable foam
US3278093A (en) 1964-01-13 1966-10-11 Valve Corp Of America Metering and non-metering aerosol actuator button
US3395215A (en) 1964-10-15 1968-07-30 Colgate Palmolive Co Pressurized lotion composition
US3384541A (en) 1964-10-28 1968-05-21 William G. Clark Spermicidal vaginal pharmaceutical concentrate for producing nonaqueous foam with aerosol propellants
US3263869A (en) 1964-11-03 1966-08-02 Calmar Inc Liquid dispenser with overcap
US3342845A (en) 1964-11-05 1967-09-19 Upjohn Co Terphenyl triisocyanates
US3419658A (en) 1965-01-25 1968-12-31 Du Pont Nonaqueous aerosol foams containing mineral oil
US3346451A (en) 1965-01-27 1967-10-10 S E Massengill Company Concentrated liquid lactic acid douche preparation containing aromatics
US3456052A (en) 1965-09-28 1969-07-15 Garrett Lab Inc Aerosol composition containing butoxymonoether of a polyoxyalkylene glycol
GB1121358A (en) 1965-10-21 1968-07-24 Bristol Myers Co Aerosol manufacture
US3849569A (en) 1965-12-02 1974-11-19 Glaxo Lab Ltd Composition containing procaine penicillin
BE692228A (en) 1966-01-10 1967-07-05
US3401849A (en) 1966-05-24 1968-09-17 Robert L. Weber Low force metering valve
US3886084A (en) 1966-09-29 1975-05-27 Champion Int Corp Microencapsulation system
US3377004A (en) 1966-10-03 1968-04-09 Gen Mills Inc Metered dispensing container
GB1201918A (en) 1966-12-21 1970-08-12 Bespak Industries Ltd Improvements in or relating to valves for pressurised dispensers
US3527559A (en) 1967-01-05 1970-09-08 Standard Pharmacal Corp Dense aqueous aerosol foam depilatory compositions containing a mixture of alkaline metal and alkali metal thioglycolates and a fatty alcohol-alkylene oxide wax emulsifying agent
US3540448A (en) 1968-01-17 1970-11-17 Joseph Sunnen Rechargeable applicator for dispensing substances in a foam condition
DE1926796A1 (en) 1968-05-27 1970-03-19 Dudiuyt Jean Paul Aerosol compsn. and container
US3878118A (en) 1968-09-06 1975-04-15 Wilkinson Sword Ltd Self-heating chemical compositions
US3667461A (en) 1968-11-05 1972-06-06 Paul A Zamarra Disposable syringe
CA975500A (en) 1969-02-06 1975-09-30 Joseph G. Spitzer Structures such as applicator pads for cleaning and other purposes, propellant compositions for forming the same, and process
US3966090A (en) 1969-02-17 1976-06-29 Dart Industries Inc. Package for dispensing an antiseptic composition
US3819524A (en) 1969-06-17 1974-06-25 Colgate Palmolive Co Cosmetic composition for thermal dispensing
US3577518A (en) 1969-07-18 1971-05-04 Nat Patent Dev Corp Hydrophilic hairspray and hair setting preparations
BE759520A (en) 1969-11-28 1971-04-30 Aspro Nicholas Ltd Compositions aspirin
GB1353381A (en) 1971-02-04 1974-05-15 Wilkinson Sword Ltd Substituted p-menthanes and compositions containing them
GB1351761A (en) 1971-02-04 1974-05-01 Wilkinson Sword Ltd Substituted p-menthane carboxamides and compositions containing them
GB1351762A (en) 1971-02-14 1974-05-01 Wilkinson Sword Ltd Tobacco and tobacco-containing manufactures
CA958338A (en) 1971-03-08 1974-11-26 Bristol-Myers Canada Limited Antiperspirant powder aerosol compositions containing aluminum chloride and water soluble aluminum compounds and methods of preparation
US3770648A (en) 1971-07-12 1973-11-06 Bristol Myers Co Anhydrous aerosol foam
US3912667A (en) 1971-09-13 1975-10-14 Spitzer Joseph G Structures such as applicator pads for cleaning and other purposes, propellant compositions for forming the same and process
BE788788A (en) 1971-09-13 1973-03-13 Treuhandvereinigung Ag Product to preserve, promote and restore the hair and method of manufacture of this product
US3997467A (en) 1971-11-26 1976-12-14 Pharmacia Aktiebolag Foam forming composition
CA983808A (en) 1971-11-26 1976-02-17 Pharmacia Aktiebolag Foam forming composition
GB1370390A (en) 1971-12-30 1974-10-16 Ciba Geigy Ag Divinyl-diphenyl compounds and processes for their manufacture and use
US3963833A (en) 1972-06-02 1976-06-15 Colgate-Palmolive Company Antiperspirant composition and method containing a dihydro-benzofuran and an astringent metal salt
US3841525A (en) 1972-06-14 1974-10-15 N Siegel Aerosol spray device with cam activator
US3849580A (en) 1972-09-05 1974-11-19 American Home Prod Aerosol dispensing system for anhydrous edible fat compositions
US3751562A (en) 1972-09-22 1973-08-07 Princeton Biomedix Medicated gelled oils
US3970584A (en) 1973-02-14 1976-07-20 S. C. Johnson & Son, Inc. Aerosol package containing a foam-forming emulsion and propellent system
US4439416A (en) 1973-03-23 1984-03-27 Colgate-Palmolive Company Self-heating shaving composition
GB1423179A (en) 1973-05-16 1976-01-28 Wilkinson Sword Ltd Pressurised shaving foam dispensers
US4110426A (en) * 1973-07-24 1978-08-29 Colgate-Palmolive Company Method of treating skin and hair with a self-heated cosmetic
US3929985A (en) * 1974-01-18 1975-12-30 Richardson Merrell Inc Anhydrous candicidin foam compositions
DE2501548A1 (en) 1974-01-25 1975-07-31 Procter & Gamble Oral treatment agents
GB1457671A (en) 1974-01-31 1976-12-08 Wilkinson Sword Ltd Flavour
US3923970A (en) 1974-03-29 1975-12-02 Carter Wallace Stable aerosol shaving foams containing mineral oil
US3962150A (en) 1974-04-10 1976-06-08 Richardson-Merrell Inc. Foam producing cleansing compositions
US3953591A (en) 1974-04-29 1976-04-27 The Procter & Gamble Company Fatty acid, polysiloxane and water-soluble polymer containing skin conditioning emulsion
US3966632A (en) 1974-06-06 1976-06-29 G. D. Searle & Co. Vegetable oil emulsion
US4145411A (en) 1974-09-05 1979-03-20 Colgate-Palmolive Company Pressurized foaming shaving composition
JPS5729213B2 (en) 1974-11-12 1982-06-21
US4052513A (en) 1974-12-13 1977-10-04 Plough, Inc. Stable topical anesthetic compositions
US3952916A (en) 1975-01-06 1976-04-27 Warner-Lambert Company Automatic dispenser for periodically actuating an aerosol container
US3970219A (en) 1975-03-03 1976-07-20 Spitzer Joseph G Aerosol containers for foaming and delivering aerosols and process
US4019657A (en) 1975-03-03 1977-04-26 Spitzer Joseph G Aerosol containers for foaming and delivering aerosols
US4018396A (en) 1975-05-05 1977-04-19 Bechtel International Corporation Embedded housing for ore crusher
US3993224A (en) 1975-09-08 1976-11-23 Aerosol Investments, Ltd. Spout for two-component resin dispenser
DE2608226A1 (en) 1976-02-28 1977-09-08 Haarmann & Reimer Gmbh Means with physiological kuehlwirkung
US4100426A (en) 1976-03-10 1978-07-11 Square D Company Load controlling means
US4102995A (en) 1976-05-13 1978-07-25 Westwood Pharmaceuticals Inc. Tar gel formulation
JPS531113A (en) 1976-06-24 1978-01-07 Nippon Steel Corp Heating of slab for producing hot rolled plate with little skit mark
US4124149A (en) 1976-07-19 1978-11-07 Spitzer Joseph G Aerosol container with position-sensitive shut-off valve
CA1089368A (en) 1976-08-02 1980-11-11 Daniel C. Geary Polyethoxylated fatty alcohol in antiperspirant sticks
FI63669C (en) 1976-08-25 1983-08-10 Mundipharma Ag Foerfarande Foer framstaellning of a germicidal sprutbar terapeutiskt anvaendbar skumkomposition
US4083974A (en) 1977-03-07 1978-04-11 The Upjohn Company Topical steroidal anti-inflammatory preparations containing polyoxypropylene 15 stearyl ether
JPS5744429Y2 (en) 1977-04-14 1982-10-01
US4386104A (en) 1977-04-19 1983-05-31 Nazzaro Porro Marcella Process for the treatment of acne
GB2004746B (en) 1977-10-03 1982-03-10 Scherico Ltd Stable hopical anaesthetic compositions
JPS5639815Y2 (en) 1977-11-25 1981-09-17
DK154187C (en) 1977-12-01 1989-03-13 Astra Laekemedel Ab Process for the preparation of the local anesthetic preparations
US4292326A (en) 1977-12-30 1981-09-29 Nazzaro Porro Marcella Process for treatment of hyperpigmentary dermatoses
US4160827A (en) 1978-02-06 1979-07-10 The Upjohn Company Metronidazole phosphate and salts
US4229432A (en) 1978-04-19 1980-10-21 Bristol-Myers Company Antiperspirant stick composition
US4603812A (en) 1978-06-27 1986-08-05 The Dow Chemical Company Foam-generating pump sprayer
US4178373A (en) 1978-08-21 1979-12-11 William H. Rorer, Inc. Coal tar gel composition
US4214000A (en) 1978-10-30 1980-07-22 Johnson & Johnson Zinc salt of all-trans-retinoic acid for the treatment of acne
JPS5569682U (en) 1978-11-08 1980-05-13
JPS5569682A (en) 1978-11-20 1980-05-26 Toyo Aerosol Kogyo Kk Foam shrinkable composition
US4213979A (en) 1978-12-18 1980-07-22 Plough, Inc. Stable sprayable hydrocortisone product
US4954487A (en) 1979-01-08 1990-09-04 The Procter & Gamble Company Penetrating topical pharmaceutical compositions
US4439441A (en) 1979-01-11 1984-03-27 Syntex (U.S.A.) Inc. Contraceptive compositions and methods employing 1-substituted imidazole derivatives
US4226344A (en) 1979-02-06 1980-10-07 Booth, Inc. Constant flow valve actuator
US4230701A (en) 1979-03-21 1980-10-28 Hoffmann-La Roche Inc. Administration of biologically active vitamin D3 and vitamin D2 materials
US4335120A (en) 1979-03-21 1982-06-15 Hoffmann-La Roche Inc. Administration of biologically active vitamin D3 and vitamin D2 materials
US4241048A (en) 1979-05-01 1980-12-23 Bristol-Myers Company Suspension composition of benzocaine
JPS5643443B2 (en) 1979-05-18 1981-10-13
US4268499A (en) 1979-06-07 1981-05-19 Dow Corning Corporation Antiperspirant emulsion compositions
US4241149A (en) 1979-07-20 1980-12-23 Temple University Canal clathrate complex solid electrolyte cell
DE2931469A1 (en) 1979-08-02 1981-02-26 Bayer Ag Oberflaechenversiegelte formkoerper made of cellular polyurethane elastomers and methods for their preparation
US4323694A (en) 1981-04-13 1982-04-06 Finetex, Inc. Benzoic acid esters
US4271149B1 (en) 1979-09-21 1983-04-19
US4299826A (en) 1979-10-12 1981-11-10 The Procter & Gamble Company Anti-acne composition
EP0032309A3 (en) 1980-01-10 1981-08-05 Imperial Chemical Industries Plc Production of catalyst component, catalyst and use thereof
FI811745L (en) 1980-06-19 1981-12-20 Draco Ab Science pharmaceutical composition of foerfarande Foer framstaellning daerav
US4338211A (en) 1980-06-30 1982-07-06 The Procter & Gamble Company Liquid surfactant skin cleanser with lather boosters
US4508705A (en) 1980-07-02 1985-04-02 Lever Brothers Company Skin treatment composition
US4323582A (en) 1980-07-21 1982-04-06 Siegel Norman H Method of treating animals and humans for internal and external parasites
JPS601113Y2 (en) 1980-07-22 1985-01-12
JPS5914282B2 (en) 1980-07-31 1984-04-04 Kobe Steel Ltd
US4329990A (en) 1980-08-07 1982-05-18 Sneider Vincent R Expanding swab applicator
US4325939A (en) 1980-09-22 1982-04-20 Richardson-Vicks Inc. Zinc derivatives and their use in dental compositions
US4305936A (en) 1980-10-09 1981-12-15 Dermik Laboratories Topical corticosteroid formulations
US4292250A (en) 1980-11-17 1981-09-29 Wisconsin Alumni Research Foundation Vitamin D derivatives
DE3176215D1 (en) 1980-11-19 1987-07-02 Procter & Gamble Non-yellowing topical pharmaceutical composition
DE3071101D1 (en) 1980-11-27 1985-10-24 Chinoin Gyogyszer Es Vegyeszet Antimycotic synergistic pharmaceutical compositions and process for the preparation thereof
DE3147726A1 (en) 1980-12-03 1982-06-24 Leo Pharm Prod Ltd Antibiotic complex, process for their production and pharmaceutical agents containing these compounds
US4352808A (en) 1980-12-12 1982-10-05 Schering Corporation 3-Aralkyloxy-2,3-dihydro-2-(imidazolylmethyl)benzo(b)thiophenes and related derivatives, their use as antimicrobials and pharmaceutical formulations useful therefore
US4522948A (en) 1981-04-24 1985-06-11 Syntex (U.S.A.) Inc. Spermicidal substituted 1-(cycloalkyl)alkylimidazoles
US4393066A (en) 1981-06-05 1983-07-12 Garrett David M Method for treatment of herpetic lesions
US4607101A (en) 1981-08-27 1986-08-19 Jaye-Boern Laboratories, Inc. Method of treating acne vulgaris with a composition containing carbamide peroxide
US4469674A (en) 1981-09-03 1984-09-04 Richardson-Vicks Inc. Stable oral compositions containing zinc and fluoride compounds
US4440320A (en) 1981-11-30 1984-04-03 Wernicke Steven A Foam dispensing apparatus
LU83949A1 (en) 1982-02-16 1983-09-02 Oreal COMPOSITION FOR treating keratin materials containing at least one cationic polymer and at least one anionic latex
JPH023768B2 (en) 1982-08-30 1990-01-24 Shiseido Co Ltd
US4529605A (en) 1983-01-12 1985-07-16 Una E. Lynch Bathing oil composition
US4661340A (en) 1983-06-06 1987-04-28 Interkemia Vegyipari Gazdasagi Tarsasag Quail egg based stabilized foam compositions for cosmetic purposes
US4552872A (en) 1983-06-21 1985-11-12 The Procter & Gamble Company Penetrating topical pharmaceutical compositions containing corticosteroids
GB8402748D0 (en) 1984-02-02 1984-03-07 Dunlop Ltd Intravaginal device
US4912124A (en) 1984-02-23 1990-03-27 Ortho Pharmaceutical Corporation Antifungal dermatological solution
GB2154875B (en) 1984-03-01 1987-10-28 Ahi Operations Ltd A device for insertion into a body cavity of an animal and/or applicator therefor
US4628063A (en) 1984-03-08 1986-12-09 Dana P. Brigham Antiviral pharmaceutical preparations and methods for their use
US4877805A (en) 1985-07-26 1989-10-31 Kligman Albert M Methods for treatment of sundamaged human skin with retinoids
US4574052A (en) 1984-05-31 1986-03-04 Richardson-Vicks Inc. Crackling aerosol foam
GB8416638D0 (en) 1984-06-29 1984-08-01 Beecham Group Plc Topical treatment and composition
DE3564973D1 (en) 1984-08-06 1988-10-20 Ciba Geigy Ag Process for paper sizing with anionic hydrophobic sizing agents and cationic retention agents
US4595526A (en) 1984-09-28 1986-06-17 Colgate-Palmolive Company High foaming nonionic surfacant based liquid detergent
DE3567798D1 (en) 1984-10-01 1989-03-02 Torkel Ingemar Fischer Hypersensitivity test means
BE903541Q (en) 1984-10-30 1986-02-17 Kanegafuchi Chemical Ind Process for producing a latex coagulates spherical configuration
CA1261276A (en) 1984-11-09 1989-09-26 Mark B. Grote Shampoo compositions
US4701320A (en) 1984-11-29 1987-10-20 Lederle (Japan), Ltd. Composition stably containing minocycline for treating periodontal diseases
US4627973A (en) 1984-12-14 1986-12-09 Charles Of The Ritz Group Ltd. Skin mousse
EP0186453A3 (en) 1984-12-20 1987-09-30 Warner-Lambert Company A non-irritating cleansing composition
US4673569A (en) 1985-02-12 1987-06-16 Faberge Incorporated Mousse hair composition
DE3670569D1 (en) 1985-03-01 1990-05-31 Procter & Gamble Mild cleansing foam.
US5002680A (en) 1985-03-01 1991-03-26 The Procter & Gamble Company Mild skin cleansing aerosol mousse with skin feel and moisturization benefits
US4752465A (en) 1985-09-20 1988-06-21 Product Resources International, Inc. Aerosol foam
WO1986005389A1 (en) 1985-03-18 1986-09-25 Product Resources International, Inc. Exothermic stable foam compositions
US4639367A (en) 1985-03-18 1987-01-27 Product Resources International, Inc. Aerosol foam
US5094853A (en) 1985-04-26 1992-03-10 S. C. Johnson & Son, Inc. Method of preparing a water-soluble stable arthropodicidally-active foam matrix
US4965063A (en) 1985-05-24 1990-10-23 Irene Casey Cleaner and disinfectant with dye
US4672078A (en) 1985-07-03 1987-06-09 Schering-Plough Corporation Urea stabilized with a lactone in various pharmaceutical and cosmetic preparations
GB8519426D0 (en) 1985-08-01 1985-09-04 Ici Plc Composition for personal care products
EP0213827A3 (en) 1985-08-14 1988-04-06 THE PROCTER & GAMBLE COMPANY Nonfoaming cleansing mousse with skin conditioning benefits
JPH0132204B2 (en) 1985-09-11 1989-06-29 Chiizuburoo Honzu Inc
FR2591331A1 (en) 1985-12-10 1987-06-12 Drevet Jean Baptiste Device for dispensing metered portions of a product contained in a pressurised receptacle
US5536743A (en) * 1988-01-15 1996-07-16 Curatek Pharmaceuticals Limited Partnership Intravaginal treatment of vaginal infections with buffered metronidazole compositions
US4837378A (en) 1986-01-15 1989-06-06 Curatek Pharmaceuticals, Inc. Topical metronidazole formulations and therapeutic uses thereof
JPS62241701A (en) 1986-04-11 1987-10-22 Maeda Kogyo Kk Quick releasing device for hub for bicycle
CA1291036C (en) 1986-04-23 1991-10-22 Edwin I. Stoltz Nasal administration of drugs
DE3614515A1 (en) 1986-04-29 1987-11-05 Pfeiffer Erich Gmbh & Co Kg Discharge device for media
FR2598392B1 (en) 1986-05-09 1988-08-26 Oreal Packaging for two Pressurized containers
EP0252286B1 (en) 1986-06-05 1992-07-08 Ciba-Geigy Ag Pharmaceutical preparations for topical use, process for their manufacture and their use
US4770634A (en) 1986-06-11 1988-09-13 Pellico Michael A Method for treating teeth with foamable fluoride compositions
JPH0380644B2 (en) 1986-06-18 1991-12-25 Matsuda Kk
US4837019A (en) 1986-08-11 1989-06-06 Charles Of The Ritz Group Ltd. Skin treatment composition and method for treating burned skin
US4906453A (en) 1986-08-12 1990-03-06 Jumpeer Nails, Inc. Mousse product
DE3778027D1 (en) 1986-09-05 1992-05-07 Upjohn Co Sebum-dissolving, non-aqueous minoxidil-formulation.
WO1988001863A1 (en) 1986-09-12 1988-03-24 The Upjohn Company Foams for delivery of minoxidil
JPH0778019B2 (en) 1986-11-08 1995-08-23 久光製薬株式会社 Foam Eazo - Le anti-inflammatory analgesic preparations
EP0270316A3 (en) 1986-12-04 1989-12-06 Pfizer Inc. Topical compositions comprising 1-substituted imidazoles and nsaids for treatment of acne
US4822613A (en) 1986-12-15 1989-04-18 S. C. Johnson & Son, Inc. Water-soluble foamable insecticidally-active compositions
US4822614A (en) 1986-12-19 1989-04-18 S. C. Johnson & Son, Inc. Bioactive film-forming composition for control of crawling insects and the like
US5389677B1 (en) 1986-12-23 1997-07-15 Tristrata Inc Method of treating wrinkles using glycalic acid
US4863900A (en) 1987-01-15 1989-09-05 The Research Foundation Of State University Of New York Method for reducing viral transmission with poly-L-histidine
JPS63119420U (en) 1987-01-30 1988-08-02
DE3704907A1 (en) 1987-02-17 1988-08-25 Bayer Ag Topically applicable preparations of gyrase inhibitors in combination with corticosteroid
US4828837A (en) 1987-03-30 1989-05-09 Liposome Technology, Inc. Non-crystalline minoxidil composition, its production and application
US4933330A (en) 1987-04-01 1990-06-12 Dak-Laboratoriet Benzoic acid derivatives and use thereof
LU86839A1 (en) 1987-04-10 1988-12-13 Oreal Cosmetic Composition detergente and foaming, delaying the regreasing of hair
WO1988008316A1 (en) 1987-04-21 1988-11-03 Chattan Nominees Pty. Ltd. Vaginal douche
FR2615173B1 (en) 1987-05-13 1989-08-18 Valois metering valve for liquid filler a liquid or liquefied gas propellant for use in an inverted position
US4867967A (en) 1987-06-04 1989-09-19 Crutcher Wilbert L Method for the treatment of pseudofolliculitis barbae
US4780309A (en) 1987-06-16 1988-10-25 Warner-Lambert Company Edible aerosol foam compositions and method of preparing same
US4849117A (en) 1987-06-17 1989-07-18 Sanitek Products, Inc. Concentrated composition for forming an aqueous foam
US4885282A (en) 1987-07-02 1989-12-05 Thornfeldt Carl R Treatment of hyperhidrosis, ichthyosis and wrinkling
US5196405A (en) 1987-07-08 1993-03-23 Norman H. Oskman Compositions and methods of treating hemorrhoids and wounds
US4847068A (en) 1987-08-06 1989-07-11 Johnson & Johnson Consumer Products, Inc. Skin care compositions
US4913893A (en) 1987-08-28 1990-04-03 Clairol Incorporated Aerosol hair setting composition containing an alginate
CA1273576A (en) 1987-09-16 1990-09-04 Patrick A. Beauchamp Topical treatment for diseased skin disorders
US4784842A (en) 1987-09-25 1988-11-15 Jean London Therapeutic composition for treatment of cuts, burns and abrasions
US4772427A (en) 1987-12-01 1988-09-20 Colgate-Palmolive Co. Post-foaming gel shower product
US5143717A (en) 1987-12-30 1992-09-01 Code Blue Medical Corporation Burn foam and delivery system
ES2037385T3 (en) 1988-01-14 1993-06-16 Akzo N.V. A method of manufacturing a pharmaceutical preparation for local administration.
JP2643217B2 (en) 1988-01-22 1997-08-20 エーザイ株式会社 Fat-soluble substance aqueous solution
LU87187A1 (en) 1988-03-31 1989-10-26 Oreal Derivative Association of pyrimidine derivatives and salicylic acid to induce and stimulate hair growth and reducing hair loss
US4873078A (en) 1988-04-22 1989-10-10 Plough, Inc. High-gloss, high-shine lipstick
GB8811409D0 (en) 1988-05-13 1988-06-15 Unilever Plc Cosmetic composition
US4827378A (en) 1988-06-15 1989-05-02 Rockwell International Corporation Jack coaxial connector EMI shielding apparatus
US5217707A (en) 1988-06-16 1993-06-08 Chinoin Gyogyszer Es Vegyeszeti Termekek Gyara Rt. Pharmaceutical composition and process for the preparation thereof
US4879083A (en) 1988-06-17 1989-11-07 Macmillan Bloedel Limited Chemically treated wood particle board
US4950420A (en) 1988-08-31 1990-08-21 Nalco Chemical Company Antifoam/defoamer composition
US4855294A (en) 1988-09-06 1989-08-08 Theratech, Inc. Method for reducing skin irritation associated with drug/penetration enhancer compositions
NL194959C (en) 1988-10-04 2003-09-02 Otsuka Pharma Co Ltd Preparation for administering iron.
US5135915A (en) 1988-10-14 1992-08-04 Genentech, Inc. Method for the treatment of grafts prior to transplantation using TGF-.beta.
US5186857A (en) 1988-11-14 1993-02-16 Imaginative Research Associates, Inc. Self-foaming oil compositions and process for making and using same
GB8828013D0 (en) * 1988-12-01 1989-01-05 Unilever Plc Topical composition
US5439670A (en) 1989-11-28 1995-08-08 Riker Laboratories, Inc. Medicinal aerosol formulations
US4970067A (en) 1988-12-12 1990-11-13 Helene Curtis, Inc. Method and composition to condition hair and impart semi-permanent hair set retention properties
US5262407A (en) 1988-12-16 1993-11-16 L'oreal Use of salicylic derivatives for the treatment of skin aging
FR2640942B1 (en) 1988-12-23 1991-04-26 Suchard Sa Jacobs
DE68913693T3 (en) 1988-12-27 2004-01-22 Osaka Shipbuilding Co., Ltd. Aerosol composition.
JP2960445B2 (en) 1988-12-28 1999-10-06 株式会社大阪造船所 Aerosol composition
FR2641185B1 (en) 1988-12-29 1991-04-05 Oreal shaving composition for the skin based on polyorganosiloxanes has acyloxyalkyl function and implementation method
JP2741230B2 (en) 1989-01-11 1998-04-15 株式会社コーセー Foam anhydrous cosmetic
LU87449A1 (en) 1989-02-09 1990-09-19 Oreal Method for manufacturing foams used in the cosmetic and pharmaceutical fields and foams obtained by such process
US4919934A (en) 1989-03-02 1990-04-24 Richardson-Vicks Inc. Cosmetic sticks
US4996193A (en) 1989-03-03 1991-02-26 The Regents Of The University Of California Combined topical and systemic method of administration of cyclosporine
US5019375A (en) 1989-03-14 1991-05-28 The Procter & Gamble Company Low residue antiperspirant creams
DE69030698D1 (en) 1989-03-17 1997-06-19 Taisho Pharma Co Ltd Aerosol composition for external use
US5221696A (en) 1989-03-29 1993-06-22 Alcon Laboratories, Inc. Use of monoacyl phosphoglycerides to enhance the corneal penetration of ophthalmic drugs
DE69020211T2 (en) 1989-04-05 1995-11-02 Kao Corp Cosmetic double emulsion.
US5204093A (en) 1989-04-06 1993-04-20 Victor Steven A Shaving cream composition for the treatment of acne vulgaris and pseudofolliculitis barbae and method of producing and using same
US5071648A (en) 1989-04-06 1991-12-10 Merocel Corporation Polymeric broad-spectrum antimicrobial materials
US5618798A (en) 1989-04-20 1997-04-08 Bar-Shalom; Daniel Use of sucralfate to treat baldness
US4874794A (en) 1989-04-28 1989-10-17 Lidak Biopharmaceuticals Inflammatory disease treatment
US5322683A (en) 1989-05-01 1994-06-21 Leonard Mackles Anhydrous aerosol foam
US5002540A (en) 1989-05-22 1991-03-26 Warren Kirschbaum Intravaginal device and method for delivering a medicament
GB8911853D0 (en) 1989-05-23 1989-07-12 Ici Plc Co2 blown integral skin foams
US5208031A (en) 1989-06-06 1993-05-04 Kelly Patrick D Sexual lubricants containing zinc as an anti-viral agent
CA1337279C (en) 1989-06-06 1995-10-10 Robert J. Borgman Intravaginal treatment of vaginal infections with buffered metronidazole compositions
US5122519A (en) 1989-06-27 1992-06-16 American Cyanamid Company Stable, cosmetically acceptable topical gel formulation and method of treatment for acne
EP0407344A3 (en) 1989-07-07 1991-06-12 Ciba-Geigy Ag Pharmaceutical preparation for topical application
US5560859A (en) 1989-07-26 1996-10-01 Pfizer Inc. Post foaming gel shaving composition
DE69020900T2 (en) 1989-07-28 1995-12-14 Hisamitsu Pharmaceutical Co Foam aerosol composition.
JPH0383914A (en) 1989-08-18 1991-04-09 W R Grace & Co Drug carrier
US5219877A (en) 1989-09-25 1993-06-15 Bristol-Myers Squibb Company Lauryl alcohol as skin penetration enhancer for topical imidazole agents
US5508033A (en) 1989-12-06 1996-04-16 Societe D'engrais Composes Mineraux Et Amendments Utilization of algae extract for the preparation of pharmaceutical, cosmetic, food or agricultural compositions
US5295984A (en) 1989-12-07 1994-03-22 Ultrafem, Inc. Vaginal discharge collection device and intravaginal drug delivery system
WO1991008779A1 (en) 1989-12-07 1991-06-27 Ultrafem Ltd Feminine hygiene device
WO1991008733A1 (en) 1989-12-20 1991-06-27 Schering Corporation Stable cream and lotion bases for lipophilic drug compositions
US4966779A (en) 1989-12-21 1990-10-30 Basf Corporation Stable, water miscible emulsion comprising a fat-soluble vitamin
US5733572A (en) 1989-12-22 1998-03-31 Imarx Pharmaceutical Corp. Gas and gaseous precursor filled microspheres as topical and subcutaneous delivery vehicles
US4963351A (en) 1989-12-26 1990-10-16 Bhn Associates Shaving aid
US5100917A (en) 1989-12-29 1992-03-31 Merrell Dow Pharmaceuticals Inc. Novel a-nor-steroid-3-carboxylic acid derivatives
US5104645A (en) 1990-02-02 1992-04-14 The Proctor & Gamble Company Antidandruff shampoo compositions
JPH05504571A (en) * 1990-02-09 1993-07-15
US5164367A (en) 1990-03-26 1992-11-17 Procyte Corporation Method of using copper(ii) containing compounds to accelerate wound healing
US5130121A (en) 1990-04-17 1992-07-14 Isp Investments Inc. Skin care compositions containing discrete microdroplets of an oil in water stabilized by in situ polymerization of water-soluble vinyl monomer
US5007556A (en) 1990-04-18 1991-04-16 Block Drug Company, Inc. Metering dispenser
US5156765A (en) 1990-05-15 1992-10-20 Fox Valley Systems, Inc. Aerosol foam marking compositions
US5112359A (en) 1990-06-04 1992-05-12 Clairol, Inc. Hair colorants
JPH0451958A (en) 1990-06-18 1992-02-20 Mitsubishi Materials Corp Treating agent for circulation type toilet filth
US5034220A (en) * 1990-06-20 1991-07-23 Gaf Chemicals Corporation Non-aerosol shaving gel
US5336692A (en) 1990-06-28 1994-08-09 Medicis Pharmaceutical Corporation Ointment base and method of use
DK0468555T4 (en) 1990-07-27 2001-04-02 Giuliani Spa A pharmaceutical composition for rectal administration of active substances with widely topical medikeringsvirkning on kolonniveauet
US5108556A (en) 1990-09-14 1992-04-28 Minnesota Mining And Manufacturing Company Process for preparing tertiary perfluoroamines
US5114718A (en) 1990-09-20 1992-05-19 The Procter & Gamble Company Sustained release compositions for treating periodontol disease
GB9021546D0 (en) 1990-10-04 1990-11-21 Beecham Group Plc Novel composition
DE9016291U1 (en) 1990-11-30 1991-03-28 Kali-Chemie Pharma Gmbh, 3000 Hannover, De
US5073371A (en) 1990-11-30 1991-12-17 Richardson-Vicks, Inc. Leave-on facial emulsion compositions
WO1992011839A1 (en) 1991-01-08 1992-07-23 Leonard Mackles Anhydrous aerosol
WO1992012717A3 (en) 1991-01-15 1992-10-15 Robert A Bok A composition containing a tetracycline and use for inhibiting angiogenesis
US5227163A (en) 1991-01-18 1993-07-13 Clilco, Ltd. Lice-repellant compositions
DE4102506C2 (en) 1991-01-29 1999-11-25 Pfeiffer Erich Gmbh & Co Kg Discharge for Media
WO1992013602A1 (en) 1991-02-05 1992-08-20 Buil Juergen Fire extinguishing and protection agent
US5948682A (en) 1991-02-22 1999-09-07 Sembiosys Genetics Inc. Preparation of heterologous proteins on oil bodies
US5650554A (en) 1991-02-22 1997-07-22 Sembiosys Genetics Inc. Oil-body proteins as carriers of high-value peptides in plants
US6753167B2 (en) 1991-02-22 2004-06-22 Sembiosys Genetics Inc. Preparation of heterologous proteins on oil bodies
RU2148647C1 (en) 1992-04-02 2000-05-10 Сембайозис Дженетикс Инк. Method of expression of interesting dna sequence in seed cell, dna-structure, expression cassette, isolated regulatory site of transcription and method of alternation of specific metabolism in seeds
US5648380A (en) 1991-03-01 1997-07-15 Warner-Lambert Company Anti-inflammatory wound healing compositions and methods for preparing and using same
US5658956A (en) 1991-03-01 1997-08-19 Warner-Lambert Company Bioadhesive-wound healing compositions and methods for preparing and using same
US5663208A (en) 1991-03-01 1997-09-02 Warner-Lambert Company Antifungal wound healing compositions and methods for preparing and using same
ES2089260T3 (en) 1991-03-06 1996-10-01 Dompe Farmaceutici Spa topical composition containing ketoprofen lysinate.
JPH04282311A (en) 1991-03-08 1992-10-07 Koike Kagaku Kk Aerosol-type foamable wound-disinfectant
FI108277B (en) 1991-03-25 2001-12-31 Yamanouchi Europ Bv Topical preparation containing a suspension of solid lipid particles
US5167950A (en) 1991-03-28 1992-12-01 S. C. Johnson & Son High alcohol content aerosol antimicrobial mousse
DE4110973A1 (en) 1991-04-05 1992-10-08 Haarmann & Reimer Gmbh Means with physiological kuehleffekt and only to those medium suitable effective connections
JP3100416B2 (en) 1991-04-11 2000-10-16 オカモト株式会社 Mousse-like lubricant
EP0510561B1 (en) 1991-04-24 1996-07-24 POLI INDUSTRIA CHIMICA S.p.A. Oral, cutaneous and intravaginal pharmaceutical compositions in the form of foam
US5204090A (en) 1991-05-30 1993-04-20 Bristol Myers Squibb Waterproof high-SPF sunscreen compositions
US5164357A (en) 1991-06-05 1992-11-17 Appleton Papers Inc. Thermally-responsive record material
FR2677544B1 (en) 1991-06-14 1993-09-24 Oreal Cosmetic composition containing a mixture of metal oxide nanopigments and melanin pigments.
DE4210165A1 (en) 1991-07-30 1993-02-04 Schering Ag Transdermal therapeutic systems
DE4127630A1 (en) 1991-08-21 1993-02-25 Bruno Jesswein Two-component siphon, particularly for 2K foams
GB9118028D0 (en) 1991-08-21 1991-10-09 Secr Defence Brit Improved transdrmal formulations
JP2969398B2 (en) 1991-09-12 1999-11-02 花王株式会社 Anhydrous foam clean Kiyoshi 拭剤
US5643600A (en) 1991-09-17 1997-07-01 Micro-Pak, Inc. Lipid vesicles containing avocado oil unsaponifiables
DE69228373D1 (en) 1991-09-27 1999-03-18 Nof Corp Cosmetic and emulsion
GB2260079B (en) 1991-10-01 1995-08-09 American Cyanamid Co Pharmaceutical composition containing felbinac
US5230897A (en) 1991-10-31 1993-07-27 G. D. Searle & Co. Transdermal pentamidine
US5236707A (en) 1991-11-08 1993-08-17 Dallas Biotherapeutics, Inc. Stabilization of human interferon
EP0613369A1 (en) 1991-11-22 1994-09-07 Richardson-Vicks, Inc. Combined personal cleansing and moisturizing compositions
DE4140474C2 (en) 1991-12-09 1995-07-13 Schuelke & Mayr Gmbh Skincare additive
US5294365A (en) 1991-12-12 1994-03-15 Basf Corporation Hydroxypolyethers as low-foam surfactants
US5314904A (en) 1991-12-17 1994-05-24 Alfa Wassermann S.P.A. Pharmaceutical compositions containing rifaximin for treatment of vaginal infections
US5252246A (en) 1992-01-10 1993-10-12 Allergan, Inc. Nonirritating nonionic surfactant compositions
EP0552612A3 (en) 1992-01-22 1993-10-20 Hoffmann La Roche Methods for determining and isolating compounds which bind directly to nucleosolic proteins
JP3146052B2 (en) 1992-01-31 2001-03-12 プレスコ株式会社 Aerosol massage agent
US5318774A (en) 1992-02-28 1994-06-07 Richardson-Vicks Inc. Composition and method for imparting an artificial tan to human skin
US5344051A (en) 1992-04-27 1994-09-06 Insta-Foam Products, Inc. Two-component foam dispensing apparatus
US5531703A (en) * 1992-04-28 1996-07-02 Schering-Plough Healthcare Products, Inc. Applicator for semisolid medications
US5409706A (en) 1992-05-04 1995-04-25 Imaginative Research Associates, Inc. Anhydrous foaming composition containing low concentrations of detergents and high levels of glycerin and emollients such as oils and esters
US5254334A (en) 1992-05-04 1993-10-19 Imaginative Research Associates, Inc. Anhydrous foaming composition containing low concentrations of detergents and high levels of glycerin amd emollients such as oils and esters
EP0576051A3 (en) 1992-05-15 1994-03-02 Akzo Nv
CA2134977C (en) 1992-05-18 1998-12-15 Deanna K. Furman Coolant compositions
US5389305A (en) 1992-06-03 1995-02-14 Colgate Palmolive Co. High foaming nonionic surfactant base liquid detergent
ES2137993T3 (en) 1992-06-11 2000-01-01 Theratech Inc The use of glycerin to moderate transdermal drug.
US5346135A (en) 1992-06-16 1994-09-13 Vincent Edward C Spraying apparatus for blending liquids in a gaseous spray system
US5300286A (en) 1992-07-14 1994-04-05 Dow Corning Corporation Silicone emulsion for personal care application
DE69310518D1 (en) 1992-07-28 1997-06-12 Procter & Gamble A pharmaceutical composition for topical application comprising a crosslinked cationic polymer, and contains an alkoxylated ether
FI933979A0 (en) * 1992-09-10 1993-09-10 Mcneil Ppc Inc Bioeroderbar an arrangement Foer dosering of aktiva ingredienser
JPH08501553A (en) 1992-09-14 1996-02-20 スミス・ウォルター・ピー Skin conditioning composition, its application and manufacturing
JPH06100414A (en) 1992-09-18 1994-04-12 Osaka Aerosol Ind Corp Composition for aerosol
US6096756A (en) 1992-09-21 2000-08-01 Albert Einstein College Of Medicine Of Yeshiva University Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other bimodally-acting opioid agonists
US5413775A (en) 1992-09-29 1995-05-09 Amerchol Corporation Hairsprays and acrylic polymer compositions for use therein
WO1994008536A1 (en) 1992-10-21 1994-04-28 Gynetech Laboratories, Inc. Vaginal sponge delivery system
EP0596304B1 (en) 1992-10-31 1998-04-01 Th. Goldschmidt AG Cosmetic and pharmaceutical compositions
DE4238860A1 (en) 1992-11-19 1994-05-26 Medicon Gmbh Skin-protecting agents for protecting human skin
US5308643A (en) 1992-11-30 1994-05-03 Osipow Lloyd I Self-lather generating shaving compositions
JP3328344B2 (en) 1992-12-22 2002-09-24 タイホー工業株式会社 Method for controlling the foaming state retention time of foam-type cleaning polishes
JPH06263630A (en) 1993-03-10 1994-09-20 Lion Corp Vitamin as-solubilizing eye drop
JPH06279228A (en) 1993-03-30 1994-10-04 Kao Corp Foaming composition
US5326557A (en) * 1993-04-06 1994-07-05 Dow Corning Corporation Moisturizing compositions containing organosilicon compounds
US5807571A (en) 1993-05-06 1998-09-15 Lts Lohmann Therapie-Systeme Gmbh Transdermal therapeutic systems for administering indole serotonin agonists
US5576016A (en) 1993-05-18 1996-11-19 Pharmos Corporation Solid fat nanoemulsions as drug delivery vehicles
DE69430917D1 (en) 1993-05-19 2002-08-08 Hisamitsu Pharmaceutical Co 3-l-menthoxy-PROPANE-1, 2-diol as a solubilizer AND EXTERNAL PREPARATION CONTAINING THESE CONTAINS
CA2161431A1 (en) 1993-05-21 1994-12-08 Barry A. Salka Mild shampoo composition
JP3161869B2 (en) 1993-05-24 2001-04-25 株式会社ダイゾー Water-in-oil aerosol compositions and their preparation
US5635469A (en) 1993-06-10 1997-06-03 The Procter & Gamble Company Foaming cleansing products
US5447725A (en) 1993-06-11 1995-09-05 The Procter & Gamble Company Methods for aiding periodontal tissue regeneration
US5744155A (en) 1993-08-13 1998-04-28 Friedman; Doron Bioadhesive emulsion preparations for enhanced drug delivery
US5398846A (en) 1993-08-20 1995-03-21 S. C. Johnson & Son, Inc. Assembly for simultaneous dispensing of multiple fluids
US6596260B1 (en) 1993-08-27 2003-07-22 Novartis Corporation Aerosol container and a method for storage and administration of a predetermined amount of a pharmaceutically active aerosol
FR2709666B1 (en) 1993-09-07 1995-10-13 Oreal Cosmetic or dermatological composition consisting of an oil in water emulsion based on oily globules provided with a lamellar liquid crystal coating.
JP2978043B2 (en) 1993-09-16 1999-11-15 高砂香料工業株式会社 (2s) -3 - {(1r, 2s, 5r) - [5- methyl-2- (1-methylethyl) cyclohexyl] oxy} -1,2-propanediol, their preparation and use
US5766632A (en) 1993-10-01 1998-06-16 Legere Pharmaceuticals, Ltd. Method of using lectins for contraception
US5578315A (en) 1993-12-01 1996-11-26 Rutgers, The State University Of New Jersey Mucosal adhesive device for long-acting delivery of pharmaceutical combinations in oral cavity
FR2713486B1 (en) 1993-12-14 1996-02-09 Scophysa New compositions for foams, notably rectal foams, and foams obtained.
CA2177682C (en) 1993-12-23 1999-12-28 Sekhar Mitra Antimicrobial wipe compositions
US5527822A (en) 1993-12-29 1996-06-18 Forest Laboratories, Inc. Method of treatment of traumatic brain injury
DE9422052U1 (en) 1994-01-04 1997-10-30 Wuerth Adolf Gmbh & Co Kg Filling device for filling a refillable dispensing container and refillable dispensing container
JP3530564B2 (en) 1994-02-03 2004-05-24 協和産業株式会社 Aerosol form cosmetics
DE4405127A1 (en) 1994-02-18 1995-08-31 Henkel Kgaa Hair treatment agents
US5514367A (en) 1994-02-28 1996-05-07 Estee Lauder, Inc. Skin tanning compositions and methods for their preparation and use
US5925669A (en) 1994-03-22 1999-07-20 Molecular/Structural Bio Technologies, Inc. Carrier compositions for anti-neoplastic drugs
ES2123206T3 (en) 1994-04-05 1999-01-01 Agis Ind 1983 Ltd Fungicidal compositions containing a combination of bifonazole and fluocinonide.
US5658749A (en) 1994-04-05 1997-08-19 Corning Clinical Laboratories, Inc. Method for processing mycobacteria
US5429815A (en) 1994-04-11 1995-07-04 Chesebrough-Pond's Usa Co., Division Of Conopco, Inc. Stable single-phase self-foaming cleanser
FR2719467B1 (en) 1994-05-05 1996-05-31 Oreal Use of flavonoids for preserving and / or enhancing the mechanical properties of hair and hair protection method using these compounds.
ES2079320B1 (en) * 1994-05-17 1996-10-16 Cusi Lab Ophthalmic solution based on a diclofenac and tobramycin and applications.
US5902574A (en) 1994-05-23 1999-05-11 The Gillette Company Shaving preparation for improved shaving comfort
US5545401A (en) 1994-06-02 1996-08-13 Shanbrom; Edward Antiviral, spermicidal vaginal gel and foam containing low molecular weight povidone-iodine
US6221381B1 (en) 1994-06-28 2001-04-24 The University Of British Columbia Enhancing milk production by adding to feed a nonionic surfactant coated on a carrier
KR100245355B1 (en) 1994-06-30 2000-03-02 데이비드 엠 모이어 Personal care compositions containing thermoplastic elastomeric graft copolymers
US5679324A (en) * 1994-07-08 1997-10-21 The Procter & Gamble Co. Aerosol foamable fragrance composition
US5976555A (en) 1994-09-07 1999-11-02 Johnson & Johnson Consumer Products, Inc. Topical oil-in-water emulsions containing retinoids
FR2722431B1 (en) 1994-07-12 1996-09-13 Lir France Sa dual dispenser for fluid products
JP3173330B2 (en) 1994-07-20 2001-06-04 トヨタ自動車株式会社 Lock-up clutch slip control system for a vehicle
US5444092A (en) 1994-07-20 1995-08-22 Collins; Jerry Method and composition for treating psoriasis
GB9414699D0 (en) 1994-07-21 1994-09-07 Slagel David Aqueous foamable composition
US5512555A (en) 1994-07-21 1996-04-30 Merck & Co., Inc. Method of treating sweat-related conditions using finasteride, epristeride and a cholestan-3-one
JP3241542B2 (en) 1994-07-29 2001-12-25 高砂香料工業株式会社 (-) - obtained by the purification method and method of n- isopulegol (-) - citrus perfume composition containing the n- isopulegol
DE4428096A1 (en) 1994-08-09 1996-02-15 Wella Ag Two-chamber container
US5656586A (en) 1994-08-19 1997-08-12 Rhone-Poulenc Inc. Amphoteric surfactants having multiple hydrophobic and hydrophilic groups
US5547989A (en) 1994-08-19 1996-08-20 Schering-Plough Healthcare Products, Inc. Compositions for treating corns and calluses
EP0777464A1 (en) 1994-08-26 1997-06-11 THE PROCTER & GAMBLE COMPANY Personal cleansing compositions
JP3558393B2 (en) 1994-08-29 2004-08-25 株式会社ダイゾー Foamable aerosol composition
JP3604177B2 (en) 1994-09-14 2004-12-22 トーアエイヨー株式会社 Percutaneous absorption preparation
US5500211A (en) 1994-09-22 1996-03-19 The Gillette Company Soap-free self-foaming shave gel composition
US5905092A (en) 1994-09-27 1999-05-18 Virotex Corporation Reel/Frame Topical antibiotic composition providing optimal moisture environment for rapid wound healing that reduces skin contraction
US5955414A (en) 1994-10-05 1999-09-21 S. C. Johnson & Son, Inc. Cleaning foam having fluorinated stain repellent and low flammability
US5540853A (en) 1994-10-20 1996-07-30 The Procter & Gamble Company Personal treatment compositions and/or cosmetic compositions containing enduring perfume
WO1996014085A1 (en) 1994-11-08 1996-05-17 Mochida Pharmaceutical Co., Ltd. External preparation for skin protection
US5567420A (en) 1994-11-16 1996-10-22 Mceleney; John Lotion which is temporarily colored upon application
US5788664A (en) 1994-11-30 1998-08-04 Scalise; Gaspare Suppository applicator
GB9424562D0 (en) * 1994-12-06 1995-01-25 Giltech Ltd Product
US5641480A (en) * 1994-12-08 1997-06-24 Lever Brothers Company, Division Of Conopco, Inc. Hair care compositions comprising heteroatom containing alkyl aldonamide compounds
JP3355257B2 (en) 1994-12-09 2002-12-09 太陽化学株式会社 Cosmetics
US5529770A (en) 1994-12-09 1996-06-25 West Agro, Inc. Viscous liquid conditioning topical germicides
DE4444238A1 (en) 1994-12-13 1996-06-20 Beiersdorf Ag Cosmetic or dermatological active compound combinations of cinnamic acid derivatives and flavone glycosides
FR2728166B1 (en) 1994-12-19 1997-02-07
DK0801554T3 (en) 1994-12-21 2003-08-04 Cosmederm Technologies Formulations and methods for reducing the skin irritation
WO1996019921A1 (en) 1994-12-23 1996-07-04 Commonwealth Scientific And Industrial Research Organisation Iodine biocidal material
DE4446891A1 (en) 1994-12-27 1996-07-04 Falk Pharma Gmbh A stable aqueous budesonide solution
US5534261A (en) 1995-01-17 1996-07-09 University Of Southern California Retinoid-based compositions and method for preventing adhesion formation using the same
FR2729855B1 (en) * 1995-01-26 1997-02-21
US5523078A (en) 1995-02-03 1996-06-04 Michael E. Baylin Method of preparing and composition for treatment of hair and scalp
US5587149A (en) 1995-02-06 1996-12-24 R.P. Scherer Corporation Topical application emulsions
FR2730930B1 (en) 1995-02-27 1997-04-04 Oreal Use of no-synthase inhibitors to reduce the cutaneous irritant effect of products used in the cosmetic or pharmaceutical field
FR2730932B1 (en) 1995-02-27 1997-04-04 Oreal transparent nanoemulsion-based fluid nonionic amphiphilic lipids and use in cosmetic or dermopharmacy
GB9504265D0 (en) 1995-03-03 1995-04-19 Medeva Plc Corticosteroid-containing pharmaceutical composition
US5558872A (en) 1995-03-07 1996-09-24 Healthpoint Medical Limited Partnership Gelled mineral oil skin protectant
US5618850A (en) 1995-03-09 1997-04-08 Focal, Inc. Hydroxy-acid cosmetics
US5783202A (en) 1995-03-14 1998-07-21 Soltec Research Pty. Ltd. Pediculicidal mousse composition for killing head lice
KR100397578B1 (en) 1995-03-29 2003-10-17 시오노기세이야쿠가부시키가이샤 Gelatin capsule with adjusted water activity
JPH08277209A (en) 1995-04-07 1996-10-22 Taisho Pharmaceut Co Ltd Revitalizing hair tonic
US5585104A (en) 1995-04-12 1996-12-17 The Procter & Gamble Company Cleansing emulsions
EP0738510A3 (en) 1995-04-20 2005-12-21 L'oreal Use of a HMG-CoA reductase inhibitor as an anti-ageing agent and as an anti-acne agent. Composition comprising at least one HMG-CoA reductase inhibitor and at least one active substance with scaling properties.
FR2733417B1 (en) 1995-04-25 1997-06-06 Oreal Emulsion foaming oil-in-water base nonionic surfactants, a fatty phase and of a cationic or anionic crosslinked polymer and use in topical application
GB9510856D0 (en) 1995-05-27 1995-07-19 Cussons Int Ltd Cleaning composition
EP0831768A1 (en) 1995-06-06 1998-04-01 Neutrogena Corporation Topical vehicles containing solubilized and stabilized azelaic acid
EP2322137A1 (en) 1995-06-22 2011-05-18 Minnesota Mining And Manufacturing Company Stable hydroalcoholic compositions
JP3542665B2 (en) 1995-07-07 2004-07-14 株式会社資生堂 Anti-aging external preparation for skin, collagen cross-linking inhibitory skin preparation for external use and anti-UV external skin preparation
FR2736824B1 (en) 1995-07-18 1997-10-10 Fabre Pierre Dermo Cosmetique capillary-based composition minoxidil low fat solvent content
DE29512760U1 (en) 1995-08-08 1995-11-16 Wella Ag Compressed gas container for dispensing foam
CN1128611C (en) 1995-09-06 2003-11-26 花王株式会社 Emulsified water-in-oil type composition and skin cosmetic preparation
US5881493A (en) 1995-09-14 1999-03-16 D. B. Smith & Co. Inc. Methods for applying foam
CN1062129C (en) 1995-09-14 2001-02-21 徐荣祥 Medicine matrix and its use
US7060253B1 (en) 1996-09-20 2006-06-13 Mundschenk David D Topical formulations and delivery systems
JPH0984855A (en) 1995-09-25 1997-03-31 Kyoto Yakuhin Kogyo Kk Aerosol preparation for administer medicine to rectum or vagina
JPH0999553A (en) 1995-10-09 1997-04-15 Fujitsu Ltd Ink jet head
JP3425019B2 (en) 1995-10-16 2003-07-07 カネボウ株式会社 Oily foam cleansing cosmetics
US6221823B1 (en) 1995-10-25 2001-04-24 Reckitt Benckiser Inc. Germicidal, acidic hard surface cleaning compositions
US6133327A (en) 1995-12-14 2000-10-17 Taisho Pharmaceutical Co., Ltd. Aerosol preparation
FR2742986B1 (en) * 1995-12-29 1998-01-30 Rhone Poulenc Chimie cosmetic compositions for the hair or the skin based sulfonated copolyesters containing polyorganosiloxane units
US5846983A (en) 1996-02-09 1998-12-08 Mayo Foundation For Medical Education And Research Colonic delivery of nicotine to treat inflammatory bowel disease
USRE38623E1 (en) 1996-02-09 2004-10-12 Topix Pharmaceuticals, Inc. Stabilization of ascorbic acid, ascorbic acid derivatives and/or extracts containing ascorbic acid for topical use
US5759524A (en) * 1996-02-09 1998-06-02 The Procter & Gamble Company Photoprotective compositions
US5889028A (en) 1996-02-09 1999-03-30 Mayo Foundation For Medical Education And Research Colonic delivery of nicotine to treat inflammatory bowel disease
CA2244089C (en) 1996-02-19 2009-06-02 Monash University Dermal penetration enhancers and drug delivery systems involving same
US5912007A (en) 1996-02-29 1999-06-15 Warner-Lambert Company Delivery system for the localized administration of medicaments to the upper respiratory tract and methods for preparing and using same
US6251369B1 (en) 1996-03-05 2001-06-26 Sultan Dental Products Dental fluoride foam
FR2745716B1 (en) 1996-03-07 1998-04-17 Oreal Oil-in-water foaming pressurizable ultrafine
WO1997039745A1 (en) 1996-04-19 1997-10-30 Sloan-Kettering Institute For Cancer Research Use of inhaled retinoids in the prevention of cancer
US5910382A (en) 1996-04-23 1999-06-08 Board Of Regents, University Of Texas Systems Cathode materials for secondary (rechargeable) lithium batteries
US6001341A (en) 1996-05-21 1999-12-14 Condea Augusta S.P.A. Deodorant and/or antiperspirant cosmetic compositions
US5797955A (en) 1996-06-11 1998-08-25 Walters; David J. Pressure application unit for positioning vertebra
US5833961A (en) 1996-06-25 1998-11-10 Inolex Investment Corporation Polyester-based suncreen formulations
WO1998000016A1 (en) 1996-07-01 1998-01-08 Sepracor, Inc. Methods and compositions for treating urinary incontinence using enantiomerically enriched (r,r)-glycopyrrolate
US5955408A (en) * 1996-07-10 1999-09-21 Steris Inc. Triclosan skin wash with enhanced efficacy
DE19631221C2 (en) 1996-08-02 1999-07-01 Beiersdorf Ag Foam shaped light protection preparations with a content of water-soluble light protection filter substances and surface-active substances
WO1998006419A1 (en) 1996-08-15 1998-02-19 Southern Illinois University Enhancement of antimicrobial peptide activity by metal ions
US5833963A (en) 1996-08-20 1998-11-10 Bristol-Myers Squibb Company Non-tacky and quick-drying aqueous-based antiperspirant compositions
US5837270A (en) 1996-08-26 1998-11-17 Burgess; Nelson Leon Topical anti-acne composition
EP0829259A1 (en) 1996-09-04 1998-03-18 Warner-Lambert Company Foam/gel with microbeads and/or fine particles
US6271295B1 (en) 1996-09-05 2001-08-07 General Electric Company Emulsions of silicones with non-aqueous hydroxylic solvents
US5952392A (en) 1996-09-17 1999-09-14 Avanir Pharmaceuticals Long-chain alcohols, alkanes, fatty acids and amides in the treatment of burns and viral inhibition
FR2754451B1 (en) 1996-10-14 1998-11-06 Oreal Self-Foaming Cream
WO1998017282A1 (en) 1996-10-23 1998-04-30 Vertex Pharmaceuticals Incorporated Methods of using sucrose octasulfate to treat or prevent enveloped virus infection
US6093408A (en) * 1996-10-25 2000-07-25 The Procter & Gamble Company Skin care compositions
CN1235547A (en) 1996-10-31 1999-11-17 里科达蒂化学药物公司 Antiherpetic pharmaceutical compositions containing acyclovir for topical applicators
WO1998019654A1 (en) 1996-11-04 1998-05-14 The Procter & Gamble Company Hair mousse composition comprising silicone emulsion
FR2755854B1 (en) 1996-11-15 1998-12-24 Oreal Nanoemulsion-based non-ionic and cationic amphiphilic lipids and Uses
US5906992A (en) 1996-11-21 1999-05-25 Colgate Palmolive Company Foam cleaning compositions
EP0944398B1 (en) 1996-11-22 2004-04-07 Connetics Australia Pty Limited Percutaneous delivery system
US5951544A (en) 1996-12-04 1999-09-14 Laser Industries Ltd. Handpiece assembly for laser apparatus
US5759579A (en) 1996-12-05 1998-06-02 American Home Products Corporation Pharmaceutical suspension systems
US5695551A (en) 1996-12-09 1997-12-09 Dow Corning Corporation Water repellent composition
US5672634A (en) 1996-12-23 1997-09-30 Isp Investments Inc. Crosslinked PVP-I2 foam product
US5879469A (en) 1997-01-06 1999-03-09 Deeay Technologies Ltd. Dishwashing method and detergent composition therefor
US6582711B1 (en) 1997-01-09 2003-06-24 3M Innovative Properties Company Hydroalcoholic compositions thickened using polymers
JP3006572B2 (en) 1997-01-17 2000-02-07 ポンスス・ファルマ・エービー Skin preparations
US5843411A (en) 1997-02-06 1998-12-01 Topix Pharmaceuticals Inc. Stabilization of ascorbic acid, ascorbic acid derivatives and/or extracts containing ascorbic acid for topical use
CA2280179A1 (en) 1997-02-11 1998-08-13 Bernard Salafsky Anti-parasitic action of n,n-diethyl-m-toluamide (deet) and formulations that prolong its activity in the skin
ES2133090B1 (en) 1997-02-21 2000-04-01 Uriach & Cia Sa J New applicator for semisolid administration of medications.
EP1250927A3 (en) 1997-02-24 2003-03-26 S.L.A. Pharma AG Pharmaceutical composition for topical application comprising nifedipine
JP3050289B2 (en) 1997-02-26 2000-06-12 日本電気株式会社 Output impedance adjusting circuit of the output buffer circuit
FR2760637B1 (en) 1997-03-11 1999-05-28 Fabre Pierre Dermo Cosmetique coal tar extract reduced content of aromatic hydrocarbons, METHOD FOR OBTAINING SAME and dermo-cosmetic preparations
US5922331A (en) * 1997-03-26 1999-07-13 Chanel, Inc. Skin cream composition
US5951989A (en) 1997-04-07 1999-09-14 Heymann; Warren R. Method for the treatment of dry skin
USH2043H1 (en) 1997-05-23 2002-08-06 The Procter & Gamble Company Skin care compositions
US6183762B1 (en) * 1997-05-27 2001-02-06 Sembiosys Genetics Inc. Oil body based personal care products
US6372234B1 (en) 1997-05-27 2002-04-16 Sembiosys Genetics Inc. Products for topical applications comprising oil bodies
DE69839148T2 (en) 1997-05-27 2009-02-12 SemBioSys Genetics, Inc., Calgary Uses of oil bodies
US6599513B2 (en) 1997-05-27 2003-07-29 Sembiosys Genetics Inc. Products for topical applications comprising oil bodies
US6217887B1 (en) 1997-06-04 2001-04-17 The Procter & Gamble Company Leave-on antimicrobial compositions which provide improved immediate germ reduction
JP3113610B2 (en) 1997-06-04 2000-12-04 東洋ガスメーター株式会社 Fittings gas meter for the transmission device
EP0884045A1 (en) 1997-06-06 1998-12-16 Pfizer Products Inc. Self-tanning dihydroxyacetone formulations having improved stability and providing enhanced delivery
US20050276836A1 (en) 1997-06-11 2005-12-15 Michelle Wilson Coated vaginal devices for vaginal delivery of therapeutically effective and/or health-promoting agents
JPH11111A (en) 1997-06-13 1999-01-06 Kagoshima Pref Gov Feed for fish breeding
KR100477498B1 (en) 1997-06-13 2005-03-18 다이쇼 세이야꾸 가부시끼가이샤 Aerosols
FR2765799B1 (en) 1997-07-08 1999-08-27 Oreal gloss composition containing aromatic oils thickened by a polysaccharide alkyl ether
JP3553767B2 (en) 1997-08-22 2004-08-11 三洋電機株式会社 Transfer assistance apparatus
JP2001515851A (en) 1997-09-08 2001-09-25 アストラゼネカ・アクチエボラーグ New foam-forming pharmaceutical compositions
US5885581A (en) 1997-09-11 1999-03-23 Merz, Incorporated Composition and method for improvement of the appearance of scars
US5939376A (en) 1997-09-25 1999-08-17 Colgate Palmolive Company Liquid cleaning compositions containing an organic ester foam control agent
US6241971B1 (en) 1997-09-25 2001-06-05 The Procter & Gamble Company Hair styling compositions comprising mineral salt, lipophilic material, and low levels of surfactant
US6214318B1 (en) 1997-10-02 2001-04-10 Oms Holdings Llc Aerosol ointment compositions for topical use
FR2769299B1 (en) 1997-10-03 1999-12-31 Oreal Packaging and dispensing dual products
US6075056A (en) 1997-10-03 2000-06-13 Penederm, Inc. Antifungal/steroid topical compositions
EP1692951A1 (en) 1997-10-17 2006-08-23 Connetics Australia Pty Limited Topical antifungal composition
US5961957A (en) 1997-10-20 1999-10-05 Mcanalley; Bill H. Foam compositions
US5911981A (en) 1997-10-24 1999-06-15 R.I.T.A. Corporation Surfactant blends for generating a stable wet foam
US5877216A (en) 1997-10-28 1999-03-02 Vivus, Incorporated Treatment of female sexual dysfunction
EP1027057A4 (en) 1997-10-28 2003-01-02 Vivus Inc Treatment of female sexual dysfunction
JP3450680B2 (en) 1997-10-28 2003-09-29 高砂香料工業株式会社 Para - method of manufacturing menthane-3,8-diol
KR100648536B1 (en) 1997-11-10 2006-11-24 셀러지 파마세우티칼스, 인크 Penetration enhancing and irritation reducing systems
DE29720316U1 (en) 1997-11-17 1998-01-29 Andris Raimund Gmbh & Co Kg Dual chamber dispensing device
US5849042A (en) 1997-11-19 1998-12-15 Bristol-Myers Squibb Hair dye compositions containing 2,3 dialkyl-4-aminophenol and a 2-alkyl-1-naphthol
WO1999029336A1 (en) 1997-12-05 1999-06-17 Eli Lilly And Company Glp-1 formulations
US6528068B1 (en) 1997-12-25 2003-03-04 Ajinomoto Co., Inc. Cosmetic composition containing N-acyl neutral amino acid esters of lower alcohols
JP3050289U (en) 1997-12-29 1998-06-30 丸隆株式会社 Pet animal indoor excretion tool
DE19802206A1 (en) 1998-01-22 1999-07-29 Beiersdorf Ag Stable cosmetic or dermatological composition with low viscosity
FR2774595A1 (en) 1998-02-06 1999-08-13 Rech D Innovation Et De Dev Ce Emulsion for the transdermal administration of steroids
DE19805918A1 (en) 1998-02-13 1999-08-19 Beiersdorf Ag Reduced lipid preparations
US6110966A (en) 1998-02-20 2000-08-29 Medi-Cell Laboratories, Inc. Triple action complex
JP3514105B2 (en) 1998-02-27 2004-03-31 ティアック株式会社 Recording medium recording and reproducing apparatus
EP0979654B1 (en) 1998-03-04 2005-08-24 Teijin Limited Activated vitamin d 3 emulsion-type lotions
US6121210A (en) 1998-03-12 2000-09-19 Dap Products Inc. Foamable silicone oil compositions and methods of use thereof
US5990100A (en) 1998-03-24 1999-11-23 Panda Pharmaceuticals, L.L.C. Composition and method for treatment of psoriasis
ES2268856T3 (en) 1998-04-22 2007-03-16 Connetics Australia Pty Limited pharmaceutical composition.
US5919830A (en) 1998-04-30 1999-07-06 Gopalkrishnan; Sridhar Stable non-aqueous blends for personal care compositions
US6649175B1 (en) 1998-05-04 2003-11-18 Schering-Plough Healthcare Products, Inc. Skin barrier composition
GB9810949D0 (en) 1998-05-22 1998-07-22 Hewlett Healthcare Limited Formulation
FR2779637B1 (en) 1998-06-15 2000-09-01 Oreal cosmetic photoprotective compositions containing a metal oxide nanopigment and an acrylic terpolymer and use of these compositions to protect keratinous substances against ultraviolet radiation
US6706290B1 (en) 1998-07-06 2004-03-16 Olvai E. Kajander Methods for eradication of nanobacteria
US6146664A (en) 1998-07-10 2000-11-14 Shaklee Corporation Stable topical ascorbic acid compositions
US6124362A (en) 1998-07-17 2000-09-26 The Procter & Gamble Company Method for regulating hair growth
US6071541A (en) 1998-07-31 2000-06-06 Murad; Howard Pharmaceutical compositions and methods for managing skin conditions
JP4017758B2 (en) 1998-08-04 2007-12-05 高砂香料工業株式会社 Cooling sensation agent composition
DE19835239A1 (en) 1998-08-04 2000-02-24 Johnson & Johnson Gmbh Foaming oil preparation and their use
GB9817817D0 (en) 1998-08-14 1998-10-14 Unilever Plc Cosmetic composition
JP2002523144A (en) 1998-08-20 2002-07-30 スリーエム イノベイティブ プロパティズ カンパニー Spraying and drug delivery system to the bandage
JP3712868B2 (en) 1998-09-02 2005-11-02 株式会社カネボウ化粧品 Aerosol compositions
ES2431330T3 (en) 1998-09-11 2013-11-26 Stiefel Research Australia Pty Ltd Aerosol foam composition
US8263580B2 (en) 1998-09-11 2012-09-11 Stiefel Research Australia Pty Ltd Vitamin formulation
US6087310A (en) 1998-09-23 2000-07-11 Castrol Limited Skin cleaning compositions and uses comprising a polymer latex emulsion
JP2002525298A (en) 1998-09-28 2002-08-13 メルク エンド カムパニー インコーポレーテッド Method of treating inflammatory diseases by administration of a thrombin inhibitor
US6914057B1 (en) 1998-09-28 2005-07-05 The Research Foundation Of State University Of New York Inhibitor of cataract formation
US6607716B1 (en) 1998-09-29 2003-08-19 Tech Labs, Inc. Pediculicidal compositions, a kit, and methods of use
RU2134052C1 (en) * 1998-10-07 1999-08-10 Нерушай Сергей Алексеевич Method and apparatus for aerosol application of perfumery liquids
US6287546B1 (en) 1998-10-09 2001-09-11 Colgate-Palmolive Company Shampoos with stabilizers
JP3876081B2 (en) 1998-10-22 2007-01-31 東洋エアゾール工業株式会社 Foam-forming aerosol composition
US6551604B1 (en) 1999-06-28 2003-04-22 The Procter & Gamble Company Skin care compositions
US6110477A (en) 1998-10-30 2000-08-29 Topix Pharmaceuticals Inc. Stabilization of ascorbic acid, ascorbic acid derivatives and/or extracts containing ascorbic acid for topical use
US7521068B2 (en) 1998-11-12 2009-04-21 Elan Pharma International Ltd. Dry powder aerosols of nanoparticulate drugs
US5980904A (en) 1998-11-18 1999-11-09 Amway Corporation Skin whitening composition containing bearberry extract and a reducing agent
US6344218B1 (en) * 1998-11-23 2002-02-05 The Procter & Gamble Company Skin deodorizing and santizing compositions
DE19855097A1 (en) 1998-11-28 2000-05-31 Wella Ag Pigment-containing, foamable gel
US20010006654A1 (en) 1998-12-09 2001-07-05 L'oreal Compositions and methods for treating hair and skin using aqueous delivery systems
US6087317A (en) 1998-12-10 2000-07-11 Dow Corning Corporation Particle size stable silicone emulsions
US6486207B2 (en) 1998-12-10 2002-11-26 Nexmed (Holdings), Inc. Compositions and methods for amelioration of human female sexual dysfunction
US6262128B1 (en) 1998-12-16 2001-07-17 3M Innovative Properties Company Aqueous foaming compositions, foam compositions, and preparation of foam compositions
FR2787728B1 (en) 1998-12-23 2001-01-26 Oreal A nanoemulsion based on fatty esters of phosphoric acid, and its uses in cosmetic, dermatological, pharmaceutical and / or ophthalmic
JP2000191429A (en) 1998-12-28 2000-07-11 Kao Corp Foamable cosmetic
CN1195550C (en) 1998-12-28 2005-04-06 大正制药株式会社 External preparation
FR2787703B1 (en) 1998-12-29 2001-01-26 Oreal Nanoemulsion-based ethers of fatty ethoxylated or ethoxylated fatty esters, and its uses in the areas cosmetic, dermatological and / or ophthalmological
FR2788007B1 (en) * 1999-01-05 2001-02-09 Oreal Nanoemulsion based on copolymers of ethylene oxide units and propylene oxide, and its uses in cosmetic, dermatological and / or ophthalmological
US6270781B1 (en) 1999-01-08 2001-08-07 Maxim Pharmaceuticals, Inc. Method and compositions for topical treatment of damaged tissue using reactive oxygen metabolite production or release inhibitors
US6486168B1 (en) 1999-01-08 2002-11-26 3M Innovative Properties Company Formulations and methods for treatment of mucosal associated conditions with an immune response modifier
EP1025836A1 (en) 1999-02-08 2000-08-09 F. Hoffmann-La Roche Ag Cosmetic light screening composition
EP1028133B1 (en) 1999-02-10 2008-03-26 Mitsui Chemicals, Inc. Flexible polyurethane cold cure molded foam and process for producing same
US6224888B1 (en) 1999-02-12 2001-05-01 The Procter & Gamble Company Cosmetic compositions
US6423329B1 (en) 1999-02-12 2002-07-23 The Procter & Gamble Company Skin sanitizing compositions
JP3641152B2 (en) 1999-02-17 2005-04-20 株式会社ヤクルト本社 External preparation for skin
US6305578B1 (en) 1999-02-26 2001-10-23 Wella Aktiengesellshaft Device for mixing, foaming and dispensing liquids from separate compressed-gas containers
US7374779B2 (en) 1999-02-26 2008-05-20 Lipocine, Inc. Pharmaceutical formulations and systems for improved absorption and multistage release of active agents
CA2333317C (en) 1999-03-22 2011-01-04 J.P.M.E.D. Ltd. Stable oil-in-glycerin emulsion
ES2272209T3 (en) 1999-03-31 2007-05-01 Firmenich Sa Use of cubebol as a flavoring ingredient.
US6383471B1 (en) 1999-04-06 2002-05-07 Lipocine, Inc. Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents
US6264964B1 (en) 1999-04-14 2001-07-24 Conopco, Inc. Foaming cosmetic products
WO2000062776A1 (en) 1999-04-16 2000-10-26 Fujisawa Pharmaceutical Co., Ltd. Antifungal compositions
US6284802B1 (en) 1999-04-19 2001-09-04 The Procter & Gamble Company Methods for regulating the condition of mammalian keratinous tissue
US6433003B1 (en) 1999-04-23 2002-08-13 Arthur M. Bobrove Method for treating hyperhidrosis in mammals
DK1178808T3 (en) 1999-04-23 2012-07-30 Leo Pharma As Non-aqueous pharmaceutical composition for dermal use to treat psoriasis, comprising a vitamin D, corticosteroids, and a solvent component
GB9909711D0 (en) 1999-04-27 1999-06-23 Unilever Plc Mousse forming hair treatment composition
FR2793479B1 (en) 1999-05-10 2001-06-29 Lir France Sa Double distributor for fluid or pasty products
US6417207B1 (en) 1999-05-12 2002-07-09 Nitromed, Inc. Nitrosated and nitrosylated potassium channel activators, compositions and methods of use
US6518228B1 (en) 1999-05-27 2003-02-11 Clairol Incorporated Ultra-mild, clear, aqueous, foamable skin cleanser
US6395300B1 (en) 1999-05-27 2002-05-28 Acusphere, Inc. Porous drug matrices and methods of manufacture thereof
JP2003500427A (en) 1999-05-28 2003-01-07 ユニリーバー・ナームローゼ・ベンノートシヤープ Foamable shower oil composition
JP2000351726A (en) 1999-06-08 2000-12-19 Lion Corp Aerosol preparation
JP2000354623A (en) 1999-06-14 2000-12-26 Shiigeru Kk Deodorant and deodorizing spray
US6113888A (en) 1999-06-15 2000-09-05 Neutrogena Corporation Self-tanning mousse
GB9913951D0 (en) 1999-06-15 1999-08-18 Unilever Plc Mousse-forming shampoo compositions
KR100352088B1 (en) 1999-06-21 2002-09-12 한미약품공업 주식회사 Dermal emulsion composition comprising minoxidil
US6190365B1 (en) * 1999-06-21 2001-02-20 Chun Lim Abbott Vaginal douche applicator and method of vaginal deodorization using the same
NL1012419C2 (en) 1999-06-23 2000-12-28 Airspray Nv Aerosol for dispensing a liquid.
US6524594B1 (en) 1999-06-23 2003-02-25 Johnson & Johnson Consumer Companies, Inc. Foaming oil gel compositions
JP2001002526A (en) 1999-06-23 2001-01-09 Koike Kagaku Kk Foam aerosol composition
US6761903B2 (en) 1999-06-30 2004-07-13 Lipocine, Inc. Clear oil-containing pharmaceutical compositions containing a therapeutic agent
US6762158B2 (en) * 1999-07-01 2004-07-13 Johnson & Johnson Consumer Companies, Inc. Personal care compositions comprising liquid ester mixtures
US20060254597A1 (en) 2000-12-14 2006-11-16 40J's Llc Method of treatment of atrophic vaginitis by topical clitoral menthol or a related cooling compound
WO2001001949A9 (en) 1999-07-01 2001-03-22 Johnson & Johnson Consumer Cleansing compositions
FR2795643B1 (en) 1999-07-02 2004-06-11 Oreal Firming cosmetic composition comprising at least one hydroxystilbene combined with ascorbic acid
JP4058199B2 (en) 1999-07-06 2008-03-05 ポーラ化成工業株式会社 Warming pack
EP1200054A1 (en) 1999-07-15 2002-05-02 Playtex Products, Inc. Sunscreen aerosol composition
US6548074B1 (en) 1999-07-22 2003-04-15 Elizabeth Arden Co., Division Of Conopco, Inc. Silicone elastomer emulsions stabilized with pentylene glycol
FR2796925B1 (en) 1999-07-29 2001-10-05 Valois Sa Distributor head hingedly distribution
WO2001008681A1 (en) 1999-08-02 2001-02-08 First Horizon Pharmaceutical Corporation Methods of administration of glycopyrrolate compositions
US6303552B1 (en) 1999-08-04 2001-10-16 Napier International Technologies, Inc. Aerosol paint stripper compositions
WO2001013956A3 (en) 1999-08-26 2001-10-04 Ganeden Biotech Inc Use of emu oil a carrier for antifungal, antibacterial, and antiviral medications
US6777591B1 (en) 1999-08-27 2004-08-17 Sembiosys Genetics Inc. Legume-like storage protein promoter isolated from flax and methods of expressing proteins in plant seeds using the promoter
US6308863B1 (en) 1999-09-02 2001-10-30 Owens-Brockway Plastic Products Inc. Dual chamber package for pressurized products
US6479058B1 (en) 1999-09-02 2002-11-12 Mccadden Michael E. Composition for the topical treatment of poison ivy and other forms of contact dermatitis
JP4394775B2 (en) 1999-09-03 2010-01-06 株式会社ダイゾー Water-in-oil foam aerosol compositions and methods of manufacturing
US6986883B2 (en) 1999-09-09 2006-01-17 Discus Dental, Inc. Increased peroxide content tooth bleaching gel
US6283336B1 (en) 1999-09-20 2001-09-04 The Procter & Gamble Company Article for the delivery of foam products
US6437006B1 (en) 1999-09-27 2002-08-20 American Cyanamid Company Pharmaceutical carrier formulation
FR2798849B1 (en) 1999-09-29 2001-11-23 Oreal materials washing keratin composition, a base of an active detergent surfactant, a homopolymer of dialkyl diallyl ammonium and an acrylic terpolymer
US6667045B2 (en) 1999-10-01 2003-12-23 Joseph Scott Dahle Topical applications for skin treatment
US6790435B1 (en) 1999-10-01 2004-09-14 Unilever Home & Personal Care Usa Division Of Conopco, Inc. Antiperspirant compositions comprising microemulsions
FR2799369B1 (en) 1999-10-08 2001-12-21 Oreal Association of escin and dextran sulfate and its use
US6186367B1 (en) * 1999-10-19 2001-02-13 Valley Design Inc. Metered liquid squeeze dispenser
FR2799963B1 (en) 1999-10-22 2002-07-19 Oreal Emulsions containing at least one insoluble organic UV filter and non-filter organomodified silicone
US6080394A (en) 1999-11-08 2000-06-27 Dow Corning Corporation Polar solvent-in-oil emulsions and multiple emulsions
US20030077301A1 (en) 1999-12-16 2003-04-24 Maibach Howard I. Topical pharmaceutical composition for the treatment of inflammatory dermatoses
US6967023B1 (en) 2000-01-10 2005-11-22 Foamix, Ltd. Pharmaceutical and cosmetic carrier or composition for topical application
US6348229B1 (en) 2000-01-10 2002-02-19 Thixo Ltd. Food comprising thixotropic composition of unsaturated fat and process for manufacture thereof
US8512718B2 (en) 2000-07-03 2013-08-20 Foamix Ltd. Pharmaceutical composition for topical application
US6528033B1 (en) 2000-01-18 2003-03-04 Valence Technology, Inc. Method of making lithium-containing materials
US7001690B2 (en) 2000-01-18 2006-02-21 Valence Technology, Inc. Lithium-based active materials and preparation thereof
FR2804016B1 (en) 2000-01-21 2006-07-28 Oreal Nanoemulsion containing amphiphilic lipid and a PEG ester and Uses
FR2804015B1 (en) * 2000-01-21 2005-12-23 Oreal Nanoemulsion containing amphiphilic lipids and a nonionic polymer and Uses
US20020006435A1 (en) 2000-01-27 2002-01-17 Samuels Paul J. Transdermal anesthetic and vasodilator composition and methods for topical administration
FR2804666B1 (en) 2000-02-04 2002-06-14 Oreal Machine for the storage of at least two components and the selective dispensing of either one component alone or a mixture thereof, and process for its implementation
US6780443B1 (en) 2000-02-04 2004-08-24 Takasago International Corporation Sensate composition imparting initial sensation upon contact
NL1014389C2 (en) 2000-02-15 2001-08-16 Dija Zeist Bv Tanning preparation for the skin.
US20040161447A1 (en) 2000-02-17 2004-08-19 Leonard Paul Liquid foam producing compositions and dispensing system therefor
US7117199B2 (en) 2000-02-22 2006-10-03 Metacarta, Inc. Spatially coding and displaying information
DE60105362T2 (en) 2000-02-22 2005-02-17 Color Access, Inc. Aqueous cosmetic gels
DE10008896A1 (en) 2000-02-25 2001-08-30 Beiersdorf Ag Improving the solubility and compatibility of benzotriazole UV filters in oils, e.g. in cosmetics or dermatological compositions, by addition of dialkylnaphthalates
DE10008837A1 (en) 2000-02-25 2001-08-30 Henkel Kgaa Propellant-containing dentifrice
US6664287B2 (en) 2000-03-15 2003-12-16 Bethesda Pharmaceuticals, Inc. Antioxidants
CA2402401C (en) 2000-03-22 2009-11-03 Uri Wormser Compositions containing molecular iodine
US6649571B1 (en) 2000-04-04 2003-11-18 Masi Technologies, L.L.C. Method of generating gas bubbles in oleaginous liquids
FR2807322B1 (en) 2000-04-10 2004-02-20 Oreal Composition, in particular cosmetic, comprising ascorbic acid in combination with an ascorbic acid derivative
US7758888B2 (en) 2000-04-21 2010-07-20 Sol-Gel Technologies Ltd. Composition exhibiting enhanced formulation stability and delivery of topical active ingredients
JP2002012513A (en) 2000-04-24 2002-01-15 Kanebo Ltd Urea-containing whipped cosmetic
US6358541B1 (en) 2000-05-03 2002-03-19 David S. Goodman Topical preparation for the treatment of hair loss
US6410036B1 (en) 2000-05-04 2002-06-25 E-L Management Corp. Eutectic mixtures in cosmetic compositions
CA2408137C (en) 2000-05-05 2011-04-19 R.P. Scherer Technologies, Inc. Oil-in-water emulsion formulation containing hydroquinone and retinol
US6433024B1 (en) 2000-05-08 2002-08-13 Karl F. Popp Topical anti-acne composition
EP1286652B1 (en) 2000-05-08 2006-09-06 Pfizer Products Inc. Skin protectant spray compositions
FR2808685B1 (en) 2000-05-12 2004-10-08 Sanofi Synthelabo Pharmaceutical compositions for transdermal administration of antiinflammatory agents
JP2001326952A (en) 2000-05-15 2001-11-22 Nec Corp Broadcast confirmation system, method and device for broadcast confirmation, and recording medium with broadcast confirmation program recorded thereon
FR2809010B1 (en) 2000-05-22 2002-07-12 Oreal Nanoemulsion-based anionic polymers, and uses especially in cosmetic, dermatological, pharmaceutical and / or ophthalmologic
DE10028638A1 (en) 2000-06-09 2001-12-20 Schuelke & Mayr Gmbh Storage-stable composition useful in cosmetic and pharmaceutical compositions comprises combination of glycerol monoalkyl ether with antioxidant
US6649178B2 (en) 2000-06-13 2003-11-18 Fatemeh Mohammadi Cosmetic composition for stressed skin under extreme conditions
US6818204B2 (en) 2000-06-23 2004-11-16 Combe Incorporated Stable foam for use in disposable wipe
US20020164381A1 (en) * 2000-06-30 2002-11-07 Medicis Pharmaceutical Corporation Mitocidal compositions and methods
CA2313659A1 (en) 2000-07-06 2002-01-06 Barry J. Barclay B complex vitamin compositions that protect against cellular damage caused by ultraviolet light
DE10033414B4 (en) 2000-07-08 2004-02-19 Wella Aktiengesellschaft Clear, two-phase, foam-forming aerosol hair care product
FR2811564B1 (en) 2000-07-13 2002-12-27 Oreal Nanoemulsion containing nonionic polymers, and uses especially in cosmetic, dermatological, pharmaceutical and / or ophthalmologic
US6468989B1 (en) 2000-07-13 2002-10-22 Dow Pharmaceutical Sciences Gel compositions containing metronidazole
DE10035930A1 (en) * 2000-07-21 2002-01-31 Clariant Gmbh fine emulsions
US20020035070A1 (en) 2000-07-26 2002-03-21 The Procter & Gamble Company Method of regulating hair growth using metal complexes of oxidized carbohydrates
FR2812191B1 (en) 2000-07-28 2003-10-17 Oreal Using receptor agonists of prostaglandin e2 (EP-3) to mitigate, reduce or stop hair growth and hair in cosmetic preparations
JP4166931B2 (en) 2000-08-02 2008-10-15 ポーラ化成工業株式会社 Fever form cosmetics
US6514487B1 (en) 2000-08-08 2003-02-04 Teresa Leigh Barr Foam and gel oat protein complex and method of use
WO2002015873A8 (en) 2000-08-22 2003-11-13 Procter & Gamble Personal care compositions containing adhesive elastomeric polymer and inorganic colloid
WO2002015860A1 (en) 2000-08-24 2002-02-28 Tim Ioannides Topical antioxidant having vitamin c and method of combination with topical agent by user
US6299023B1 (en) 2000-08-24 2001-10-09 Miles Arnone Device for dispensing two substances in a user selectable ratio with replaceable cartridges
FR2813189B1 (en) 2000-08-31 2003-02-28 Oreal Foaming cosmetic cream for treating greasy skin
WO2002022086A3 (en) 2000-09-14 2003-01-30 Keith H Johnson Application of water nanoclusters to skin
WO2002024161A1 (en) 2000-09-21 2002-03-28 Taisho Pharmaceutical Co., Ltd. Suppositories sustained in the lower rectum
CA2444533C (en) 2000-10-02 2010-07-20 Connetics Australia Pty Ltd Pharmaceutical vehicle
DE10049147A1 (en) 2000-10-04 2002-04-25 Wella Ag Hair wax product with waxes, non-volatile oils and volatile, hydrophobic materials
FR2814959A1 (en) 2000-10-09 2002-04-12 Menarini France Atomiser for pharmaceutical products based on antiinflammatory agents comprises pressurized container, dosing pouch and metering valve
US6547063B1 (en) 2000-10-10 2003-04-15 The Procter & Gamble Company Article for the delivery of foam products
GB0025026D0 (en) 2000-10-12 2000-11-29 Bespak Plc Dispensing apparatus for a pressurised dispensing container
FR2815616B1 (en) 2000-10-20 2003-01-24 Oreal intended distribution assembly for the extemporaneous dispensing two products
US6403069B1 (en) 2000-10-20 2002-06-11 Colgate-Palmolive Company High oil clear emulsion with elastomer
DE10058384B4 (en) 2000-11-24 2004-12-16 Wella Aktiengesellschaft Cosmetic or dermatological composition in the form of a creamy foam permanent or stable foamed cream, their use and process for the preparation of the agent
US6299032B1 (en) 2000-11-27 2001-10-09 George W. Hamilton Disposable actuator with cap opener for aerosol cans
WO2002043490A8 (en) 2000-11-28 2003-03-13 Avon Prod Inc Foaming insect repellent compositions
US6969521B1 (en) 2000-11-28 2005-11-29 Avon Products, Inc. Aerosol insect repellent composition having low VOC content and method of applying same to the skin
US6774100B2 (en) 2000-12-06 2004-08-10 Imaginative Research Associates, Inc. Anhydrous creams, lotions and gels
GB0030068D0 (en) 2000-12-11 2001-01-24 Lawrence Malcolm Highway vehicular traffic flow control
JP3497466B2 (en) 2000-12-12 2004-02-16 高砂香料工業株式会社 Warming composition
DE10063342A1 (en) 2000-12-19 2002-06-20 Beiersdorf Ag Cosmetic or dermatological composition contains three-part emulsifier system and gas
US6749860B2 (en) 2000-12-22 2004-06-15 Kimberly-Clark Worldwide, Inc. Absorbent articles with non-aqueous compositions containing botanicals
US20040079361A1 (en) 2001-01-17 2004-04-29 Clayton Colin D. Medicinal aerosols
FR2819427B1 (en) 2001-01-18 2003-04-11 Oreal translucent nanoemulsion, process for its manufacture and its uses in cosmetic, dermatological and / or ophthalmological
US20030013692A1 (en) 2001-01-19 2003-01-16 Gullans Steven R. Methods of treating neurological disorders
EP1357905A2 (en) 2001-02-05 2003-11-05 Michael Albert Kamm A treatment of oesophageal motility disorders and gastro-oesophageal reflux disease
WO2002069906A3 (en) 2001-03-06 2003-11-20 Cellegy Pharma Inc Compounds and methods for the treatment of urogenital disorders
CA2448231A1 (en) 2001-03-07 2002-10-03 The Procter & Gamble Company Cosmetic topical composition comprising a functional aromatic derivative bonding agent
ES2224063T3 (en) * 2001-03-26 2005-03-01 3M Innovative Properties Company Metering valve for metered dose inhaler having improved flow.
WO2002076401A3 (en) 2001-03-26 2003-02-27 Dana Farber Cancer Inst Inc Method of attenuating reactions to skin irritants
EP1372605A2 (en) 2001-03-27 2004-01-02 Galen (Chemicals) Limited Intravaginal drug delivery devices for the administration of an antimicrobial agent
CA2441730C (en) 2001-03-29 2008-11-18 The Dial Corporation Antibacterial compositions for skin care
JP2002302419A (en) 2001-03-30 2002-10-18 Aldeep Cosmetics Japan Inc Cosmetic composition
EP2311440A1 (en) 2001-04-05 2011-04-20 Collagenex Pharmaceuticals, Inc. Controlled delivery of tetracycline compounds and tetracycline derivatives
US6848597B2 (en) 2001-04-18 2005-02-01 James A. Vlodek Methods and apparatus for extruding foam through orifices
US20030053980A1 (en) 2001-04-30 2003-03-20 The Gillette Company Shaving compositions containing highly lubricious water soluble polymers
US20020187181A1 (en) 2001-05-14 2002-12-12 3M Innovative Properties Company System for delivering cosmetics and pharmaceuticals
DE60224928D1 (en) 2001-05-17 2008-03-20 Relivia S R L Dermatological and cosmetic compositions containing a furfuryl
US20030017181A1 (en) 2001-05-31 2003-01-23 Rood Gloria A. Dermatological compositions and methods
US7270828B2 (en) 2001-06-20 2007-09-18 The Procter & Gamble Company Personal care composition comprising hydrophobic gel
EP1397118A1 (en) 2001-06-20 2004-03-17 THE PROCTER & GAMBLE COMPANY Personal care composition comprising polyol-in-silicone emulsion
FR2826292B1 (en) 2001-06-22 2004-01-23 Rhodia Chimie Sa Emulsions comprising oil-in-oil silicone, emulsions and dispersions of such use
US6428772B1 (en) 2001-06-25 2002-08-06 Blistex Inc. Acne treatment composition with cooling effect
US6544562B2 (en) 2001-06-25 2003-04-08 Blistex Inc. Acne treatment including dual-package system
WO2003002082A1 (en) 2001-06-26 2003-01-09 The Procter & Gamble Company Pressurized anhydrous antiperspirant emulsions
JP2003012511A (en) 2001-06-27 2003-01-15 Rohto Pharmaceut Co Ltd Aerosol composition
JP4051412B2 (en) 2001-06-27 2008-02-27 株式会社カネボウ化粧品 Mixing dispensing equipment
US6777011B2 (en) * 2001-06-28 2004-08-17 Crosswind Industries, Inc. Multi-layer food product, system and process
JP2004536839A (en) 2001-07-13 2004-12-09 ザ プロクター アンド ギャンブル カンパニー Mousse-forming composition comprising a quaternary ammonium agent
US20060194773A1 (en) 2001-07-13 2006-08-31 Paratek Pharmaceuticals, Inc. Tetracyline compounds having target therapeutic activities
DE10134786A1 (en) 2001-07-17 2003-02-06 Beiersdorf Ag foamable preparations
US7960416B2 (en) 2001-08-03 2011-06-14 Takeda Pharmaceutical Company Limited Stable emulsion composition
DE10138495B4 (en) 2001-08-04 2004-11-11 Beiersdorf Ag Foaming preparations and their use
ES2346955T3 (en) 2001-08-08 2010-10-22 Btg International Limited injectable foam and novel pharmaceutical applications thereof.
US7091243B2 (en) 2001-08-09 2006-08-15 Croda, Inc. Anti-irritants
JP4707279B2 (en) 2001-08-09 2011-06-22 ポーラ化成工業株式会社 Cosmetics for massage with a cool-down effect
WO2003013984A1 (en) 2001-08-11 2003-02-20 Aventis Pharma Limited Pressurised aerosol dispenser
US6638981B2 (en) 2001-08-17 2003-10-28 Epicept Corporation Topical compositions and methods for treating pain
US20030049218A1 (en) 2001-08-28 2003-03-13 Amit Patel Antiperspirant deodorant emulsion
US20050054991A1 (en) 2001-08-29 2005-03-10 Tobyn Michael John Topical administration device
US6709663B2 (en) 2001-08-31 2004-03-23 Healthpoint, Ltd. Multivesicular emulsion drug delivery systems
US6479060B1 (en) 2001-09-04 2002-11-12 Healthpoint, Ltd. Elegant hydrogenated castor oil ointments
FR2829693B1 (en) 2001-09-20 2004-02-27 Oreal Foaming cosmetic cream
DE10147820A1 (en) 2001-09-27 2003-04-10 Beiersdorf Ag Self-foaming, foam-like, after-foaming or foamable cosmetic or dermatological preparations with a content of waxes or solid at room temperature and / or semi-solid lipids
US7931533B2 (en) 2001-09-28 2011-04-26 Igt Game development architecture that decouples the game logic from the graphics logics
US20030185839A1 (en) 2001-10-05 2003-10-02 Podolsky Daniel K. Methods and compositions for treating dermal lesions
CA2463308C (en) 2001-10-10 2010-12-14 Exxonmobil Research And Engineering Company Biodegradable non-toxic gear oil
US20030082120A1 (en) 2001-10-26 2003-05-01 Milstein Harold J. Method for reducing systemic effects of aging, effects of aging on the skin, and incidence of skin damage from sun exposure using antibiotics of the tetracycline family
DE60230893D1 (en) 2001-10-26 2009-03-05 Taiyo Kagaku Kk Oily foamable aerosol composition
US7255869B2 (en) 2001-10-30 2007-08-14 The Procter & Gamble Company Anhydrous cosmetic compositions containing polyols
DE10154324A1 (en) 2001-11-06 2003-08-07 Merz Pharma Gmbh & Co Kgaa Topically administrable compositions with an external active ingredient depot formation, their preparation and their use
DE10155956A1 (en) 2001-11-09 2003-05-22 Beiersdorf Ag Self-foaming, foam-like, after-foaming or foamable cosmetic or dermatological preparations
CN1612722A (en) 2001-11-13 2005-05-04 宝洁公司 Compositions containing enzymes stabilized with certain osmo-protectants and methods for using such compositions in personal care
DE10155792A1 (en) 2001-11-14 2003-05-22 Beiersdorf Ag Self-foaming, foam-like, after-foaming or foamable cosmetic or dermatological preparations with a content of siloxane elastomers
EP1565189A4 (en) 2001-11-16 2006-11-02 Beatrice M Klysz Anti-aging skin care composition and uses thereof
DE10159002A1 (en) 2001-11-30 2003-06-18 Clariant Gmbh Use of means for multi-phase foaming of foam dispensers
FR2833246B1 (en) 2001-12-06 2005-06-24 Beatrice France Touteau Device for simultaneously actuating two aerosols containing two products to be mixed at the time of use
US6531118B1 (en) 2001-12-11 2003-03-11 Avon Products, Inc. Topical compositions with a reversible photochromic ingredient
US8226972B2 (en) 2001-12-20 2012-07-24 Femmepharma Holding Company, Inc. Vaginal delivery of drugs
US20030118515A1 (en) 2001-12-21 2003-06-26 Robert Jew Cosmetic composition containing carbon dioxide
US6765001B2 (en) 2001-12-21 2004-07-20 Medicis Pharmaceutical Corporation Compositions and methods for enhancing corticosteroid delivery
JP2005519887A (en) 2001-12-21 2005-07-07 ポンスス ファルマ アーベー New composition
US20030129259A1 (en) 2001-12-28 2003-07-10 Avon Products, Inc. Topical lightening compostitions and methods of use
JP4549625B2 (en) 2002-01-05 2010-09-22 株式會社アモーレパシフィック Fine emulsified particles and a manufacturing method thereof and ginseng saponin metabolite of the active ingredient, as well as cosmetic composition for preventing skin aging containing the same
US7192601B2 (en) 2002-01-18 2007-03-20 Walker Edward B Antimicrobial and sporicidal composition
US6992049B2 (en) 2002-01-31 2006-01-31 Exxonmobil Research And Engineering Company Lubricating oil compositions
US20050245902A1 (en) 2002-02-08 2005-11-03 Brian Cornish Substance delivery device
WO2003068777A1 (en) 2002-02-14 2003-08-21 Quimversion, S.L. Aluminium and hexamethylenetetramine complex and the applications thereof
US6589216B1 (en) 2002-02-20 2003-07-08 Abbott Research Group, Inc. Vaginal douches, vaginal douche applicators and methods of vaginal douching
US6682511B2 (en) 2002-02-21 2004-01-27 Robert Wallace Besoyan Brief protector
US6691898B2 (en) 2002-02-27 2004-02-17 Fomo Products, Inc. Push button foam dispensing device
WO2003075851A3 (en) 2002-03-06 2009-06-18 Cellegy Pharma Inc Compositions and methods for the treatment of anorectal disorders
US20050281766A1 (en) 2002-03-11 2005-12-22 Avon Products, Inc. Method of improving the aesthetic appearance of epithelia
US6736860B2 (en) 2002-03-12 2004-05-18 Unilever Home & Personal Care Usa Division Of Conopco, Inc. Gradual permanent coloring of hair using dye intermediates dissolved in alkaline water with fatty alcohol
US6848601B2 (en) 2002-03-14 2005-02-01 Homax Products, Inc. Aerosol systems and methods for mixing and dispensing two-part materials
US7654415B2 (en) 2002-03-19 2010-02-02 Airspray International B.V. Dispensing unit
US20030180347A1 (en) 2002-03-19 2003-09-25 W.F. Young, Incorporated Patch for the delivery of topical agents
EP1500385B1 (en) 2002-03-28 2008-06-25 Hakuto Co., Ltd Method of foam stabilization for foam cosmetic
US20040078896A1 (en) 2002-04-12 2004-04-29 Dreamwell, Ltd. Cassette bedding system
US8192749B2 (en) 2003-04-16 2012-06-05 Galderma Laboratories Inc. Methods of simultaneously treating ocular rosacea and acne rosacea
US8846039B2 (en) 2002-04-26 2014-09-30 Asan Laboratories Company (Cayman), Limited Method for ameliorating pruritus
US6875438B2 (en) 2002-04-27 2005-04-05 Aventis Pharma Deutschland Gmbh Preparations for topical administration of substances having antiandrogenic activity
CA2384922C (en) 2002-05-03 2008-09-02 Purepharm Inc. Topical glycopyrrolate product for the reduction of sweating
CA2500134A1 (en) 2002-05-06 2003-11-13 Collagenex Pharmaceuticals, Inc. Methods of simultaneously treating mucositis and fungal infection
US7459417B2 (en) 2002-05-10 2008-12-02 Unilever Home & Personal Care Usa Division Of Conopco, Inc. Hair conditioning composition comprising a silicone oil and a poloxamer or poloxamine block copolymer
US6783027B2 (en) 2002-05-15 2004-08-31 The Procter & Gamble Company Metered-dose underarm product and package
US20030215472A1 (en) 2002-05-16 2003-11-20 Bonda Craig A Methods and compositions employing a dialkyl amide
EP1505961A4 (en) 2002-05-20 2009-09-02 Collagenex Pharm Inc Methods of treating allergic reactions
JP4050094B2 (en) 2002-05-28 2008-02-20 株式会社三谷バルブ Metering valve mechanism and aerosol products
US6723309B1 (en) 2002-06-10 2004-04-20 Jeffrey Alan Deane Hair cleansing conditioner
FR2840903B1 (en) 2002-06-13 2005-01-28 Oreal Derive glucose and vitamin f, including the compositions and uses to improve the condition of hair and hair
US7763587B2 (en) 2002-06-13 2010-07-27 L'oreal S.A. Derivative of glucose and of vitamin F, compositions comprising it, uses and preparation process
US7163669B2 (en) 2002-06-19 2007-01-16 J.M. Huber Corporation Cosmetic compositions comprising calcium silicates
DE60335275D1 (en) 2002-06-26 2011-01-20 Daizo Co Ltd VERPACKUNGSBEHuLTER TO UNSUBSCRIBE FROM MULTIPLE CONTENT, PACKAGING PRODUCT WITH VERPACKUNGSBEHuLRODUKTS
JP2004026605A (en) 2002-06-27 2004-01-29 Asahi Fiber Glass Co Ltd Greige goods for glass fiber yarn and glass fiber yarn made using this
US6785629B2 (en) 2002-07-02 2004-08-31 Agilent Technologies, Inc. Accuracy determination in bit line voltage measurements
JP3833972B2 (en) 2002-07-08 2006-10-18 古河オートモーティブパーツ株式会社 Assembly system of the wire harness
US7137536B2 (en) 2002-07-22 2006-11-21 Seaquist Perfect Dispensing Foreign, Inc. Inverted aerosol dispenser
DE10233330B4 (en) 2002-07-22 2007-04-26 Sasol Germany Gmbh Microemulsion containing UV photoprotective filters and / or anti-dandruff agents
US6897195B2 (en) 2002-07-24 2005-05-24 Nanjing Zhongshi Chemical Co. Composition of menthol and menthyl lactate, its preparation method and its applications as a cooling agent
US20020182162A1 (en) 2002-08-07 2002-12-05 Mohsen Shahinpoor Nitric oxide (NO) donor+cGMP-PDE5 inhibitor as a topical drug for enhanced hair growth
FR2843373B1 (en) 2002-08-12 2005-03-04 Jean Augustin Device for packaging and applying a product in fluid form
US7939170B2 (en) 2002-08-15 2011-05-10 The Rockefeller University Water soluble metal and semiconductor nanoparticle complexes
ES2312847T3 (en) 2002-08-26 2009-03-01 S.L.A. Pharma Ag topical formulation comprises at least 10% of metronidazole in white petrolatum and use in anal and rectal region.
US6770607B2 (en) 2002-09-12 2004-08-03 Unilever Home & Personal Care Usa, Division Of Conopco, Inc. Viscoelastic cleansing gel with micellar surfactant solutions
US7906473B2 (en) 2002-09-13 2011-03-15 Bissell Homecare, Inc. Manual spray cleaner
US6968982B1 (en) 2002-09-18 2005-11-29 Burns Caleb E S Multiple-mist dispenser
GB0221697D0 (en) 2002-09-18 2002-10-30 Unilever Plc Novel compouds and their uses
US7179481B2 (en) 2002-09-19 2007-02-20 Kimberly-Clark Worldwide, Inc. Vaginal health products
US6949037B2 (en) 2002-09-27 2005-09-27 Richard A. Enos Quick-release fastener for releasably attaching lacrosse stick head to shaft
FR2845672B1 (en) 2002-10-09 2006-02-10 Airlessystems A fluid dispenser
US8232304B2 (en) 2002-10-24 2012-07-31 G & R Pharmaceuticals, Llc Antifungal formulations
WO2004037225A3 (en) 2002-10-25 2004-12-29 Foamix Ltd Cosmetic and pharmaceutical foam
US20160158261A1 (en) 2002-10-25 2016-06-09 Foamix Pharmaceuticals Ltd. Antibiotic Kit and Composition and Uses Thereof
US20050186142A1 (en) 2002-10-25 2005-08-25 Foamix Ltd. Kit and composition of imidazole with enhanced bioavailability
US9265725B2 (en) 2002-10-25 2016-02-23 Foamix Pharmaceuticals Ltd. Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof
US20080138296A1 (en) 2002-10-25 2008-06-12 Foamix Ltd. Foam prepared from nanoemulsions and uses
US20070292359A1 (en) 2002-10-25 2007-12-20 Foamix Ltd. Polypropylene glycol foamable vehicle and pharmaceutical compositions thereof
US20050271596A1 (en) 2002-10-25 2005-12-08 Foamix Ltd. Vasoactive kit and composition and uses thereof
US20080317679A1 (en) 2002-10-25 2008-12-25 Foamix Ltd. Foamable compositions and kits comprising one or more of a channel agent, a cholinergic agent, a nitric oxide donor, and related agents and their uses
US20080152596A1 (en) 2005-07-19 2008-06-26 Foamix Ltd. Polypropylene glycol foamable vehicle and pharmaceutical compositions thereof
US20070292355A1 (en) 2002-10-25 2007-12-20 Foamix Ltd. Anti-infection augmentation foamable compositions and kit and uses thereof
US9668972B2 (en) 2002-10-25 2017-06-06 Foamix Pharmaceuticals Ltd. Nonsteroidal immunomodulating kit and composition and uses thereof
US20060233721A1 (en) 2002-10-25 2006-10-19 Foamix Ltd. Foam containing unique oil globules
WO2009087578A3 (en) 2008-01-08 2010-06-10 Foamix Ltd. Sensation modifying topical composition foam
US20120156144A1 (en) 2002-10-25 2012-06-21 Foamix Foamable Compositions, Kits and Methods for Hyperhidrosis
ES2532906T3 (en) 2002-10-25 2015-04-01 Foamix Pharmaceuticals Ltd. cosmetic and pharmaceutical foam
US20060193789A1 (en) 2002-10-25 2006-08-31 Foamix Ltd. Film forming foamable composition
US8119109B2 (en) 2002-10-25 2012-02-21 Foamix Ltd. Foamable compositions, kits and methods for hyperhidrosis
US7700076B2 (en) 2002-10-25 2010-04-20 Foamix, Ltd. Penetrating pharmaceutical foam
US8486376B2 (en) 2002-10-25 2013-07-16 Foamix Ltd. Moisturizing foam containing lanolin
US9211259B2 (en) 2002-11-29 2015-12-15 Foamix Pharmaceuticals Ltd. Antibiotic kit and composition and uses thereof
US8900554B2 (en) 2002-10-25 2014-12-02 Foamix Pharmaceuticals Ltd. Foamable composition and uses thereof
US20050205086A1 (en) 2002-10-25 2005-09-22 Foamix Ltd. Retinoid immunomodulating kit and composition and uses thereof
US20080206161A1 (en) 2002-10-25 2008-08-28 Dov Tamarkin Quiescent foamable compositions, steroids, kits and uses thereof
US20080031907A1 (en) 2002-10-25 2008-02-07 Foamix Ltd. Cosmetic and pharmaceutical foam
US8093290B2 (en) 2002-10-28 2012-01-10 Givaudan Sa Coolant solutions and compositions comprising the same
JP2004250435A (en) 2002-11-21 2004-09-09 Dai Ichi Seiyaku Co Ltd Composition for hair growth
JP4282311B2 (en) 2002-11-26 2009-06-17 三洋電機株式会社 Ice-making equipment
WO2008075207A3 (en) 2006-04-04 2009-01-29 Foamix Ltd Anti-infection augmentation foamable compositions and kit and uses thereof
EP1569598A1 (en) 2002-12-12 2005-09-07 Neubourg Skin Care GmbH & Co. KG Stable foam cream
GB0229071D0 (en) 2002-12-13 2003-01-15 Unilever Plc Cosmetic method and composition for enhancing attractiveness
US20040191196A1 (en) 2002-12-16 2004-09-30 Dov Tamarkin Novel conjugate compounds and dermatological compositions thereof
FR2848847B1 (en) 2002-12-18 2005-10-14 Coletica Cosmetic or dermopharmaceutical composition comprising an insoluble enzyme in aqueous medium, and uses thereof
US7842791B2 (en) 2002-12-19 2010-11-30 Nancy Jean Britten Dispersible pharmaceutical compositions
FR2848998B1 (en) 2002-12-20 2006-04-07 Oreal Dispenser device having means for dispensing two products in varying proportions
CA2764405A1 (en) 2003-01-02 2004-07-22 Femmepharma Holding Company, Inc. Pharmaceutical preparations for treatments of diseases and disorders of the breast
WO2004064769A3 (en) 2003-01-21 2005-07-14 Hector Herrera Methods for making and using topical delivery agents
JP4828404B2 (en) 2003-01-24 2011-11-30